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Celiac disease (CD) is a chronic enteropathy triggered by cereal gluten proteins 
in genetically predisposed individuals. The etiology is strongly associated with 
the genes of the human leukocyte antigen (HLA) encoding the DQ2/DQ8 mol-
ecules. Most CD patients carry this genotype but this is also present in the 40% 
of the general population and only a small percentage develops the disease. Thus, 
the HLA-DQ genotype is necessary but not solely responsible for the disease de-
velopment. Gluten is the main environmental trigger but its intake neither fully 
explains the onset nor its clinical manifestations. Other environmental factors 
(e.g. early feeding practices, infections, intestinal microbiota) have been associat-
ed with the risk of developing CD.
The only treatment for CD patients is the adherence to a gluten free diet (GFD), 
but the compliance with this dietary strategy is complicated because gluten is 
present in many foods. Therefore, the identification of modifiable environmental 
factors that contribute to CD onset is critical for the development of strategies to 
reduce its incidence. 
Observational studies in CD patients revealed imbalances in the intestinal micro-
biota which could contribute to the pathogenesis of the disease. It has been pro-
posed that these imbalances are not only a secondary consequence of the disease 
but could also be a predisposing factor. To understand whether gut microbiota 
imbalances play a role in CD onset and pathogenesis, in vitro, animal and human 
prospective and intervention studies have been conducted in the context of the 
present PhD Thesis. 
The global aim of this Thesis has been to improve the understanding of the role 
played by intestinal microbiota in the pathogenesis and risk of CD, and the pos-
sibilities of contributing to disease prevention and treatment by modulating gut 
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microbiota composition. Chapter 1 includes two in vitro studies investigating 
the influence of components of the gut microbiota (bifidobacteria and entero-
bacteria) on the maturation and functions of immunocompetent cells  (dendritic 
cells), and on  gluten toxicity in the intestinal epithelium (Caco-2 cells). We have 
observed that some Bifidobacterium strains are able to reduce the activation of 
dendritic cells and ameliorate the toxicity of gluten on intestinal epithelial cells.
In Chapter 2 the effects of the administration of  Bifidobacterium longum CECT 
7347 was evaluated in an in vivo model of gluten induced enteropathy in new-
born rats, resulting in a reduced  proinflammatory cytokine production in the 
small intestine and CD4+T cell numbers in peripheral blood. 
Chapter 3 includes two observational studies in humans to unravel whether 
breast-feeding and human milk composition and/or the host genotype (HLA-
DQ) are related to the microbiota, thereby influencing the later development 
of CD. We concluded that both factors may contribute to the early intestinal 
colonization of the infant, influencing the Bifidobacterium spp. numbers. Human 
milk composition also varies in CD and non-CD mothers, modifying the supply 
of bifidobacteria and protective immune factors to the offspring.
Finally, in Chapter 4 we have studied the potential beneficial effects of the ad-
ministration of B. longum CECT 7347 in addition to the GFD to children with 
newly diagnosed CD. This study demonstrates that the bifidobacteria slightly re-
duces serum inflammatory markers and restored the gut microbiota composition. 
11
La enfermedad celíaca (EC) es una enteropatía crónica de carácter autoinmune 
que sufren individuos genéticamente predispuestos tras la ingesta de gluten. La 
etiología está asociada con los genes del sistema “Antígeno Leucocitario Humano” 
(HLA) que codifican las moléculas DQ2/DQ8. Los pacientes con EC presentan 
este genotipo, sin embargo este también está presente en ~40% de la población 
general y sólo un pequeño porcentaje desarrolla la enfermedad. Por lo tanto, el 
genotipo HLA-DQ resulta necesario pero no suficiente para que se desarrolle la 
enfermedad. El gluten es el principal desencadenante pero su ingesta tampoco 
explica su desarrollo ni sus manifestaciones clínicas. Otros factores ambientales 
(p.e. la lactancia, infecciones, microbiota intestinal) se han asociado con el riesgo 
de desarrollar la EC.
El único tratamiento para los pacientes celíacos es el seguimiento de una dieta 
exenta de gluten (DEG), sin embargo su cumplimiento es complicado debido a 
que el gluten está presente en la mayoría de los alimentos procesados. Por ello, la 
identificación de factores ambientales modificables que contribuyan al desarrollo 
de la enfermedad, resulta fundamental para desarrollar estrategias que permitan 
reducir su  incidencia. 
Estudios observacionales realizados en pacientes con la EC, han demostrado la 
existencia de desequilibrios en su microbiota intestinal, que podrían contribuir 
a la patogénesis de la enfermedad. Se ha propuesto que estos desequilibrios no 
son sólo una consecuencia secundaria de la EC, sino que podrían ser un factor 
predisponente. Para entender si la microbiota está implicada en el desarrollo y 
patogénesis de la EC, en la presente Tesis se han desarrollado estudios in vitro, con 
animales y estudios prospectivos y de intervención en  humanos.  
El objetivo de esta Tesis ha sido avanzar en el conocimiento de la función que la 
microbiota intestinal desempeña en la patogénesis de la EC, así como, acerca de 
las posibilidades de tratar o prevenir esta enfermedad mediante  la modulación de 
RESUMEN
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la composición de la microbiota intestinal.
El Capítulo 1 incluye dos estudios in vitro en los que se ha estudiado la influencia 
de componentes de la microbiota intestinal (bifidobacterias y enterobacterias) 
en la maduración y las funciones de células inmunocompetentes (células den-
dríticas), y en la toxicidad del gluten en el epitelio intestinal (células Caco-2). 
Hemos observado que algunas cepas de Bifidobacterium son capaces de reducir la 
activación de las células dendríticas y de reducir la toxicidad del gluten sobre el 
epitelio intestinal.
El Capítulo 2 incluye el estudio de los efectos de la administración de B. longum 
CECT 7347 en un modelo de enteropatía inducida por gluten en ratas recién na-
cidas, observándose una reducción de citoquinas proinflamatorias en el intestino 
y de células T CD4+ en sangre periférica.
El Capítulo 3 incluye dos estudios observaciones en humanos en los que se ha 
investigado si la lactancia y composición de la leche materna y/o el genotipo 
(HLA-DQ) están relacionados con la microbiota y, si así, podrían influir en el 
desarrollo de la EC. Concluimos que ambos factores contribuyen a la coloniza-
ción intestinal del niño en los primeros meses de vida, afectando especialmente al 
número de Bifidobacterium spp.. La composición de la leche maternal varía entre 
madres celíacas y sanas, lo que podría modificar el aporte de bifidobacterias y 
factores inmunológicos protectores al lactante. 
Por último, el Capítulo 4 incluye el estudio del potencial efecto beneficioso de 
la administración de B. longum CECT 7347 junto con la DEG en niños recién 
diagnosticados de EC. Este estudio demuestra que la bifidobacteria reduce ligera-
mente los marcadores inflamatorios en sangre periférica y contribuye a restablecer 
la composición de la microbiota intestinal. 
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La malaltia celíaca (MC) és una enteropatia crònica provocada per les proteï-
nes del gluten de cereals en individus predisposats genèticament. L’etiologia està 
fortament associada amb els gens de l’antigen leucocitari humà (HLA). Pacients 
amb MC son portadors d’aquest genotipus però també està present en aproxi-
madament el 40% de la població general i només un petit percentatge (1-3%) 
desenvolupa la malaltia. Per tant, HLA-DQ genotip és necessària, però no l’únic 
responsable. El gluten és el principal desencadenant ambiental però la seva in-
gesta no explica completament l’inici ni les seves manifestacions clíniques. Altres 
factors ambientals, com la microbiota intestinal, s’han associat amb el risc de 
desenvolupar la MC.
Els estudis observacionals en pacients amb MC van revelar desequilibris en la 
microbiota intestinal que podrien contribuir a la patogènesi de la malaltia. S’ha 
proposat que aquests desequilibris no només són una conseqüència secundària de 
la malaltia, si no que també podrien ser un factor de predisposició. Per entendre 
si els desequilibris de la microbiota intestinal podrien tenir un paper en l’aparició 
de MC, un estudi prospectiu amb el gen en risc la família està en marxa. 
L’únic tractament per als pacients amb MC és l’adherència a una dieta lliure de 
gluten, però el seu compliment és complicat a causa del gluten present en molts 
aliments. La identificació de factors ambientals modificables que contribueixen a 
l’aparició de CD és fonamental per a les estratègies de desenvolupament que porten 
a una reducció de la incidència. Aquest pot ser el cas per als components de la micro-
biota intestinal, l’adquisició podria ser modulada per factors ambientals i dietètics. 
L’objectiu global de la tesi és desentranyar els coneixements actuals sobre el paper 
exercit per la microbiota intestinal en la patogènesi de l’MC, i les possibilitats de 
contribuir a la prevenció i tractament de la malaltia mitjançant la modulació de 
la composició de la microbiota intestinal. 
En el Capítol 1 hem estudiat l’ús de models in vitro de la influència de la micro-
biota intestinal durant la maduració i funcions del sistema immunològic (cèl·lules 
RESUM
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dendrítiques), i les interaccions entre el gluten i l’intestí i la resposta de l’epiteli 
intestinal resultant d’aquesta interacció. Hem observat que algunes cepes de Bi-
fidobacterium són capaç de reduir l’activació del sistema immune i millorar la 
resposta nociva de l’epiteli intestinal a l’estimulació amb gluten.
En el Capítol 2 hem estudiat els efectes de l’administració d’una cepa de Bifido-
bacterium (B. longum CECT 7347) per a un model animal de rates nounades. El 
tractament amb els bacteris es va associar amb una reducció en la producció de 
citoquines proinflamatòries i la resposta immune de cèl·lules T CD4 +. 
En el Capítol 3 es va descriure que alguns genotipus (HLA-DQ genotip) i fac-
tors ambientals (llet materna) influeixen en la colonització intestinal primerenca, 
especialment en Bifidobacterium spp., que poden influir en l’aparició de MC més 
tard.
Finalment, en el Capítol 4 s’ha estudiat l’efecte probiòtic de l’administració de 
B. longum CECT 7347 en xiquets que acaben de ser diagnosticats d’MC i el seu 
paper en el restabliment de la salut intestinal.
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I - INTRODUCTION
1-Celiac disease
1.1-Historical introduction
Celiac disease (CD) likely appeared with one of the first environmental changes 
associated with human civilization, the development of the agriculture and the 
introduction of cereals in the human diet. In the first century of Common Era 
(C.E.) Cappadoce provided the first description of the common manifestation of 
the disease (chronic diarrhea, abdominal distension and cachexia) and used the 
term “Koliakos” to name the subjects suffering from this disorder. The etiology of 
the disease was not discover until the 1950, when the Dutch pediatrician W. K. 
Dicke associated the CD symptoms with the consumption of bread and proposed 
a diet without these cereals to the patients, who showed a clear improvement (1).
In 1957, the development of the Crosby-Kugler capsule to obtain biopsies from 
the small bowel mucosa, allowed M. Shiner studying duodenal biopsies and 
demonstrating the typical villous atrophy that characterizes the disease (2). Then, 
A. Ferguson described the massive infiltration of the small intestinal epithelium 
by lymphocytes and helped to complete the histological picture of CD (3). In 
the early 1960, family studies showed the contribution of predisposing genetic 
factors (4); and 10 years later, new diagnostic tools were developed, based on 
the detection of circulating immunoglobulin (Ig)-G and IgA antibodies against 
gluten and the autoantigen tissue transglutaminase (tTG) that underscored the 
immune-mediated nature of the disease (5). The identification of the human 
leukocyte antigen (HLA)-DQ2 and HLA-DQ8 as the major predisposing factors 
(6, 7) and their role in the development of an intestinal inflammatory CD4+ T 
lymphocyte response to gluten was crucial to establish the link between the trig-
ger environmental factor and the major predisposing genes (8).
Despite the huge advances in the understanding of CD pathogenesis, many piec-
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es of the puzzle remain to be assembled. It is unclear why only a small subset of 
individuals with the HLA genotype develops the disease and which are the roles 
of different environmental factors in the onset of the disease. It also remains to 
be unraveled why the incidence of CD is globally increasing, a phenomenon that 
cannot be solely explained by improvements in the diagnosis. It is also unclear 
why some subjects develop CD very early in infancy after the first exposures to 
gluten; meanwhile others do so lately in the adulthood. 
1.2-Definition and classification of celiac disease 
The members of the European Society for Pediatric Gastroenterology, Hepatol-
ogy, and Nutrition (ESPGHAN) group in the year 2012 established the new 
guidelines for the diagnostic criteria of CD (9). The working group decided to 
define CD as an immune-mediated systemic disorder elicited by gluten in genet-
ically susceptible individuals and characterized by the presence of a variable com-
bination of gluten-dependent clinical manifestations, CD-specific antibodies, 
HLA-DQ2 or HLA-DQ8 haplotypes, and enteropathy. CD specific antibodies 
comprise autoantibodies against tissue transglutaminase 2 (tTG-2), endomysial 
antibodies (EMA), and antibodies against deamidated forms of gliadin peptides. 
In these guidelines, it is also indicated that intestinal biopsy may be omitted in 
symptomatic children with high level of serological markers and HLA-DQ2 or 
HLA-DQ8 positive. In all other cases, the intestinal biopsy is required in order 
to avoid misdiagnosis (9).
The ESPGHAN group also reviewed the classifications of CD and distinguished 
two forms of clinical manifestation: with “gastrointestinal symptoms and signs” 
and with “extra-intestinal symptoms and signs”. In the first form symptoms such 
as chronic, diarrhea, abdominal pain, or distension were considered; while the 
second manifestation included symptoms such as anemia, neuropathy, decreased 
bone density, or increased risk of fractures. Also, three specific denominations 
of the clinical manifestations of the disease were established when the defined 
symptomatology is not sufficient:
Silent CD is defined as the presence of positive CD-specific antibodies, HLA-
Introduction
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DQ2/DQ8 genotype, and small-bowel biopsy findings that are compatible with 
CD but without sufficient symptoms and signs to warrant clinical suspicion of 
CD.
Latent CD is defined by the presence of compatible HLA-DQ2/DQ8 genotype 
but without enteropathy in a patient who has had a gluten-dependent enteropa-
thy at some point in his or her life. The patient may or may not have symptoms 
and may or may not have CD-specific antibodies. 
Potential CD is defined by the presence of CD-specific antibodies and compati-
ble HLA-DQ2/DQ8 genotype but without histological abnormalities in duode-
nal biopsies. The patient may or may not have symptoms and signs and may or 
may not develop a gluten-dependent enteropathy later.
Originally, CD was thought to affect to almost exclusively white Europeans, but 
now it is known to be widely distributed worldwide and seems to have followed 
the mankind wheat consumption and the migratory flows (10). The prevalence 
of the disease ranks between 1 to 3% of the general population (11, 12), even 
though the existence of the sub-clinical forms described above makes difficult 
the diagnosis and underestimates the incidence, often represented by an iceberg 
in which the no symptomatic cases are underwater (Figure 1). Some estimations 
indicate that only 1 of every 5-9 affected individuals is correctly diagnosed and 
Figure 1: The clinical presentation of CD is often described as an iceberg model. The tip of the 
iceberg constitutes the diagnosed fraction of CD patients and the part underwater those who are 
undiagnosed.
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treated. 
1.3-Pathogenesis of celiac disease
CD is a multifactorial disorder involving genetic and several environmental 
factors. The disease is strongly associated with the HLA genes that codify the 
expression of the HLA-DO2/DQ8 heterodimers in the surface of the antigen 
presenting cells (APC). Most CD patients present this genotype; however this is 
also present in ~40% of the general population and only a small percentage (1-
3%) finally develops the disease (11, 12). Thus, the genotype HLA-DQ2/DQ8 
is needed but it’s no sufficient to explain the onset of CD (13). Currently, non-
HLA genes are known to be involved as described below. Gluten intake is the 
environmental factor responsible for the manifestation of the disease; however, 
the number of patients diagnosed during the adulthood after many years of glu-
ten exposure is increasing demonstrating that gluten intake may not be the only 
trigger (14). Epidemiological studies indicate that other factors may increase or 
reduce the risk of developing CD. The amount and timing of gluten introduction 
to the infant diet, the type of delivery, the milk feeding practices, the incidence 
of infections and the intestinal microbiota composition have been proposed to 
influence the CD risk. However, no conclusive results have been obtained so far 
(reviewed in 15).
1.3.1-Genetics 
Different studies in siblings have demonstrated the strong genetic component of 
CD, showing a concordance of around 80% in monozygotic twins versus less than 
20% among dizygotic twins, and 10% in first degree relatives of CD patients (16-
18). HLA-DQ has been the locus more widely studied in the context of CD. The 
HLA-DQ genes encode molecules expressed on the surface of the APCs involved 
in the recognition of the gluten peptides. It has been described that approximate-
ly 90-95% of CD patients carry HLA-DQ2 heterodimers formed by a β-chain 
encoded by HLA-DQB1*02 allele (either*0201 or *0202) and an α-chain encod-
ed by HLA-DQA1*05 allele. HLA-DQB1*02 and HLA-DQA1*05 alleles can 
be inherited in cis (when both are present on one parental chromosome), or in 
Introduction
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trans (when the α- and β-chains are encoded by chromosomes from each parent). 
The remaining percentage (5-10%) of patients express the HLA-DQ8 heterod-
imer formed by β and α-chains encoded by HLA-DQB1*0302 allele and HLA 
DQA1*0301 allele, respectively. HLA-DQ2 and HLA-DQ8 molecules share 
peptides binding motifs characterized by a preference for hydrophobic and neg-
atively charged amino acids, such as the deaminated gluten peptides (Figure 2).
Figure 2: Representation of genes, combination of alleles (haplotypes) and codified HLA-DQ or 
HLA-DQ8 heterodimers (α and β chanis). Celiac disease patients who are DR3 or DR5/DR7 ex-
press the same molecule: HLA-DQ2. The genes DQB1 and DQA1 can be inherited in cis (in the 
same parental chromosome), or in trans (when the α- and β-chains are encoded by the correspond-
ing chromosome from each parent). CD patients who are DR4 express the molecule HLA-DQ8. 
Adapted from Dieli-Crimi et al., 2015 (19). 
Over the last decades, different genetic studies have been performed in order to 
reveal all the genetic factors involved in CD. Nowadays, CD is well established as 
a polygenic disease with a complex non-Mendelian pattern of inheritance. So far, 
58 genetic variants located within 36 non-HLA regions have also been associated 
with the susceptibility to suffer from CD, being located only 3 of these variants 
on protein coding regions and the remaining variants located in non-coding reg-
ulatory regions and intergenic regions of unknown function. Thus, CD onset is 
influenced by the accumulation of risk due to HLA and non-HLA genes together 
Introduction
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with different environmental factors (reviewed in 19). 
1.3.2-Gluten as environmental trigger 
In 1950, wheat was described as causal agent (antigen) of the CD (1). Then, 
barley and rye grains were described as toxic for CD patients. Still there are con-
troversies about the possible toxic effects of oats (reviewed in 20). Because of the 
ubiquity of wheat in the diet and the controversy with oats, both cereals have been 
the most widely studied. The gluten fraction soluble in alcohol and characterized 
by having a high content in proline is denominated prolamin; while the fraction 
insoluble in alcohol is the glutenin. Prolamin proteins are named more specifi-
cally based on the cereal where they come from. Thereby in wheat, barley and 
rye, the prolamins are called gliadin, hordein and secalin, respectively. Gliadin, 
hordein and secalin have a high proline and glutamine content. These particular 
amino acid residues confer to these proteins a partial resistance to the proteolytic 
digestion since gastric, pancreatic and brush border enzymes are deficient in pro-
lyl-endopeptidases with the consequent accumulation of immunogenic peptides 
in the intestinal lumen (21). However, the relatively poor digestion of these pro-
teins alone is not sufficient to cause CD, and indeed there is no known difference 
between healthy individuals and susceptible CD subjects in their ability to digest 
gluten proteins (22).
In the small intestine gliadin peptides interact with the CXCR3 receptor that 
leads to the release of zonulin (a regulatory protein of the tight junctions between 
enterocytes) that, in turn, increases intestinal permeability. This mechanism may 
facilitate the passage of gluten peptides by the paracellular pathway to the lamina 
propria (23). Besides, gluten peptides can also cross the intestinal barrier using 
the ability of enterocytes to capture molecules from the luminal space, through 
the so-called transcellular route via transcytosis. For instance, the translocation 
of the 33-mer peptide (p57-89 from the α-gliadin) can occur by transcytosis 
regulated by interferon (IFN)-γ. This uptake has been observed to be higher in 
untreated CD than in controls and CD patients on a GFD (24). Moreover oth-
er peptides, such as the p31-49 from the α-gliadin, can be transported intact 
through an abnormal retrotranscytosis process mediated by secretory immuno-
Introduction
23
globulin A (sIgA) and the CD71 receptor (25). In normal conditions, this recep-
tor plays a major role in iron uptake and metabolism, and it is only expressed in 
the basolateral membrane of enterocytes and mainly in the crypts. In active CD, 
CD71 is massively upregulated and expressed in the apical membrane of en-
terocytes where the sIgA1-gliadin complexes present in the lumen can bind and 
translocate intact into the lamina propria (25). This mechanism, seen in patients 
with active CD but not in controls or treated patients, represents an exception to 
the well-characterized protective effect of sIgA in the mucosal surface, where it 
binds antigens and facilitates their secretion in faeces (reviewed in 26). Interest-
ingly, some authors have proposed that the over-expression of CD71 receptor is 
probably due to iron deficiency, which is frequent in CD patients (27).
In recent years the role of the alterations in the intestinal permeability in CD is 
attracting attention as may be one of the first events that precede the onset of 
the disease. Nevertheless, gluten is also known to activate an inflammatory re-
sponse with production of cytokines that cause gut barrier disruption, creating a 
vicious-circle where both mucosal inflammation and the leaky gut influence one 
another as explained below. 
The patter and timing of gluten introduction into the infant’s diet has been con-
sidered as one of the critical factors that determines CD risk. In this regard, two 
independent intervention studies have investigated whether there is a window 
of opportunity to introduce gluten into the diet that confers protection against 
CD in genetically predisposed individuals. One randomized double-blinded in-
tervention study (PreventCD) in which infants at genetic risk of developing CD 
(HLA-DQ positive) (n=944) received a small dose of gluten or a placebo daily 
between 4-6 months of age, showed no differences between groups in the prev-
alence of CD at 3 years of age (28). The second study (CELIPREV) found that 
the introduction of gluten at 12 months (compared to 6 months) in infants ge-
netically predisposed to develop CD (n=832) may delay the onset of the disease 
but does not modified its incidence at 5 years of age (29). 
Regarding CD in the adulthood, a recent study in mice with altered stress-re-
lated behavior and premature immune senescence suggests that aging and an 
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altered-stress response play a role in the CD susceptibility through the altered 
immune response to gluten and intestinal bacteria (30).   
1.3.3-Immunopathogenesis 
The immunopathogenic process of CD involves both innate (gluten direct effect 
on the epithelium and innate immune cells) and adaptive immunity (through the 
lamina propria CD4+ and CD8+ T lymphocytes) (Figure 3).
Figure 3: Schematic representation of CD pathogenesis Some gluten peptides cross the intestinal 
epithelium and can be deamidated by the tissue transglutaminase (tTG), which increases their abil-
ity to bind the HLA-DQ2/DQ8 molecules of APCs and to trigger an adaptive immune response, 
involving Th1, Th2 and Th17 cells that lead to the release of pro-inflammatory cytokines and the 
production of CD antibodies; other gluten peptides activate an  innate immune response by inter-
acting with epithelial cells and APCs and, thus, triggering the production of the pro-inflammatory 
cytokines In particular, IL-15 increases the expression of the MICA molecule in epithelial cell sur-
face and triggers activation of intraepithelial lymphocytes through engagement of NKG2D, leading 
to an innate-like cytotoxicity toward epithelial cells and enhanced CD8+ T cell-mediated adaptive 
response, contributing to villous atrophy. Adapted from Olivares and Sanz, 2015 (31). 
Regarding the adaptive immune response, once gluten peptides reach the lamina 
propria though the different mechanisms described above, the enzyme tTG de-
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aminates the glutamine residues (positively charged) to glutamic acid (negatively 
charged). The HLA-DQ2 and HLA-DQ8 molecules expressed in the surface of 
the APCs (basically dendritic cells) have in their peptide binding groove several 
“pockets” that favor binding of negatively charged residues. Thus, tTG signifi-
cantly increases the affinity and the capture of gliadin peptides, constituting a key 
factor in the CD pathogenesis (reviewed in 32).
APCs are very efficient at internalizing gluten peptides and, then, displaying 
some of the fragments on their surface. The specific gluten epitopes that can be 
displayed by a person’s APCs depend on the set of antigen-presenting molecules 
encoded by that person’s genome within the HLA locus. The union HLA-DQ-
gluten on the surface of the APCs is recognized by the T cell receptor (TCR) 
presented on the surface of the CD4+T lymphocytes, triggering the activation of 
CD4+T lymphocytes into the pro-inflammatory T helper (Th) 1 profile with the 
release of mainly IFN-γ, as well as tumor necrosis factor (TNF)-α and interleukin 
(IL)-2;  and also the Th17 response with the release of IL-6, IL-17A and IL-22 
(reviewed in 32).
These cytokines cause tissue damage and the loss of the normal intestinal archi-
tecture through the infiltration of CD8+ T lymphocytes and the release of metal-
loproteinases (reviewed in 32). Activated CD4+ T lymphocytes can also drive 
a Th2-type response that leads to the release of other cytokines (IL-4, IL-10, 
IL-13). The Th2-type response leads to clonal expression of differentiated B lym-
phocytes into plasma cells (effector B cells) that produce anti-transglutaminase 
and anti-gliadin antibodies (33) which induce changes in the cytoskeleton and 
the structure of the enterocytes. Overall, this causes the development of typical 
lesions of CD, with crypt hyperplasia and villous atrophy (reviewed in 32).
Furthermore, it has been recently described that certain peptides present toxic 
actions on the epithelium not related to the adaptive response mediated by T 
lymphocytes. These peptides induce the release of IL-15 by enterocytes, dendritic 
cells and macrophages. In turn, this cytokine induces the expansion of intraepi-
thelial lymphocytes (IELs) and the adquisition of a natural killer cell phenotype. 
IL-15 also induces the expression of the stress MICA molecule (MHC class I 
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chain-related molecule A) in the epithelial cells. Finally, the binding of the MICA 
to the NKG2D receptors on the lymphocytes with natural-killer activity (CD8+ 
IELs) promotes the destruction of enterocytes (34).
1.4-Therapeutic strategies
Life-long gluten exclusion from the diet is the only available treatment for CD 
patients. In all cases, CD patients should exclude wheat, barley, rye and oats 
and derivatives from the diet. After two weeks of adherence to a gluten free diet 
(GFD), an improvement in symptoms is observed; then, the serological nor-
malization appears between 6-12 months and the recovery of the intestinal villi 
around two years after the adherence to the diet depending on the severity of the 
disease and the age (reviewed in 35).
However, this dietary restriction often affects the social life of CD patients, limits 
the variety of food choices in their diets and it is difficult to maintain because 
gluten is present in most of the processed foods. The progress in the understand-
ing of the molecular and cellular events involved in the abnormal response to 
gluten has led to the development of alternative or complementary therapeutic 
strategies to the GFD. Briefly, some of the alternatives that are being investigated 
are described below.
- Prolyl-endopeptidases and glutamine-endopeptidases from bacterial and fungi 
sources to break down the resistant immunogenic gluten peptides and detoxify 
gluten (36).
- Inhibition of the tTG activity to reduce the affinity of the gluten peptides for 
the HLA-DQ2/DQ8 molecules (37)
- Blockade the HLA-DQ2/DQ8 molecules using synthetic peptides agonists that 
compete with gluten peptides for the binding sites of the HLA-DQ molecules 
(38).
- Immunomodulation by the induction of anti-inflammatory cytokines (IL-10) 
(39) or by the administration of antagonists of pro-inflammatory cytokines such 
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as IL-15 (40) or TNF-α and IL-18 (41).
2-Celiac disease and microbiota
2.1-The intestinal ecosystem 
It has been estimated that the intestine harbors 1013 to 1014 microorganisms (42), 
which means that the bacterial cells in the intestine are ten times more numerous 
than the total number of human body cells. Additionally, the collective genome 
of the microbiota, named microbiome, contains at least 100‐fold more genes 
than the complete human genome (42, 43). The intestinal microbiota is consid-
ered to play numerous functions in the human body, including metabolic, pro-
tective and structural functions (Figure 4). Despite the important role that the 
intestinal microbiota seems to play in human health, it is not known yet which 
are the components of the microbiota that are responsible for specific conditions 
and those that provide protection from disease. Cultivation techniques have lim-
ited resolution because only a small fraction (20‐40%) of the intestinal bacterial 
species is able to grown using culture‐based techniques (45, 46). In this context, 
the development and use of high-throughput DNA sequencing platforms applied 
to 16S rRNA gene and metagenomic analyses have rapidly increased the under-
standing of the taxonomy and diversity of the human intestinal microbiota and 
Figure 4: Main functions of the intestinal microbiota impacting on the human health. Adapted 
from Grenham et al., 2011 (44).
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their relationship with health and disease.
16S rRNA and metagenomic studies have revealed that the majority of gut mi-
crobiota sequences belong to the Bacteria, which is the predominant kingdom in 
the human adult gut (45, 46). Despite the complexity of the human intestinal 
ecosystem, the majority of the bacteria belong to 6 dominating phyla Bacteroi-
detes, Firmicutes, Actinobacteria, Proteobacteria, Verrucomicrobia, and Fusobac-
teria. Actinobacteria is the most abundant phylum in infants because of the pre-
dominant colonization by the genus Bifidobacterium in the first stages of life (47, 
48), meanwhile Firmicutes and Bacteroidetes dominate the intestinal microbiota 
of the adult population (45, 49).
2.2-Early factors influencing gut microbiota and CD risk
The primary colonization of the intestinal tract begins at birth with the acqui-
sition of microbes from the environment, mainly from the maternal vagina and 
the skin. It is a dynamic process that involves interactions of co-occurrence and 
exclusion between intestinal bacteria, reflecting life events of the newborn and 
undergoing changes until the first 2-3 years of age when the microbiome starts to 
converge toward an adult-like profile (47, 50). The intestinal colonization process 
leads to the acquisition and establishment of a protective microbiota that could 
modulate the risk of developing immune-mediated diseases in adulthood (51). 
This influence is mediated by the interactions between the gut microbiota, the 
diet and immune system, which are crucial for the development of tolerance 
towards harmless antigens from the diet and the commensal microbiota and ap-
propriate defenses against pathogens.
Perinatal and early postnatal environmental factors influencing the microbiota 
composition have been associated with CD susceptibility (Figure 5). The greater 
risk of children born by caesarean section of developing CD (53) might be related 
to the delay in intestinal colonization by bifidobacteria and the reduced bacteri-
al diversity observed in caesarean-born compared to naturally-delivered infants 
(54). Longer breast-feeding and particularly maintenance of breast-feeding when 
gluten is introduced seem to reduce the risk of developing CD or, at least, delay 
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its onset in most case-control retrospective studies included in the meta-analysis 
by Akobeng et al. (55). Also, feeding practices involving the gradual introduction 
of gluten simultaneous to breastfeeding were proposed as the protective factor 
responsible for reducing CD prevalence in one birth cohort compared to the 
“Swedish CD epidemic” cohort (56). However, other prospective epidemiolog-
ical and intervention studies failed to find a protective effect of breast-feeding 
in either CD autoimmunity or biopsy proven CD (57, 58). This inconsistency 
could be due to the lack of control of other confounding variables that have not 
been systematically investigated so far. 
Figure 5: Proposed model for CD pathogenesis. Specific host genetic make-up and environmental 
factors could promote the colonization of pathobionts and reduce symbionts, thus leading to dys-
biosis.  Dysbiosis may contribute to disrupting the immune homeostasis and gut integrity, thereby 
favoring CD onset or aggravating the pathogenesis. Adapted from Cenit et al., 2015 (52).
Duration of breast-feeding could be associated with a reduced or delayed expo-
sure of the newborn to dietary gluten, which might contribute to the protective 
effect of breast milk. Plausibly bioactive breast milk components may also be 
involved in the potential protective effect of breast-feeding on CD development. 
For instance, breast milk seems to be a main source of bacteria for the infant’s gut 
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(59, 60) and of human milk oligosaccharides (HMOs), which promote coloniza-
tion of Bifidobacterium spp.. This could explain the differences observed between 
the intestinal microbiota of breast-fed and formula-fed infants (61-63). Besides 
human milk provides many others bioactive substances involved in passive im-
mune protection and in immunological development of the neonate (64).
On the other hand, a positive association between antibiotics use and 
subsequent development of CD has been found in a case-control study when the 
histopathology data of nearly 3,000 subjects with CD were linked to the Swedish 
Prescribed Drug Register (65). Based on these results, the authors concluded that 
antibiotics intake may increase the risk of suffering CD due to their profound 
impact on intestinal microbiota. However, this association was not found when 
the exposure to antibiotics during pregnancy and the development of CD in 
the offspring was investigated (66), although this last study was most probably 
underpowered for this purpose.
The host genotype has also been described to influence the composition of the 
human gut microbiota and modulate the phenotype (67). In the case of CD, a 
prospective study in a cohort of 164 infants with a family history of the disease 
reported associations between genetic risk (HLA-DQ) and alterations in the in-
testinal microbiota composition (68-70). The HLA-DQ2/DQ8 genotype and 
the type of feeding (maternal or formula) influenced in conjunction the intesti-
nal colonization analyzed by fluorescence in situ hybridization (FISH), real time 
PCR and denaturing gradient gel electrophoresis (DGGE) techniques (68-70). 
In addition, specific decreases in Bifidobacterium spp. and B. longum and increas-
es Staphylococcus spp. were associated with higher genetic risk of developing CD 
irrespective of milk-feeding type (69).
In conclusion a number of epidemiological studies indicate that several perinatal 
and early postnatal factors influence the intestinal microbiota composition and 
participate in conjunction to modulate CD risk. However, there are no large 
prospective studies revealing how the differences in the intestinal microbiota ac-
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quisition in early life might ultimately protect or contribute to the development 
of CD.
2.3-Influence of intestinal microbiota in CD pathogenesis
Several observational studies in children and adults with CD have shown al-
terations in the intestinal microbiota composition compared to control subjects 
(Table 1). Our studies using molecular quantitative methods, such as FISH and 
quantitative PCR, found reduced numbers of Bifidobacterium spp. and B. longum 
and increased numbers of Bacteroides spp. in stools and duodenal biopsies of CD 
patients untreated and treated with a GFD compared to control subjects (71, 
72). Also enterobacteria and staphylococci numbers were higher in untreated 
CD patients than in controls, but these differences were almost restored in CD 
subjects on a long-term GFD (72). Likewise, other studies in children reported 
increased prevalence of Bacteroides vulgatus and Escherichia coli in CD biopsies 
before and after the GFD by temporal temperature gradient gel electrophore-
sis (TTGE) compared to controls (73) and lower numbers of Lactobacillus and 
Bifidobacterium and higher numbers of Bacteroides, Staphylococcus and entero-
bacteria in stools of children with CD compared to healthy controls (77). Other 
studies performed by DGGE of the microbiota of adults clustered the dominant 
microbial communities of healthy individuals together and separated from those 
of untreated CD patients (76). However, the above study reported an increased 
prevalence in Bifidobacterium bifidum in patients with active CD as opposed to 
the lower bifidobacteria numbers detected in CD patients in our studies (71, 
72, 77) or the absence of differences reported in another study (79). In Sweden, 
an early study with samples collected in 1985-1996 revealed that rod-shaped 
bacteria were frequently associated with the mucosa of CD patients; both in the 
active phase and treated with a GFD, as detected by scanning electron microsco-
py (SEM) (74). Later, these SEM analyses were complemented with 16S rDNA 
sequencing to identify the bacterial communities detected in the samples of the 
Swedish epidemic (1985-1996) and in a new cohort of patients (2004-2007) 
(75). Only one CD biopsy collected during 2004-2007 contained rod-shaped 
bacteria in contrast to the frequency described in the samples of the Swedish 
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epidemic, invalidating the initial theory that these bacteria were causative factors 
of the CD epidemic.
The analysis of metabolites derived from intestinal microbiota activity has also 
revealed significant differences between treated CD patients and healthy controls 
and suggests that there is a metabolic signature for the CD microbiome (76, 
77). One recent study reported that CD patients with gastrointestinal symptoms 
had different microbiota composition when compared with controls and patients 
with dermatitis herpetiformis, suggesting that the microbiota may play a role in 
the manifestation of the disease (81). Dysbiosis of the gut microbiota has been 
also associated with persistent gastrointestinal symptoms in treated CD patients 
(82). 
Nevertheless, we should also mention that other authors report no differences 
in mucosa-associated duodenal microbiome composition and diversity using a 
16S-23S rRNA interspacer region-based profiling method (80). There is also lack 
of consensus and understanding of what constitutes a CD-promoting microbio-
ta. A deeper characterization of the CD microbiota by isolating bacterial strains 
and analyzing their pathogenic features (83-85) showed that the E. coli clones be-
longing to virulent phylogenetic groups (B2 and D) isolated from untreated and 
treated CD patients presented a higher number of virulence genes encoding for 
P fimbriae, capsule K5 and hemolysin than those isolated from healthy controls 
(83). Also, the abundance of the species Bacteroides fragilis coding for metallopro-
teases was increased in both untreated and treated CD patients, and thus could 
presumably play a pathogenic role in CD (84). The isolation and identification of 
clones belonging to the genus Staphylococcus also revealed that the species S. epi-
dermidis carrying the mecA gene (methicillin resistant gene) was more abundant 
in the CD patients (treated and untreated) than in controls (85).
The only treatment for CD is the adherence to a life-long GFD, which implies 
important dietary changes. These dietary differences also seem to cause changes 
in the intestinal microbiota composition and in the immune response to the 
altered microbiota in vitro. In healthy adults the GFD caused shifts in gut micro-
biota composition, characterized by reduced numbers of Bifidobacterium spp., B. 
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longum and the Lactobacillus group, and increased numbers of Enterobacteriaceae 
and E. coli (78). This led to suggest that GFD should be considered as an envi-
ronmental factor that may contribute to shaping the microbiota composition in 
treated CD patients (78).
2.4-Mechanism of action of intestinal microbiota in CD
The microbiota could contribute to the etiopathogenesis of CD by at least three 
mechanisms: by mediating host-microbe interactions that influence the immune 
function and the intestinal barrier; and providing proteolytic activities that influ-
ence the generation of immunogenic peptides from gluten (Figure 6).
Figure 6: Schematic representation of the potential role of intestinal microbiota .The microbiota 
could contribute to the etiopathogenesis of CD by (1) the modulation of the immune function, (2) 
mediating host-microbe interactions which could influence the intestinal barrier, or (3) providing 
proteolytic activities that influence the generation of toxic and immunogenic peptides from gluten.
1- Gut bacteria present immunomodulatory properties that may exert a harmful 
or beneficial effect on the host’s health. For instance, it has been described that a 
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mixture of isolated bacteria from CD patients (Prevotella spp., Lachnoanaerobac-
ulum umeaense and Actinomyces graevenitzii) induced IL-17A mRNA expression 
in ex vivo biopsies of intestinal mucosa of CD patients (86). It was hypothesized 
that those bacteria could modulate the IL-17 response by helping to break-down 
the gluten tolerance (86). On the other hand and as an opposite potential effect 
of the intestinal microbiota, B. longum CECT 7347 and B. bifidum CECT 7365 
reduced the inflammatory response (IFN-γ and TNF-α) observed in peripheral 
blood mononuclear cells (PBMCs) exposed to faeces of CD patients (87).
2- Gut bacteria can also strengthen or damage the intestinal integrity. For instan-
ce, CD-triggers (gliadin and IFN-γ) decreased the goblet cell numbers in intesti-
nal loops of inbred Wistar-AVN rats, and the presence of enterobacteria isolated 
from CD patients (E. coli CBL2 and Shigella CBD8) aggravated this effect (88). 
By contrast, B. bifidum CECT 7365 increased the number of goblet cells and the 
production of inhibitors of metalloproteinases, and also reduced gliadin translo-
cation to the lamina propria, which could contribute to gut mucosal protection 
(88). Changes in tight junctions were measured and meanwhile the exposure to 
B. bifidum CECT 7365 together with gliadin and IFN-γ increased ZO-1 levels, 
the addition of E. coli CBL2 reduced ZO-1 levels (88). Other probiotic bacteria 
such as L. rhamnosus GG have shown to contribute in vitro to the maintenance of 
normal intestinal permeability in Caco-2 cells exposed to gliadin (89).
3- Gut microbiota provide proteolytic activities to break-down gluten peptides. 
As described above, some gluten peptides resist gastrointestinal digestion and 
disturb the intestinal homeostasis (90). This may facilitate the access of gluten to 
the lamina propria and their interaction with immune cells. In vitro studies indi-
cate that the proteolytic activity of the intestinal microbiota may modify gluten 
peptides differently, increasing or reducing their toxicity. B. fragilis strains isolated 
from CD patients when incubated with gliadin generated immunogenic peptides 
that preserved or increased the production of TNF-α, and showed increased abil-
ity to permeate through Caco-2 cells (91). Meanwhile, different Bifidobacterium 
spp. and especially B. longum CECT 7347 attenuated the pro-inflammatory re-
sponse of gliadin-derived peptides after the in vitro digestion (84).
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II - OBJETIVES
The general objective of this Doctoral Thesis was to study the influence of the 
intestinal microbiota and specific components on CD pathogenesis and risk.
In order to achieve this main objective, the following specific objectives were 
proposed:
1. To evaluate the in vitro effects of different bifidobacteria and enterobacteria 
identified in CD patients on the regulation of the production of proinflammato-
ry markers and the proteomic response to gliadins in cell cultures.
2. To evaluate the in vivo effect of the administration of a strain of the genus Bi-
fidobacterium in an animal model of gliadin induced enteropathy.
3. To investigate the potential role of environmental and genetic factors on 
breast-milk composition of healthy mothers and mothers with CD, and on the 
intestinal colonization process in a cohort of healthy children at family risk of 
developing CD. 
4. To evaluate the effect of the administration of a Bifidobacterium strain on the 
intestinal ecosystem and immunological markers in children newly diagnosed 
with CD.
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III – RESULTS AND DISCUSSION 
Chapter 1
- Modulation of phenotypic and functional maturation of 
dendritic cells by intestinal bacteria and gliadin: relevance for 
celiac disease.
- Influence of Bifidobacterium longum CECT 7347 and gliadin 
peptides on intestinal epithelial cell proteome
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Modulation of phenotypic and functional 
maturation of dendritic cells by intestinal 
bacteria and gliadin: relevance for celiac 
disease
42
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ABSTRACT 
Dendritic cell (DC) maturation and functions are influenced by 
microbial and environmental stimuli, which could contribute to immune 
dysfunction. Here, we have investigated the role of enterobacteria (E. coli 
CBL2 and Shigella CBD8) isolated from celiac disease (CD) patients, 
bifidobacteria (B.longum CECT 7347 and B. bifidum CECT 7365) and 
gliadins on phenotypic and functional features of monocyte-derived 
dendritic cells (MDDCs) and in co-culture with Caco-2 cells. The 
ultimate goal of our study is to understand the roles played by specific 
components of the gut microbiota in CD. Enterobacteria induced 
marked alterations in MDDCs morphology, inducing podosome 
dissolution and dendrites, and activated MDDC adhesion and spreading. 
Enterobacteria also induced inflammatory cytokine production (IFN-γ, 
TNF-α, IL-12), partially resembling the gliadin-induced Th1-type 
cytokine profile.  B. longum CECT 7347 and B. bifidum CECT 7365 
induced minor MDDCs morphological changes, and activated adhesion 
and spreading and inflammatory cytokine production to a lesser extent 
compared to enterobacteria. B. longum CECT 7347 also induced lower 
CD86 and CD40 expression on MDDCs than the two enterobacteria. 
The aforementioned bifidobacterial strain also reduced gliadin-induced 
IFN-γ production and increased IL-10 secretion when both stimuli 
were combined. Similar trends were detected for MDDCs co-cultured 
with Caco-2 cells. B. longum CECT 7347 reversed the gliadin-reduced 
ZO-1 expression in Caco-2 cells. Thus, our results suggest that specific 
components of the gut microbiota may influence phenotypic and 
functional maturation of DCs differently, and their interactions with 
epithelial cells. This could ultimately define the role of DCs in celiac 
disease progression. 
Keywords: dendritic cells, celiac disease, bifidobacteria, enterobacteria, 
gliadin
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promoting Th17 cell development, 
is also overproduced in CD. This 
cytokine is also associated with the 
local production of IFN-γ by CD4+ 
Th1 cells (6). More recently, the 
presence of gluten-specific IL17A-
producing cells secreting IL-21 and 
high levels of IL-22 and regulated 
by TGFβ through a RORC- and 
IRF-4-dependent mechanism had 
been reported in duodenal biopsies 
of CD patients (7). In active CD 
patients, gut permeability is also 
increased and related to dysfunction 
of the intercellular junction between 
epithelial cells due to reorganization 
and changes in expression of tight 
junction (TJ) related proteins (1).
This pathological process leads to 
typical histological characteristics 
of CD, including small intestinal 
mucosal villous atrophy, crypts 
hyperplasia, abnormal surface 
epithelium and increased infiltration 
of the lamina propria and 
intraepithelial compartments with 
inflammatory cells (8). Currently, 
the only way to normalize the typical 
clinical manifestations of the disease 
is to adhere to a life-long gluten-free 
diet, although some patients continue 
having gastrointestinal symptoms 
and tissue lesions and, especially, 
in refractory CD the activation 
of intraepithelial lymphocytes is 
not controllable with this diet and 
this situation can turn into T cell 
lymphoma (3).
Dendritic cells (DCs) are professional 
antigen presenting cells (APCs), 
which play a key role in intestinal 
INTRODUCTION
Celiac disease (CD) is a chronic 
inflammatory disorder of the small 
intestine characterized by an aberrant 
immune response to gluten proteins 
(gliadin) in genetically predisposed 
individuals.  The disease is caused 
by the interaction between genetic 
and environmental factors (1). CD 
shows a strong association with 
Human Leukocyte Antigen (HLA)-
DQ genes, with most patients 
carrying a variant of DQ2 or DQ8. 
The association between HLA and 
CD is stronger than for other HLA-
linked diseases, contributing 53% 
to disease risk (1). Dietary gluten 
is the key environmental factor 
involved in the disease. Gluten 
proteins are rich in proline and 
glutamine residues, making them 
resistant to proteolytic degradation 
within the gastrointestinal tract 
and good substrates for the enzyme 
tissue transglutaminase. This enzyme 
deamidates glutamine into negatively 
charged glutamic acid, increasing the 
affinity of gluten peptides for HLA-
DQ2 and HLA-DQ8 molecules of 
antigen presenting cells (APCs) (2,3). 
Both innate and adaptive immune 
responses contribute to triggering 
mucosal inflammation in the patients 
(3). CD is described as a Th-1 cell 
mediated disorder because Th1-
type cytokines are overproduced in 
intestinal CD mucosa (4). Moreover, 
Th17 cells contribute to the ongoing 
inflammation in CD (5). IL-21, 
which is a Th17 cell-derived cytokine 
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immune homeostasis, maintaining 
tolerance towards commensal 
microbes and generating appropriate 
immune responses against pathogens 
and antigens (9). Intestinal DCs 
are found in close association with 
epithelial cells and concentrated at 
sites of antigen entry (10). There 
are several possible routes by which 
DCs pick up antigens. One is 
after the transport of antigens to 
the lamina propria by transcytosis 
through M cells present in the 
follicle-associated epithelium of the 
Peyer’s Patches. Another is by direct 
sampling of the antigens from the 
intestinal lumen by DCs, which 
can form TJ-like structures with 
intestinal epithelial cells and project 
dendrites through the epithelial cell 
layer and into the lumen (10,11). 
Untreated celiac disease mucosa 
harbors elevated numbers of 
activated DCs (12) and has recently 
been reported that those DCs are 
in fact newly recruited monocytes 
expressing CD14+CD11c+ whose 
accumulation is specific to CD 
and precedes changes in mucosal 
architecture (13). Moreover, in vitro 
studies reported that gliadins are able 
to induce phenotypic and functional 
maturation of DCs (14) as well as 
migration (15).
There have also been recent 
suggestions of the potential role 
of bacteria in the pathogenesis of 
CD as patients have an unbalanced 
gut microbiota composition in 
comparison with controls (16-19). 
Our previous research has shown that 
immune responses of monocytes to 
gliadins and IFN-g can be regulated 
by specific intestinal bacteria, which 
could contribute to the Th1-type 
cytokine profile characteristic of the 
disease differently (20). Moreover, 
our studies report that different 
intestinal bacteria distinctly affect 
the permeability of the intestinal 
mucosal layer and the architecture of 
the epithelium layer in rat intestinal 
loops exposed to gliadin and IFN-g 
(21).
The aim of this study was to 
investigate the interactions of 
monocyte-derived DCs (MDDCs) 
with different intestinal bacteria 
(commensal and potential 
pathogens) in combination, or not, 
with gliadins, and co-cultured, or 
not, with Caco-2 cells. The effect 
on MDDCs morphology, adhesion 
and spreading, cytokine production 
and cell surface marker expression 
were determined. The ultimate 
purpose of our research is to gain a 
better understanding of the possible 
contribution of different intestinal 
bacteria to CD, based on their effects 
on the immune response to the main 
celiac disease trigger (gliadin). 
MATERIALS AND METHODS
Gliadin fragments 
Peptic fragments of gliadin (Sigma, 
St Louis, MO) were prepared using 
pepsin agarose gel (ICN, Biomedicals, 
Ohio) as previously described 
(22). Protein concentrations were 
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measured by Bicinchoninic acid 
assay (BCA Protein assay, Pierce, 
Rockford, IL). 
Bacterial strains and culture 
conditions 
The following strains were used in 
the study: B. longum CECT 7347 
(IATA-ES1), B. bifidum CECT 7365 
(IATA-ES2), Shigella CBD8 and E. 
coli CBL2. B. longum CECT 7347 
and B. bifidum CECT 7365 were 
previously isolated from healthy 
human feces and identified, as 
previously described (23-24). E. coli 
CBL2 was isolated from symptom-
free CD patients and Shigella CBD8 
was isolated from untreated CD 
patients, as previously described (25). 
Bifidobacteria were grown routinely 
in de Man, Rogosa and Sharpe 
(MRS) broth (Scharlau Chemie 
SA, Barcelona, Spain) with 0.05% 
cysteine (MRS-C) and incubated at 
37°C under anaerobic conditions 
(AnaeroGen; Oxoid, Basingstoke, 
UK) for 22 h. Enterobacteria were 
routinely grown in Violet Red Bile 
Dextrose (VRBD) agar or Brain 
Heart broth (Scharlau Chemie SA, 
Barcelona, Spain) at 37º C for 24 h 
under aerobic conditions. 
Cells were harvested by 
centrifugation (6,000 g for 15 min) 
at stationary growth phase, washed 
twice in phosphate buffered saline 
(PBS, 130 mM sodium chloride, 10 
mM sodium phosphate, pH 7.4), 
and re-suspended in PBS containing 
20% glycerol. Aliquots of these 
suspensions were frozen in liquid 
nitrogen and stored at -80ºC until 
used. The number of live cells after 
storage was determined by colony-
forming unit (CFU) counting on 
MRS-C or VRBD agar after 48 h 
incubation in optimal conditions. 
For all strains tested, more than 90% 
cells were alive upon thawing and no 
significant differences were found 
during storage time (4 months). One 
fresh aliquot was thawed for every 
new experiment to avoid variability 
in CFU/ml between experiments.
Monocyte-derived DC (MDDC) 
isolation and stimulation  
MDDCs were generated as previously 
described (14). Briefly, peripheral 
blood mononuclear cells (PBMCs) 
were isolated from buffy coats of 
healthy donors (provided by the 
Department of Blood Transfusion at 
Thomayer‘s Hospital, Prague, Czech 
Republic) by centrifugation over a 
Ficoll density gradient (Amersham 
Biosciences, Piscataway, NJ) and 
adjusted to 3 x 106 cells/ml in 75-
cm2 plastic culture flasks (Corning, 
Costar, Madrid, Spain) in RPMI 
1640 medium (BioWhittaker, 
Lonza, Belgium), supplemented 
with 10 % fetal bovine serum 
(FBS) (BioWhittaker, Lonza, 
Belgium), 2 mM L-glutamine, 
100 μg/ml streptomycin and 100 
U/ml penicillin (Sigma, Madrid, 
Spain). After 2 h, the non-adherent 
fraction of cells was washed away 
thoroughly and the isolated adherent 
monocytes were incubated with 
500 U/ml GM-CSF (Immunotools, 
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Friesoythe, Germany) and 20 
ng/ml recombinant human 
IL-4 (Immunotools, Friesoythe, 
Germany) in RPMI 1640 medium 
(BioWhittaker, Lonza, Belgium), 
supplemented with 10 % fetal bovine 
serum (FBS) (BioWhittaker, Lonza, 
Belgium), 2 mM L-glutamine, 100 
μg/ml streptomycin and 100 U/ml 
penicillin (Sigma, Madrid, Spain) 
at 37º C under 5% CO2. After 
5-6 days, the generated MDDCs 
were harvested and seeded at 1 x 
106 cells/ml in 24-well flat-bottom 
polystyrene microtiter plates 
(Corning, Costar, Madrid, Spain). 
Then, cells were incubated for 24 
hours with the following stimuli: 
gliadin (100 μg/ml) or bacterial cell 
suspensions (106 CFU/ml) alone 
or in combination with gliadin. 
Purified lipopolysaccharide (LPS) 
from Salmonella enterica subsp. 
enterica serotype Typhimurium 
(Sigma, St. Louis, MO) was used 
at a concentration of 1 μg/ml as a 
positive control. Non-stimulated 
PBMCs were also evaluated 
as controls of basal cytokine 
production. All reagents were tested 
by the E-toxate test for LPS (Sigma) 
and shown to be below the limit 
of detection (2 pg/ml). Cells were 
used for the experiments and cell 
culture supernatants were collected 
by centrifugation, fractionated in 
aliquots, and stored at -20ºC until 
cytokines were analyzed. Every 
stimulus was assayed in duplicate in 
six different experiments.
Determination of cell adhesion 
and spreading
Impedance measurements using 
xCelligence system in E-plates 
(Roche, Mannheim, Germany) were 
used to determine MDDCs adhesion 
and spreading. E-plates were coated 
with fibronectin (20  μg/ml, Roche) 
in PBS for 1 h at room temperature, 
washed with PBS and background 
was determined in 80 μl of medium 
using Real-Time Cell Analyzer 
(RTCA) station. Subsequently, 100 
l of the MDDC suspension (1×105 
cells/well), and 20 μl of stimulus (20 
μg of gliadin, 105 CFU bacterial cells, 
0.2 μg of LPS, 5 μg of poly I:C or 
a cocktail of cytokines) were added. 
Cells in E-plates were placed in the 
RTCA station for 24 h cultivation 
at 37°C in a 5% CO2 atmosphere. 
Impedance was measured every 
5 min for an initial 5 h period of 
cultivation, and every 15 min for the 
remaining period of 19 h. Impedance 
is a measure of the relative change in 
the electrical impedance at a certain 
frequency (fn) and was represented 
by the cell index (CI) values ((Ri-R0) 
(Ohm) / 15 (Ohm); R0: background 
resistance, Ri: individual time 
point resistance). Increase in cell 
spreading and adhesiveness leads to 
an increase in impedance, as cells 
attached on the electrode sensor 
surfaces act as insulators and, vice 
versa, cell detachment or rounding 
up leads to decrease in impedance. 
All experiments were performed in 
triplicate.  
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Fluorescence microscopy of the 
actin cytoskeleton 
For fluorescence microscopy of the 
DC cytoskeleton, coverslips were 
coated with fibronectin (20 μg/
ml, Roche) in PBS for 1 h at room 
temperature. Then, 2×105 MDDCs 
were seeded on fibronectin-coated 
coverslips and treated with the 
desired agents for 24 h at 37°C in 
a 5% CO2 atmosphere before being 
fixed with 4% paraformaldehyde 
in PBS (20 min, RT). Cells were 
permeabilized with 0.1 % Triton 
X-100 in PBS (5 min), and incubated 
with TRITC-conjugated phalloidin 
(0.5 μg/ml, Sigma) in 2% BSA-PBS 
for 30 min to detect F-actin. Images 
were taken using an Olympus CellR 
fluorescence microscope.  
Flow cytometry analysis of cell-
surface markers
MDDCs were stained with the 
following monoclonal antibodies 
at optimal concentrations: CD11c-
allophycocyanin, CD14-APC-alexa 
fluor 750, CD83-PE (CALTAG), 
CD86-PE (Immunotech), CD40-
FITC and HLA-DR-FITC 
(Pharmingen). MDDCs from 
migration assays were stained for 
surface expression of CCR7 with 
CCR7-PE Ab (R&D System, 
Minneapolis). Cells were also 
incubated with irrelevant antibodies 
at the same concentration and 
isotype. After two washing steps, 
the cells were resuspended in ice-
cold PBS with 0.1% NaN3 or fixed 
with 2% paraformaldehyde, and 
surface markers were analyzed by 
flow cytometry (BD FACS Vantage 
SE, San Jose, California). Staining 
with Hoechst (Invitrogen, Gibco) 
was performed to assess cell viability. 
Data were analyzed using CellQuest 
software (BD Bioscience). 
Enzyme linked immunosorbent 
assay (ELISA)
Cytokine concentrations of cell 
supernatants were measured by 
enzyme-linked immunosorbent 
assay (ELISA) kits according to the 
manufacturer’s instructions. The 
cytokines analyzed were IL-10, IL-
12, TNF-α, IFN-γ (DuoSet Kit, 
R&D System, Minneapolis), IL-15 
(eBioscience, San Diego, CA, USA) 
and IL-21 (Biolegend, San Diego, 
CA, USA). 
Gene expression by Reverse-
Transcription (RT) PCR
The mRNA expression of the TJ 
proteins ZO-1 and occludin was 
analyzed by RT-PCR in Caco-2 
and in MDDCs cultured alone 
or with Caco-2 cells as described 
below. Total RNA extraction was 
conducted with RNeasy mini kit 
(Qiagen, Madrid, Spain) according 
to the manufacturer’s instructions. 
Total RNA was reversely transcribed 
to cDNA with ImProm-II Reverse 
Transcription System (Promega, 
Madison, Wisconsin, USA) 
according to the manufacturer’s 
instructions. cDNA was then 
amplified with LightCycler® 480 
SYBR Green I Master mix (Roche, 
Results and discussion
49
Barcelona, Spain) in a LightCycler® 
480 Real-Time PCR System (Roche, 
Barcelona, Spain) using the primers 
shown in Table 1. The primers for 
occludin were designed using the 
Pubmed Primer Blast designing 
tool and the corresponding 
accession number is NM 002538.2. 
Data were normalized referring 
to glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) expression 
and analyzed with the ΔΔCt method. 
Caco-2 cell culture and co-cultures 
The human enterocyte-like cell line 
Caco-2 was obtained from European 
Cell Culture collection (ECACC, 
86010202, Salisbury, UK) and 
cultured in Dulbecco’s Modified 
Eagle Medium (DMEM) Glutamax, 
containing 10% of inactivated (56º 
C for 30 min) fetal bovine serum 
(FBS) (Gibco, Barcelona, Spain), 100 
μg/ml streptomycin and 100 U/ml 
penicillin (Sigma), 1% concentrated 
nonessential amino acid solution 
(Sigma) and 1% HEPES solution 
(Lonza, Madrid, Spain). For co- 
cultures, 3.5 x 105 Caco-2 cells were 
seeded on the apical compartment 
of 6.5 mm Transwell® polycarbonate 
inserts  (24 wells, 3 μm membrane 
pore size) (Corning, Costar, 
Madrid, Spain) and cultivated for 
10 ± 2 days. During cell growth 
and differentiation, the medium in 
both compartments was replaced 
three times a week. Confluence 
was controlled by measurement of 
transepithelial electrical resistance 
(TEER; Millicell ERS Ohmmeter, 
Millipore, Madrid, Spain) and by 
visually detecting cell layer integrity 
under the microscope. Co-culture 
experiments of differentiated 
Caco-2 cells and MDDCs were 
performed in duplicate in five 
independent experiments. On day 
10-12, MDDCs were added (1 x 
106 cells per well) in the basolateral 
compartment of the transwell, 
while Caco-2 cells were previously 
cultured in the apical compartment. 
The stimuli were added to the 
apical compartment representing 
the intestinal epithelium. Controls 
of basal cytokine production by 
non-stimulated cells were run 
simultaneously in each assay. The 
following stimuli were added: 
 
Target gene Sequence (5'–3') References 
ZO-1 ATCCCAAATAAGAACAGAGC (11) 
 GGCGTTACATCTAATAAAGC  
Occludin GGTGTGGGAAGCAGGACCGC This study 
NM-002538.2 
 
 GGAGAGGTGGACGCGGGAGT  
GAPDH CCACCCATGGCAAATTCCATGGCA (27) 
 TCTAGACGGCAGGTCAGGTCCACC  
   
   
Table 1. Primers used in the study to analyze gene expression by RT-PCR.
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gliadin (100 μg/ml), bacterial 
cell suspension (106 CFU/ml) or 
bacterial cell suspension (106 CFU/
ml) plus gliadin (100 μg/ml). 
Purified lipopolysaccharide (LPS) 
from Salmonella enterica subsp. 
enterica serotype Typhimurium 
(Sigma, St. Louis, MO) was used at a 
concentration of 1 μg/ml as positive 
control. Supernatants were collected 
after 24 hours and were stored 
at – 20º C until cytokines were 
analyzed. Cells were also recovered 
and immediately kept at -80ºC for 
further RNA extraction and gene 
expression analyses.  
Statistical analyses
Statistical analyses were performed 
using SPSS version 17.0 software 
(SPSS Inc, Chicago, IL, USA). 
The Levene test was run in order 
to establish the homogeneity of 
variances and data distribution. Data 
distribution was not normal and 
variances were not homogeneous; 
therefore, Mann-Whitney U test 
was used to assess the effect of 
each variable. Data are expressed as 
medians and quartiles. Significant 
differences were established at a P 
value less than 0.05. 
RESULTS
MDDC morphologic changes after 
interaction with intestinal bacteria 
Actin cytoskeleton is known 
to be crucially involved in cell 
adhesion and spreading, which in 
turn influence DC activation and 
maturation. Therefore, we evaluated 
the possible rearrangements of the 
actin cytoskeleton of MDDCs after 
stimulation with different intestinal 
bacteria (commensal and pathogens). 
As previously reported and shown in 
Figure 1, non-stimulated immature 
MDDCs exhibited the classical 
podosome structures, characterized 
by the actin-dense core which is 
surrounded by ring of cytoskeletal 
proteins (28, 29). On the contrary, 
gliadin fragments caused podosome 
dissolution and cytoskeletal 
remodeling as shown in Figure 1. 
Interestingly, MDDCs stimulated 
with B. bifidum CECT 7365 for 24 h 
were morphologically similar to non-
stimulated cells. In a cell fraction 
stimulated with B. longum CECT 
7347 for 24 h, podosome dissolution 
was observed, although a substantial 
portion of B. longum-stimulated cells 
still exhibited morphology similar to 
unstimulated cells or cells stimulated 
with B. bifidum CECT 7365. In 
contrast, MDDCs stimulated with 
Shigella CBD8 and E. coli CBL2 
presented complete loss of podosomes 
and a strong amount of actin-rich 
protrusions, as observed for LPS-
treated cells (Figure 1). MDDCs 
treated with LPS (1 μg/ml) for 24 h 
also displayed an evident induction 
of actin-rich protrusions (dendrites) 
and complete podosome dissolution. 
However, the enterobacteria-treated 
cells appeared more spread with 
irregular shapes, comparing to more 
cell-rounded morphology induced 
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Figure 1. Morphology and cytoskeletal remodeling in MDDCs plated on fibronectin-coated 
coverslips and under the effect of different stimuli: Immature MDDCs (iDC), gliadin (100 μg/ml), 
LPS (1 μg/ml), B. bifidum CECT 7365 (106 CFU), B. longum CECT 7347 (106 CFU), Shigella 
CBD8 (106 CFU) and E. coli CBL2 (106 CFU) for 24 h. 
by LPS. The observed changes seem 
to be in line with those observed 
with the dynamic monitoring of cell 
adhesion and spreading described 
below. The enterobacteria seemed to 
induce cytoskeletal remodeling and 
mediate the morphological transition 
from immature DC to mature DC, 
whereas activation of MDDCs by 
bifidobacteria was weaker. 
MDDC adhesion and spreading 
influenced by intestinal bacteria 
DC activation and maturation 
affects cell adhesion and spreading 
(30, 31). Therefore, to characterize 
the immunoregulatory potential 
of different intestinal bacteria 
(commensal and potential 
pathogens), we further sought to 
non-invasively determine their 
impact on MDDC adhesion and 
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spreading. To achieve this aim, 
impedance measurements were 
employed using the xCelligence 
system in fibronectin-coated E-plates. 
Indeed, the interaction of cells with 
fibronectin-coated microelectrodes 
in the E-plate generates an 
impedance change reflected in the CI 
that is proportional to the number of 
adhered cells and overall morphology 
and adhesion quality of the cells 
(31). The stimulation of DCs with 
maturation-inducing agents (e.g. 
a cocktail of pro-inflammatory 
cytokines, LPS,  gliadins or poly 
I:C) resulted in a rapid increase in 
CI values corresponding to elevated 
cell adhesion and spreading when 
compared to non-stimulated cells. 
Within 24 h, however, the CI of 
stimulated DC dropped below the 
CI of control cells due to progressing 
maturation and cell rounding up 
(representative example shown in 
Figure 2A).It should be noted that 
the absolute CI values differ among 
individual donors (e.g. for iDC 
ranges from 0.5.to 1.2). However,   
the pattern  of   induced changes  in 
response to tested components  was 
very similar  across various donors 
(see representative experiments Fig. 
2, B and C). Importantly,  addition 
of bifidobacteria (B. longum CECT 
7347 and B. bifidum CECT 
7365) led to a slight increase in 
cell adhesion (Figure 2B), while 
exposure to enterobacteria (E. coli 
CBL2 and Shigella CBD8) yielded 
greater activation of cell adhesion and 
spreading (Figure 2C). Although the 
CI curves of enterobacteria exhibited 
a maximum which was followed by 
CI decrease, they did not generally 
drop below the CI of control cells 
within 24 h (6 experiments out 
of 9). Overall, the results indicate 
stronger activation of MDDCs by 
enterobacteria than by bifidobacteria 
consistently with data demonstrated 
in Figure 1. When gliadins were 
added to bifidobacteria, a slight 
increase in MDDC adhesion and 
spreading was observed, compared 
to stimulation with bifidobacteria 
alone. In contrast, the addition of 
gliadins to enterobacteria did not 
significantly change their response 
curves (data not shown).
MDDCs cytokine production in 
response to intestinal bacteria and 
gliadin
Cytokine production by MDDCs 
after stimulation with cell suspensions 
of different bacterial strains is shown 
in Figure 3. All the stimuli applied 
induced a higher production of 
IL-10, IL-12 and TNF-α (P ≤ 
0.001-0.001) in comparison with 
control cells. However, only Gram-
negative bacteria (E. coli CBL2 and 
Shigella CBD8) and LPS induced 
a greater secretion of IFN-γ than 
non-stimulated cells (P ≤ 0.001-
0.028). Gliadin also increased IFN-γ 
secretion to a greater extent than B. 
bifidum CECT 7365 (P = 0.025). 
When comparing different bacterial 
strains, the Gram-negative bacteria 
Shigella CBD8 induced a greater 
secretion of IL-12, TNF-α and 
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Figure 2. Representative data are shown for the different attachment and spreading of MDDCs 
(from 3 different donors) under different stimuli, in a 24 h time-course experiment. The attachment 
and spreading of MDDCs is expressed as CI/Time (see Materials and Methods). iDCs form donor 
A were exposed to gliadin, LPS; polyI:C and cocktail of cytokines; from donor B to bifidobacteria 
and from C to enterobacteria; Shigella CBD8 was used with B and C cells for comparison.  
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IFN-γ than the Gram-positives B. 
bifidum CECT 7365 and B. longum 
CECT 7347 (P= 0.028 and P= 
0.025, P= 0.028 and P<0.001, P= 
0.009 and P= 0.016, respectively). 
Similarly, the Gram-negative bacteria 
E. coli CBL2 induced a greater 
secretion of IL-12 and IFN-γ than B. 
bifidum CECT 7365 (P=0.004 and 
P=0.006, respectively) and B. longum 
(P=0.004 and P=0.006, respectively). 
Moreover, E. coli CBL2 induced a 
greater secretion of TNF-α than B. 
longum CECT 7347 (P= 0.003). 
Shigella CBD8 and E. coli CBL2 
also induced a greater secretion 
of IL-10 than B. longum CECT 
7347 (P= 0.018). B. longum CECT 
7347 induced lower production 
of TNF-α than B. bifidum CECT 
7365 (P<0.001). IL-21 secretion 
was extremely low and no differences 
were detected between the different 
stimuli applied (data not shown). IL-
15 was not detected in supernatants 
of stimulated MDDCs. 
Cytokine production by MDDCs 
after stimulation with cell 
suspensions of different bacterial 
strains combined with gliadins is also 
shown in Figure 3. The effects of 
stimulating MDDCs with bacterial 
strains plus gliadins on cytokine 
production were similar to those 
exerted by the bacterial strains alone 
with some exceptions; the Gram-
positive B. longum CECT 7347 
plus gliadins reduced the IFN-γ 
production induced by gliadins 
alone (P=0.010). Furthermore, B. 
longum CECT 7347 induced higher 
secretion of IL-10 when combined 
with gliadin than when used as sole 
stimulus (P= 0.045). No differences 
were detected for the other strains.
MDDCs surface molecule 
expression in response to intestinal 
bacteria and gliadin
MDDCs surface molecule expression 
is shown in Figure 4. Expression 
of all surface molecules, HLA-DR, 
CD-86, CD-40 and CD-83, was 
up-regulated by all stimuli applied 
when compared with non-stimulated 
cells (P<0.001-0.009). The Gram-
negative bacteria Shigella CBD8 
and E. coli CBL2 induced higher 
CD-86 and CD-40 expression than 
B. longum CECT 7347 (P=0.002 
-0.007). B. bifidum CECT 7365 
induced higher HLA-DR, CD-86, 
CD-40 and CD-83 expression than 
B. longum CECT 7347 (P=0.002 
-0.009). All stimuli combined with 
gliadins upregulated the expression 
of all surface markers in comparison 
with non-stimulated cells and the 
effects were similar to those exerted 
by the bacterial strains alone.  B. 
bifidum CECT 7365 and Shigella 
CBD8 plus gliadins induced higher 
CD-86 and CD-83 expression than 
gliadins alone (P=0.008-0.046). 
Likewise, E. coli CBL2 plus gliadins 
also induced higher CD-86 than 
gliadins alone (P=0.033). 
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Cytokine production and surface 
molecule expression by MDDCs 
co-cultured with Caco-2 cells 
stimulated with intestinal bacteria 
and gliadin
Cytokine production by MDDCs 
in co-culture with Caco-2 cells, 
after stimulation of Caco-2 cells 
with bacterial cell suspensions was 
evaluated (Supplementary Table 
1).The Gram-negative bacteria 
Shigella CBD8 and E. coli CBL2 
induced higher IFN-γ and TNF-α 
secretion by MDDCs than B. bifidum 
CECT 7365 (P=0.010-0.035). 
Shigella CBD8 also induced higher 
IFN-γ secretion (P=0.010) and E. 
coli CBL2 higher TNF-α secretion 
(P=0.088) by MDDCs than B. 
longum CECT 7347 although in the 
last case statistical significance was 
not reached. 
Cytokine production by MDDCs 
in co-culture with Caco-2 cells, after 
stimulation of Caco-2 cells with 
bacterial cell suspensions combined 
with gliadins, was also analyzed, 
but no differences were detected 
compared to cytokine production 
induced by each bacterial strain 
alone (Supplementary Table 2). No 
statistically significant differences 
were detected for IL-21, IL-15 and 
IL-12 production possibly due to the 
low concentrations detected. 
For surface marker expression in 
MDDCs co-cultured with Caco-2 
cells, significant effects were only 
detected when Shigella CBD8 was 
used to stimulated Caco-2 cells, 
which increased CD-83 expression 
by MDDCs compared to non-
stimulated cells (P=0.029), gliadins 
(P=0.029) and B. longum CECT 
7347 (P=0.029). No differences were 
detected among different stimuli 
or between each stimulus alone or 
the stimulus plus gliadins (data not 
shown).
TJ protein mRNA expression 
in cultures of Caco-2 cells and 
MDDC analyzed by RT-PCR
The effects of intestinal bacteria and 
gliadins on TJ protein expression in 
a differentiated monolayer of Caco-
2 cells were analyzed after 24 h of 
stimulation. In these conditions, the 
expression of ZO-1 and occludin 
genes differed significantly among 
different stimuli (Table 2). B. longum 
CECT 7347 alone significantly 
up-regulated ZO-1 expression 
compared with non-stimulated 
cells (P=0.005), LPS (P=0.009) and 
gliadins (P=0.009), whereas LPS 
and gliadins significantly down-
regulated ZO-1 expression compared 
to controls (P=0.005). Moreover, B. 
longum CECT 7347 up-regulated 
ZO-1 expression in comparison 
with B. bifidum CECT 7365 
(P=0.028). B. longum CECT 7347 
plus gliadins also increased ZO-1 
expression in comparison to gliadins 
alone (P=0.009) and B. longum 
CECT 7347 alone (P=0.047). 
Occludin expression followed a 
slightly different pattern, since 
gliadins did not significantly affect 
the expression. However, the other 
stimuli, including B. bifidum CECT 
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7365, E. coli CBL2, Shigella CBD8 
and B. longum CECT 7347, slightly 
down-regulated occludin expression 
(P=0.014-21) with the exception 
of LPS, which up-regulated it 
(P=0.014). On comparing different 
bacterial stimuli, Shigella CBD8 
decreased occludin gene expression 
to a lower extent than B. bifidum 
CECT 7365, B. longum CECT 7347 
and E. coli CBL2 (P=0.021). When 
combined with gliadins, B. bifidum 
CECT 7365 and Shigella CBD8 
decreased occludin expression to 
a significantly greater extent than 
the corresponding strains alone 
(P=0.021), whereas B. longum 
CECT 7347 significantly increased 
it compared to the strain alone 
(P=0.021). 
When gene expression of TJ proteins 
was analyzed in MDDCs co-cultured 
with Caco-2 cells, differences were 
detected for ZO-1 and occludin 
expression among different stimuli 
(Table 3), but not when MDDCs 
were cultured alone. In MDDCs 
co-cultured with Caco-2 cells, ZO-1 
gene expression was down-regulated 
by LPS (P<0.001) and gliadins 
(P=0.017) in comparison with non-
stimulated cells, while the effects 
of the bacterial strain tested were 
not significant due to their large 
variability. When the bacterial cell 
suspensions were combined with 
gliadins, differences were detected 
for Shigella CBD8 plus gliadins, 
which decreased ZO-1 expression 
in MDDCs as compared with 
Shigella CBD8 alone (P=0.043) or 
non-stimulated cells (P<0.001) or 
B. bifidum CECT 7365 (P=0.010). 
Furthermore, B. bifidum CECT 
7365 plus gliadins upregulated ZO-1 
expression compared to gliadins alone 
 
 
 
 
 
Stimuli ZO-1 (Min-Max) Occludin (Min-Max) 
Non-stimulated cells (control) 1.00 (1.0-1.0) 1.00 (1.0-1.0) 
B. bifidum CECT 7365 0.99 (0.40-1.14) 0.63 (0.5-0.8) 
B. bifidum CECT 7365 plus gliadins 0.81 (0.17-0.95) 0.39 (0.38-0.40) 
B. longum CECT 7347 1.18 (1.03-2.57) 0.66 (0.64-0.69) 
B. longum CECT 7347 plus gliadins 1.68 (1.48-3.81) 0.89 (0.70-1.09) 
E. coli CBL2 1.01 (0.28-1.27) 0.56 (0.44-0.71) 
E. coli CBL2 plus gliadins 1.70 (0.17-1.79) 0.57 (0.41-0.80) 
Shigella CBD8 1.81 (0.76-1.98) 0.91 (0.89-0.92) 
Shigella CBD8 plus gliadins 1.36 (0.46-1.46) 0.86 (0.84-0.89) 
LPS 0.76 (0.12-0.89) 1.35 (1.29-1.42) 
Gliadins 0.84 (0.09-0.99) 1.02 (0.98-1.06) 
Table 2: ZO-1 and occludin mRNA expression in differentiated monolayer of Caco-2 cells after 24 
h stimulation analyzed by RT-PCR.
Data are expressed as median with maximum and minimum of ΔΔCt values.
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(P=0.050). In relation to occludin 
gene expression in MDDCs co-
cultured with Caco-2 cells, the effects 
of gliadin alone were not significant, 
however LPS enhanced occludin 
expression in comparison with cells 
alone (P=0.050).  Moreover, B. 
longum CECT 7347 plus gliadins 
enhanced occludin expression in 
comparison to B. longum CECT 
7347 alone (P=0.010). 
DISCUSSION
This is the first study to provide 
evidence for the differential 
influence of intestinal bacteria and 
their interactions with gliadins on 
MDDCs morphology and dynamic 
attachment and spreading. These data 
may reflect the phenotypic changes 
DCs undergo, upon stimulation, 
associated with their maturation 
process and conversion from a 
tissue resident, antigen-capturing 
cell to a highly migratory antigen-
presenting cell (32, 33). Extensive 
changes in morphology, cytoskeletal 
organization and cell adhesion are 
considered indexes of the maturation 
and transition process that may 
ultimately influence T-cell activation 
(33). In particular, podosomes are 
sites of active matrix degradation, 
which promote cell migration and 
invasion, and their presence is 
peculiar to immature DCs, whereas 
mature DCs are loosely adherent 
and not forming podosomes on 
fibronectin but characteristic actin-
rich extensions (dendrites) that 
maximize the contact area with T-cells 
(33). In our study, Shigella CBD8, 
E. coli CBL2, LPS and gliadins 
induced major changes in MDDC 
morphology, which could reflect 
a mature phenotype, whereas B. 
 
 
 
 
 
Stimuli ZO-1 (Min-Max) Occludin (Min-Max) 
Non-stimulated cells (control) 1.00 (1.0-1.0) 1.00 (1.0-1.0) 
B. bifidum CECT 7365 1.41 (0.15-3.45) 1.26 (0.91-1.42) 
B. bifidum CECT 7365 plus gliadins 4.43 (0.53-11.08) 1.20 (1.20-1.21) 
B. longum CECT 7347 0.72 (0.16-5.54) 0.77 (0.42-1.16) 
B. longum CECT 7347 plus gliadins 3.26 (0.21-7.81) 2.20 (1.91-2.57) 
E. coli CBL2 1.20 (0.22-4.57) 1.07 (1.04-1.11) 
E. coli CBL2 plus gliadins 1.51 (0.43-3.27) 1.68 (1.58-1.77) 
Shigella CBD8 0.82 (0.20-2.25) 1.28 (1.11-1.36) 
Shigella CBD8 plus gliadins 0.48 (0.11-0.81) 1.02 (0.99-1.06) 
LPS 0.0027 (0.0027-0.59) 2.47 (2.42-2.52) 
Gliadins 0.58 (0.11-1.03) 1.18 (1.13-1.23) 
Table 3: ZO-1 and occludin mRNA expression in MDDCs co-cultured with stimulated Caco-2 
cells analyzed by RT-PCR. 
Data are expressed as mean and standard deviation of ΔΔCt values.
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bifidum CECT 7365 and B. longum 
CECT 7347 did not induce evident 
morphological changes. These results 
are in agreement with those by 
Chladkova et al. (15) who described 
that gliadin is able to induce the loss 
of podosomes in a dose-dependent 
manner and that gliadin fragments 
induce cytoskeletal remodeling and 
mediate the morphological transition 
from immature DC to mature DC.
These morphological data are in 
agreement with dynamic adhesion 
and spreading assays. When DCs are 
immature they are highly adhesive 
and possess podosomes, then on 
undergoing maturation they start 
to change their morphology, lose 
podosomes and acquire dendrites. 
We observed that Shigella CBD8, 
with and without gliadins, induced 
faster and more remarkable changes 
in adhesion and spreading in 
MDDCs than the other stimuli. 
E. coli CBL2 also induced changes 
while the bifidobacterial strains, 
particularly B. bifidum CECT 7365, 
had no significant effect on the cells 
and even reduced the effect of gliadins 
resembling the situation of non-
stimulated cells (data not shown). 
The attachment and spreading 
experiments show the interaction of 
MDDCs with fibronectin, which 
composes ECM components and 
interacts specifically with the cells 
through specialized cell-surface 
receptors called integrins. The latter 
recognize and bind to specific motifs 
within the ECM proteins, thereby 
mediating the ability of cells to 
specifically adhere to and interact 
with the appropriate matrix protein 
(31). Integrins also initiate an 
intracellular signaling cascade that 
directs cellular processes such as cell 
survival, proliferation, differentiation 
and migration (31, 34). 
Overall, the differential effects of the 
intestinal bacteria tested on MDDCs 
morphology, adhesion and spreading 
suggest that enterobacteria, in 
particular, or their cell-wall 
components could contribute 
to inducing a full phenotypic 
and functional DC maturation 
process and thus enhance antigen 
presentation and stimulation of 
specific T-cell responses. 
Subsequently, we also evaluated the 
effects of different intestinal bacteria 
on direct markers of MDDC 
immune function, such as cytokine 
production and surface molecule 
expression, as well as their ability to 
modify the response to gliadin. The 
two enterobacteria and, especially, 
Shigella CBD8 that represent a real 
pathogen triggered a stronger Th1-
type inflammatory response, with 
particularly high IFN-γ, TNF-α 
and IL-12 secretion compared to 
the effects of the two bifidobacterial 
strains tested. Similarly, E. coli CBL2 
also induced greater IFN-γ and IL-12 
secretion than the two bifidobacterial 
strains tested. These effects on the 
cytokine profile followed a similar 
trend to those detected in PBMCs 
in our previous study (20), but were 
more pronounced. In addition, this 
study shows that gliadin stimulation 
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induced higher IFN-γ secretion than 
B. bifidum CECT 7365, which was 
not evident in previous studies with 
PBMCs (20). Moreover, B. longum 
CECT 7347 plus gliadins reduced 
the levels of IFN-γ production 
induced by gliadins alone and also 
induced higher secretion of IL-10 
than when the bacterium was used as 
the sole stimulus. This would suggest 
its potential role in the regulation of 
the aberrant immunological response 
induced by wheat gluten proteins. In 
relation to MDDC surface molecule 
expression, the differences between 
enterobacteria and bifidobacteria 
were not as remarkable as those 
detected in PBMCs (20). However, 
B. longum CECT 7347 clearly 
induced lower expression of most 
of the activation markers when 
compared with Shigella CBD8, E. 
coli CBL2 and B. bifidum CECT 
7365 in the presence or absence of 
gliadins. 
Our study also examined the role 
of the epithelial cell layer in the 
response of MDDCs to different 
stimuli. Similar results were observed 
when MDDCs were co-cultured 
with differentiated Caco-2 cells 
and stimulated with gliadin and 
different bacterial strains. Unlike 
bifidobacteria, enterobacteria 
induced higher production of 
pro-inflammatory cytokines, with 
predominant increases in IFN-γ and 
TNF-α, which could contribute to 
the intestinal inflammatory milieu 
characteristic of CD patients. 
Accordingly, stool samples of CD 
patients, representing an unbalanced 
microbiota, were also shown to induce 
a pro-inflammatory cytokine pattern 
characterized by high levels of IFN-γ 
and TNF-α production by PBMCs. 
However, this imbalance could be 
reversed by the two bifidobacterial 
strains tested in this study (35), 
suggesting that intestinal bacteria 
could influence the polarization of 
the immunological responses in the 
presence of factors influencing CD, 
including the luminal bacterial load 
and wheat-gluten-derived peptides. 
The effects of different bacterial 
strains and gliadins on expression of 
TJ-related proteins in Caco-2 cells 
were also studied as CD has also 
been associated with increases in 
intestinal permeability and changes 
in expression of TJ related proteins 
(36, 37). In this study, gliadin and 
LPS were shown to reduce ZO-1 
gene expression in Caco-2 cells, while 
B. longum CECT 7347 increased 
ZO-1 expression alone and in 
combination with gliadins, reversing 
this adverse effect. The effects of the 
different bacterial strains on occludin 
expression followed opposite trends, 
but their meaning in the context 
of CD is unclear since gliadins did 
not modify occluding expression. 
Previous in vitro studies, using 
monolayer Caco-2 cell cultures 
and three-dimensional Lovo cell 
line culture, indicated that gliadin 
directly damages TJ, for example 
decreasing expression of ZO-1 
and occluding proteins, thereby 
contributing to gut barrier disruption 
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(37, 39). In patients with active 
coeliac disease, both ZO-1 protein 
levels and mRNA were reduced and 
F-actin organization was disrupted 
(40). Similarly, Drago et al. (38) 
reported significant lower expression 
of both ZO-1 and occluding genes in 
the intestinal tissues obtained from 
CD patients, compared to non-CD 
controls, which represent the effect 
of chronic exposure to gluten. 
DCs expressing TJ proteins are 
reported to open the TJ between 
epithelial cells and directly take up 
microorganisms or other antigens, 
thus contributing to antigen 
translocation, while preserving 
integrity of the epithelial barrier 
(11, 41). Thus the effects of different 
bacterial strains and gliadins on the 
expression of TJ related proteins 
in MDDCs were also evaluated in 
our study. Differences in TJ protein 
gene expression on MDDCs among 
different stimuli were only detected 
when these cells were co-cultured 
with Caco-2 cells. These findings 
suggest that the interactions with 
Caco-2 cells play an important role 
in MDDC recognition of different 
stimuli, which may lead to different 
TJ protein expression during trans-
epithelial exchanges. In this context, 
previous studies demonstrated that 
particle uptake by MDDCs was also 
higher in co-cultures with epithelial 
cells (41).  LPS and gliadins reduced 
ZO-1 expression in agreement with 
the effects on Caco-2 cells. However, 
B. bifidum CECT 7365 plus gliadins 
upregulated ZO-1 expression 
compared to gliadins alone. In 
relation to occludin, LPS increased 
the expression of this protein gene 
while gliadins and most of the 
bacteria did not exert significant 
effects. Only B. longum CECT 7347 
combined with gliadin increased 
occludin expression compared 
with the strain alone. Bacterial 
components, such as LPS, are 
reported to trigger the reorganization 
of TJ proteins via up-regulation of 
ZO-1 and slight down-regulation 
of occludin, allowing DCs to detach 
from junctions with epithelial cells 
and migrate to draining lymph 
nodes (11). By contrast, in our study 
the effects of LPS on ZO-1 and 
occludin expression and those of the 
enterobacteria, which represent an 
LPS stimulus, on occludin expression 
followed the opposite trend. These 
differences could be explained by 
differences in mRNA expression 
of these genes at different stages of 
DCs maturation and exposure time 
as indicated previously (11). In our 
study, the effects of B. longum CECT 
7347 on ZO-1 expression were 
opposite to those of LPS. This would 
suggest that this bifidobacterial 
strain could play a positive role 
in the regulation of TJ related 
protein expression; however, further 
investigations are required to provide 
direct evidence of the physiological 
significance of the effects detected in 
TJ protein gene expression.
In conclusion, this study confirms 
that enterobacteria could exert 
pathogenic effects similar to those 
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exerted by gliadins, contributing to 
phenotypic DC maturation. This is 
reflected in morphological changes 
and increased attachment/spreading 
ability, and the induction of high 
inflammatory cytokine production, 
particularly of IFN-g. In contrast, B. 
bifidum CECT 7365 and B. longum 
CECT 7347 did not cause gliadin-
induced morphological changes, 
and induced adhesion and spreading 
ability of MDDCs and inflammatory 
cytokine production to a lesser extent. 
In particular, B. longum CECT 
7347 reduced IFN-γ production 
induced by gliadins and increased 
IL-10 secretion when both stimuli 
were combined and also reversed the 
gliadin-reduced ZO-1 expression in 
Caco-2 cells. Altogether this could 
ultimately contribute to ameliorating 
the response to gluten peptides in the 
context of CD. Based on these results, 
we suggest that specific components 
of the gut microbiota may influence 
phenotypic and functional 
maturation of DCs differently and 
their interactions with epithelial 
cells, and could ultimately define the 
role of DCs in T-cell activation and 
disease progression.
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Influence of Bifidobacterium longum 
CECT 7347 and gliadin peptides on 
intestinal epithelial cell proteome
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ABSTRACT 
Celiac disease is an enteropathy caused by an abnormal immune response 
to cereal gluten proteins (gliadin). To unravel the possible role of the 
interactions between gliadin peptides and specific intestinal bacteria, 
the response of intestinal epithelial (Caco-2) cells to gliadin subjected to 
gastrointestinal digestion in the presence or absence of Bifidobacterium 
longum CECT 7347 has been studied. Changes in the proteome of Caco-
2 cells were determined by 2DE and MALDI-TOF. Gliadins digested 
without B. longum altered the expression of a higher number of proteins 
than in the presence of the bacterium (21 versus 9) and these proteins 
were involved in disorganization of cell cytoskeleton, inflammation and 
apoptosis. Gliadins digested in the presence of the bacterium influenced 
the production of proteins involved in calcium homeostasis and cell 
survival and function. Therefore, B. longum CECT 7347 might ameliorate 
gliadin toxicity and modify the responses of intestinal epithelial cells to 
the gliadin challenge.
Keywords: Bifidobacterium longum, celiac disease, Caco-2 cells, probiotic, 
proteome
INTRODUCTION
Cereal gluten proteins (gliadin a, b, 
g and v ) are the main environmental 
factors causative of celiac disease 
(CD) pathogenesis. The incomplete 
hydrolysis of gliadin by human 
enzymes during gastrointestinal 
digestion leads to the generation of 
peptides able to trigger cytotoxic and 
inflammatory signals in intestinal 
epithelial cells of CD patients (1). 
Clinical manifestations of the disease 
often include intestinal symptoms and 
nutrient malabsorption associated 
with severe mucosal damage (2). 
Currently, the only available therapy 
for CD patients is the adherence 
to a strict life-long gluten-free diet. 
However, compliance with this 
dietary recommendation is complex 
and other alternative or adjuvant 
strategies are needed (3). 
Alterations in the composition of 
the gut microbiota of CD patients 
are characterized by decreased 
Bifidobacterium numbers (4, 5). 
The association of imbalances in the 
intestinal microbiota and the positive 
reported roles that bifidobacteria 
plays on intestinal health has led 
to propose the use of probiotics as 
part of additional and alternative 
nutritional strategies for improving 
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the quality of life of CD patients. 
Certain strains of the Bifidobacterium 
genus effectively reduced in vitro the 
toxicity and inflammatory potential 
of gliadin-derived peptides (6). 
The positive effect of bifidobacteria 
was attributed to their proteolytic 
capacity on gliadin peptides; 
however, the effects produced by 
different bifidobacteria seemed to be 
strain-dependant demonstrating the 
most positive effect produced by B. 
longum CECT 7347 strain, which 
motivated the present study. 
Gliadin-derived peptides are thought 
to stimulate enterocytes (7, 8) and 
macrophages (9) via specific surface 
receptors such as the chemokine 
CXCR3, a 7-transmembrane 
G-protein, present in the brush 
border membrane, causing the up-
regulation of pro-inflammatory 
cytokine expression (10, 11). 
These effects have been linked 
to the activation of the nuclear 
transcription factor kappa-B (NF-
kB) pathway in the small intestinal 
mucosa of CD patients (12). After 
sensing an inflammatory stimulus, 
the inhibitor IκB is phosphorylated 
triggering its degradation, thereby 
allowing the translocation of NF-
κB to the nucleus where it induces 
the expression of a variety of genes 
involved in inflammation, immune 
regulation, and cell survival and 
proliferation (13). Furthermore, 
alterations in the integrity and 
function of the intestinal barrier have 
also been associated to gliadin toxicity 
(14). Gliadin-derived peptides can 
mediate the disorganization of tight 
junction-related proteins leading 
to increased intestinal permeability 
(15), and expression (mRNA) of 
ionic channels and the chemokine 
CXCR3 receptor (6, 7). However, 
there is limited knowledge of 
the possible role of the interplay 
between gliadin peptides and 
intestinal bacteria in the activation of 
pathogenic or protective responses in 
the intestine. 
The objective of this study was to 
evaluate the changes in the proteome 
of Caco-2 cells, widely used as human 
intestinal model, exposed to gliadin 
digested in vitro, in the presence or 
absence of B. longum CECT 7347, 
and in response to the bifidobacteria 
alone. The ultimate goal of the study 
was to gain a better understanding of 
early alterations induced by gliadin 
in enterocytes, and their possible 
modulation by components of the 
intestinal microbiota.
MATERIAL AND METHODS
Bacterial cultures
Bifidobacterium longum CECT 7347 
was isolated from faeces of healthy 
infants as described elsewhere (15). 
The bacterial cultures were grown 
in Man-Rogosa-Sharpe broth and 
agar (Scharlau, Barcelona, Spain) 
supplemented with 0.05% (w/v) 
cysteine (MRSC) (Sigma, St. Louis, 
MO), and incubated at 37ºC under 
anaerobic conditions (AnaeroGen, 
Oxoid, Basingstoke, UK) for 24 h. 
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The studies employed bacterial cell 
suspensions with absorbance of 0.5 
(l, 600 nm) corresponding to 108 
colony forming units (CFU)/mL.
Cell culture conditions
The human colon carcinoma (Caco-
2) cell-line was obtained from the 
American Type Culture Collection 
(Rockville, MD, USA) at passage 
17, and used in experiments at 
passages 33-42. Caco-2 cells were 
grown in DMEM (AQ-Media, 
Sigma, USA) containing 4.5 g 
L-1 glucose, and supplemented 
with 25 mM 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid 
(HEPES) buffer (Biowhittaker, 
Schiedam, Holland), 10% (v/v) fetal 
bovine serum (Sigma), 1% (v/v) non-
essential amino acids (Biowhittaker), 
1% (v/v) L-glutamine (Sigma) 
and 1% (v/v) antibiotic solution 
(penicillin, streptomycin and 
fungizone) (Sigma). Cells were 
maintained at 37 °C in 5% CO2/ 
95% relative humidity and culture 
medium was changed every 2 days 
(6).
For experimental studies, Caco-2 cells 
were seeded at densities of 50,000 
cells/cm2 onto 6-well plates (Costar, 
Corning, USA). Cell cultures were 
grown with DMEM, and culture 
medium was changed every 2 days. 
Experiments were performed 5 days 
post seeding. Cell cultures exposed to 
DMEM were used as controls.
In vitro digestion of gliadin
The gastrointestinal digestion process 
was simulated as previously described 
(16), using porcine pepsin (P-
7000, Sigma) (800-2500 units/mg 
protein), pancreatin (P1750, Sigma) 
(activity 4×USP specifications) 
and bile (B3883, Sigma). Three 
mL of a saline solution (140 mM 
NaCl, 5 mM KCl adjusted to pH 
3) was added to aliquots (150 mg) 
of a commercially available gliadin 
extract (G3375, Sigma). The mixture 
was immersed in a water bath (60 
ºC) for 30 minutes with gentle 
agitation. Once the samples were 
at room temperature, gastric and 
intestinal digestions were conducted 
on a rocking platform shaker 
placed in an incubator (37°C/5% 
CO2/95% relative
 humidity). After 
the gastric digestion (pepsin in 0.1 
M HCl/pH 3/1h), the intestinal 
digestion (pancreatin-bile in 0.1 
M NaHCO3/pH 6.8-7.0/2 h) was 
carried out in the upper chamber 
of a two-chamber system in 6-well 
plates formed by fitting the bottom 
of a Transwell insert ring (Costar) 
with a 15,000 molecular mass cut-
off dialysis membrane (Spectra/Por 
2.1, Spectrum Medical, Gardena, 
CA, USA). Aliquots (1.5 mL) of the 
gastro-intestinal digests, inoculated 
or not with bacterial cell suspensions 
(108 CFU/mL), were loaded into 
the upper chambers and 1 mL of 
saline solution (pH 7) was added 
to the bottom chamber. Afterwards, 
the inserts were removed and total 
protein content in the dialysates was 
quantified using a Lowry method 
based on a commercial kit (TP0200, 
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Sigma). 
Toxicity experiments
Caco-2 cell viability in cultures 
exposed (6 h) to digested gliadin 
(0.25 mg/mL), inoculated or not 
with B. longum CECT 7347, were 
determined by the neutral red 
(NR) (3-amino-7-dimethylamino-
2-methylphenazine hydrochloride) 
(Sigma) uptake assay (6). The culture 
medium was removed and kept to 
determine cytokines as described 
below. Cells were washed twice with 
phosphate buffer saline (PBS) at pH 
7.2 (Sigma) and NR uptake was 
measured using a commercial kit 
(No. 7H092, Sigma) at 540 nm with 
background subtraction at 690 nm. 
Control cells exposed to DMEM 
were analyzed in every assay.
Analysis of cytokines
Tumor necrosis factor (TNF)-a 
(eBioscience Inc, San Diego, 
CA, USA), interleukin (IL)-1b 
(eBioscience) and IL-10 (eBioscience) 
were determined in the supernatant 
from cell cultures by ELISAs 
according to the manufacturers’ 
instructions. The results of the ELISA 
assays are expressed as picograms per 
mL (pg/mL). 
Protein Extraction and 2-DE 
separation
Caco-2 cells were exposed for 6 hours 
to digested gliadins (0.25 g/mL), 
inoculated or not with B. longum 
CECT 7347, or to the bifidobacteria 
(108 CFU/mL). The culture 
supernatant was removed and kept 
to determine cytokines as described 
below, and cells were washed twice 
with PBS for proteome analyses (pH 
7.2) (Sigma). 
Protein extraction was performed as 
described elsewhere (17) by pipetting 
with lysis buffer [7 M urea (GE 
Healthcare, Princeton, USA), 2 M 
thiourea (GE Healthcare), Nonidet 
p-40 (USB Corporation, Queveland, 
USA) (1% v/v), and protease 
inhibitors (Roche, Complete 04 693 
116 001)]. After centrifugation at 4 
°C and 11,000 g for 10 min, total 
protein content was determined as 
previously described. Aliquots (200 
μg of protein/2 μL) were mixed with 
rehydration solution (340 mL) [7 M 
urea, 2 M thiourea, DTT (Fluka, 
Arjeplog, Sweden) (0.2%, v/v), 
Nonidet p-40 (1%, v/v), Pharmalyte 
3-10 (GE Healthcare) (1%, v/v) and 
bromophenol blue] and loaded in the 
dry polyacrylamide gel strips with 
an immobilized pH gradient (IPG) 
(GE Healthcare, ImmobilineTM 
DryStrip pH 3-10 NL, 18 cm). 
The IPG strips were covered with 
mineral oil (GE Healthcare) and 
kept at room temperature overnight. 
Protein separation according to the 
isoelectric point (pI) was conducted 
with an Ettan IPG-Phor II cuvette 
and the program was visualized 
through Ettan control software 1.0. 
Isoelectric focusing (IEF) was carried 
out under the following conditions: 
step 1, increase from 0 to 500 V in 
5 h; step 2, 500 V for 5 h; step 3, 
increase from 500 to 3,500 V in 
75
9.5 h; and step 4, 3,500 V for 4 h. 
Focused IPG strips were equilibrated 
with equilibration buffer [50 mM 
Tris-HCl (pH 8.8) (Sigma), SDS 
(2%, v/v), 6 M urea, glycerol (30%, 
v/v), dithiothreitol (DTT) (1%, v/v) 
and iodoacetamide (IAA) (Sigma) 
(2.5%, w/v)]. The second dimension 
was run (Ettan Dalt Six cuvette) in 
pairs side by side. The strips were 
sealed with an agarose solution 0.5% 
(w/v) and run overnight at a constant 
voltage in a polyacrylamide gel (Bio-
Rad, California, USA) (acrylamide-
bisacrylamide, 12.5%-0.27%, 2.2 
C). The analyses were performed in 
triplicate for each treatment.
 
Tryptic digestion and analysis of 
protein spots
Two dimensional (2-D) gels of 
independent triplicates of each 
treatment were revealed by silver 
staining as described elsewhere (18). 
The stained gel was digitally scanned 
and spot detection, quantification 
and analysis were managed using 
PDQuest software (Bio-Rad). 2-D 
gel data were normalized by dividing 
each spot quantity by the total of all 
of the valid spots in the 2-D gel image 
to obtain a normalized spot quantity 
value. For each matched spot, the 
mean of the values from three 2-D 
gels was calculated. The differences in 
protein expression between controls 
and treated groups were considered 
statistically significant at P < 0.05 
applying the Student’s t test. Gel 
spots were excised from the gels using 
biopsy punches. Proteins selected 
for analysis were in-gel reduced, 
alkylated, and digested with trypsin 
(Promega, Madison, WI). Briefly, 
spots were washed twice with water, 
shrunk for 15 min with acetonitrile 
(ACN) 50% (v/v), and dried in a 
vacuum centrifuge for 30 min. After 
reduction with 10 mM DTT in 25 
mM NH4HCO3 for 30 min at 55 
°C, the samples were alkylated with 
55 mM IAA in 25 mM NH4HCO3 
in ACN 50% (v/v) for 20 min. Then, 
samples were dehydrated with ACN 
100% for 5 min and digested with 
12.5 ng/mL sequencing grade trypsin 
(Promega) in 25 mM NH4HCO3 
(pH 8.5) for at least 16 h at 37 °C.
Identification of peptides and 
database search
Peptide analyses were performed 
using an Applied Biosystems 
4700 Proteomics Analyzer mass 
spectrometer (Applied Biosystems, 
Framingham, MA) equipped with 
a 355 nm pulsed nitrogen laser and 
operated in reflectron positive ion 
mode as previously reported (19). 
Briefly, the digested samples were 
mixed with a 5 mg/mL α-Cyano-
4-hydroxycinnamic acid (CHCA) 
matrix solution and dissolved in 
ACN 50% (v/v) with formic acid 
0.1% (v/v). The indicated collision 
cell pressure was increased from 
4.0 × 10-8 mbar (no collision gas) 
to 6.6 × 10-7 mbar. At a resolution 
above 10,000 in MS mode, the 
monoisotopic peptide signals could 
be accurately mass measured (<50 
ppm). The mass spectrometry (MS) 
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and MS/MS spectrum data of 
tryptic peptides were obtained from 
MALDI-TOF MS in the reflector 
mode and used to search for protein 
candidates in SwissProt and/or 
National Center for Biotechnology 
Information (NCBI) databases using 
MASCOT v 2.3. Only those spots 
that were found in all the independent 
replicates were considered for further 
protein fingerprinting and database 
interrogation. We determined that a 
protein was correctly identified if the 
search results satisfied the following 
criteria: (i) protein is from the correct 
species (Homo sapiens); (ii) peptide 
mass tolerance of 50 ppm; (iii) MS/
MS ion mass tolerance of 0.25 Da; 
(iv) allow up to one missed cleavage; 
(v) variable modifications considered 
were Cys as S-carbamidomethyl 
derivative and Met in oxidized form.
Statistical analysis
One-way analysis of variance 
(ANOVA) and the tukey post test 
were applied. Statistical significance 
was established at <0.05 for all 
comparisons. SPSS v.15 software 
(SPSS Inc., Chigado, USA) was used 
for the statistical analysis.
RESULTS AND DISCUSSION 
A recent proteomic approach 
demonstrated that Caco-2 cells, 
although they have a tumoral origin, 
express proteins that are characteristic 
of human intestinal epithelium at 
comparable levels to small intestinal 
scrapings supporting their use to 
mimic the small intestine (20). 
Representative 2-D gels of Caco-
2 cell proteomes after the different 
treatment are shown in Figure 1. The 
proteome of cell cultures exhibited 
different protein expression patterns 
(Table 1). 
In Caco-2 cultures exposed to gliadin 
digested without B. longum CECT 
7347 the spots that were up-regulated 
included proteins that participate 
in the cellular signalling of gliadin 
(G12); proteins of the actin filaments 
and cycle progression (G13), proteins 
of the outer nuclear membrane that 
are linked to intermediate filaments 
(G9) and proteins associated with 
microtubules (G6 and G5); proteins 
that regulate apoptosis via apoptotic 
protease activating factor 1 (APAF-1) 
and stress-induced apoptosis (G20); 
and proteins that participate in the 
cross-talk between intestinal and 
immune cells (G15 and G17).
The up-regulation detected in 
regulator G-protein signalling 5 
(G12) could reflect the cellular 
response to counteract the cytotoxic 
effect of gliadin through their 
interaction with the CXCR3, a 
7-transmembrane G-protein coupled 
receptor (7). This result is concordant 
with the significant inhibition of 
NF-kB activation mediated by both 
G-protein coupled receptor kinase-2 
and -5 reported in other studies 
(21). It has been also reported that 
gliadin induced deterioration of 
actin cytoskeleton and function of 
intestinal proteins in Caco-2 cells 
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(22). The up-regulation of proteins 
such as Sorting nexin-20 (G15) in 
response to the gliadin challenge 
could be related to the activation 
of interactions between intestinal 
epithelial cells and immune cells. 
This protein cycles P-selectin 
glycoprotein ligand 1 (PSLG1) into 
endosomes, via high affinity calcium-
dependent interactions with E-, P- 
and L-selectins (23). Enterocytes, 
which express human leukocyte 
antigen (HLA)-DR proteins, are 
capable of processing transcytosing 
Figure 1: 2-D gel images of the proteins extracted from the Caco-2 cells exposed to gliadin (A) and 
gliadin inoculated with B. longum CECT 7347 (B). The first dimension was run on an inmobilized 
pH gradient (3-10) and the second dimension resolved in a SDS-PAGE 18 cm gel. Proteins were 
visualized by silver staining. Images show one representative gel of three independent samples. 
Arrows refer to spots that have been identified by MALDI-TOF MS. The name of the spots 
corresponds to the nomenclature used in Table 1.
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Table 1. List of identified protein spots of Caco-2 cultures exposed to digested gliadin, inoculated 
(GB) or not (G) with B. longum CECT 7347, and to B. longum CECT 7347 (108 CFU/mL) alone 
(B) showing differential production compared to control cultures. 
 
        Protein identified (Mr/PI) a Accession number b 
Score/ 
peptides 
matched 
(%) 
Seq 
Cover  
Express
ion to 
control c 
G1 AN1-type zinc finger protein 3 (26023/7.42) Q9H8U3 28 / 2 14 7.72 
G2 Coiled-coil domain-containing protein 29 (32003 /6.41) Q4UJ79 41 / 3 12 0.01 
G3 DNA topoisomerase 3-alpha (114239 /8.69) Q13472 57 / 9 8 48.69 
G4 Keratin, type I cytoskeletal 17 (48361 /4.97) Q04695 72 / 8 19 0.06 
G5 Kinetochore protein Spc25 (26194 /7.71) Q9HBM1 47 / 4 15 5.73 
G6 Microtubule-actin cross-linking factor 1 (623626 /5.27) Q9UPN3 52 / 8 1 1.31 
G7 Myosin-Vc (203978 /7.69) Q9NQX4 51 / 7 4 19.81 
G8 NEDD4-binding protein 3 (60889 /8.33) O15049 50 / 6 12 1.91 
G9 Nesprin-3 (112774 /5.88) Q6ZMZ3 61 / 9 12 1.25 
G10 Probable global transcription activator SNF2L1  (123211 /8.26) P28370 43 / 7 5 22.40 
G11 Protein SSX5 (21647 /9.35) O60225 37 / 2 14 0.66 
G12 Regulator of G-protein signalling 5 (21104 /6.85) O15539 27 / 3 8 1.50 
G13 RhoGEF and PH domain-containing prot 1 (107691 /6.14) P98174 36 / 3 4 5.80 
G14 Secretagogin (32190 /5.25) O76038 47 / 4 17 1.65 
G15 Sorting nexin-20 (36668 /8.94) Q7Z614 27 / 2 8 3.60 
G16 Tetratricopeptide repeat protein 38 (53267 /5.61) Q5R3I4 44 / 3 7 2.20 
G17 T-cell receptor  chain V region CTL-L17(15545 /8.54) P04437 41 / 3 14 4.71 
G18 Ubiquitin-protein ligase E3A (101593/5.12) Q05086 42 / 4 5 0.31 
G19 UV excision repair protein RAD23 homolog A  (39642 /4.56) P54725 57 / 7 17 0.24 
G20 Uveal autoantigen with coiled-coil domains (163545 /6.60) Q9BZF9 33 / 5 3 3.90 
G21 V-set and transmembrane domain-containing prot 1  (26405 /4.98) Q6UX27 27 / 2 17 0.57 
B1 Cell death activator CIDE-A (24899 /9.34) O60543 41 / 3 21 1.67 
B2 Docking protein 6 (38692 / 8.72) Q6PKX4 31 / 3 10 1.41 
B3 Elongation factor 2 (96246 /6.41) P13639 31 / 3 3 75.70 
B4 Leucine-rich repeat-containing prot 45 (76475 /5.95) Q96CN5 50 / 6 10 0.08 
B5 SH3 domain-binding glutamic acid-rich-like protein 2 (12375 /6.29) Q9UJC5 21 / 1 16 3.26 
B6 Spectrin alpha chain (280884 /4.96) P02549 42 / 5 2 0.09 
B7 U6 snRNA-associated Sm-like protein LSm4 (15511/10.02) Q9Y4Z0 38 / 3 17 2.68 
B8 Zinc finger protein 540 (79325/9.58) Q8NDQ6 54 / 4 5 0.72 
GB1 Dynein heavy chain 10, axonemal (517677 /5.64) Q8IVF4 50 / 10 3 1.38 
GB2 EF-hand domain-containing (24092 /8.95) A8MZ26 44 / 3 14 3.68 
GB3 EF-hand domain-containing (67022 /9.51) Q6NXPO 41 / 4 8 1.68 
GB4 Golgin subfamily A member 4 (261892 /5.33) Q13439 85 / 17 8 0.61 
GB5 Myosin-4 (223844 /5.67) Q9Y623 50 / 8 6 0.33 
GB6 RWD domain-containing protein 4A (21238 /5.24) Q6NW29 36 / 2 14 23.27 
GB7 Signal recognition particle 54 kDa protein (55953 /8.87) P61011 51 / 4 10 229.80 
GB8 Trafficking protein particle sub 26 (18199 /8.88) Q86SZ2 29 / 2 13 4.39 
GB9 Zinc finger protein 64 homolog (74565 /8.80) Q9NTW7 46 / 5 9 472.01 
a Theoretical molecular mass (Mr, Da) and theoretical pI of the corresponding protein based on 
the SwissProt database. b SwissProt accession number. c The relative expression to controls was 
determined by comparing the mean value of each spot to that of the corresponding spots of control 
cultures and expressed as a ratio. Significant differences in protein expression were calculated from 
triplicate analyses applying the Student’s t test (p<0.05).
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and presenting food antigens to 
T-lymphocytes of the lamina propria 
(24). PSGL1 is critical to initial 
leukocyte capture (25), and could 
mediate the interactions between 
enterocytes and T-lymphocytes in 
response to gliadin. Gliadin exposure 
also caused up-regulation of the 
T-cell receptor alpha chain V region 
CTL-L17 (G17) in Caco-2 cells. 
Accordingly, the presence of β/α 
T-cell receptors has been identified in 
large vacuoles and Golgi complexes 
of enterocytes from patients with 
active CD, but not in those from 
patients on a gluten-free diet (26). 
The exposure of Caco-2 cells to 
digested gliadin also caused the 
down-regulation of proteins involved 
in structural functions such as 
forming stiff bundles of fibres (G2); 
in DNA-dependent transcription 
(G11); in post-replication repair 
functions (G19); in protein synthesis 
and epithelial cell growth through 
binding to the adapter protein 
stratifin and stimulation of the 
protein kinase B/mammalian target 
of rapamycin (Akt/mTOR) pathway 
(G4); and in the cell cycle (G18). 
Cytoskeletal (CK) proteins are 
major structural proteins in 
eukaryotic cells, which are usually 
over-expressed in colon carcinoma 
(27) and gastric cancer cells (28). 
However, some CK proteins (CK-18 
and -19) are down-regulated during 
apoptosis (29). Apoptosis has been 
proposed as a major event underlying 
villous atrophy in CD (30). In the 
present study, the down-regulation 
of gliadin-mediated Keratin type I 
cytoskeletal 17 (G4) in Caco-2 cells 
would suggest a pro-apoptotic effect 
of gliadin. This suggestion is also 
supported by the up-regulation of 
Uveal autoantigen with coiled-coil 
domains (G20), which promotes 
apoptosis by causing the up-
regulation of apoptosome, the down-
regulation of lectin galactoside-
binding soluble 3 (LGALS3) 
and the inactivation of NF-κB. 
However, different in vitro studies 
have reported conflicting results 
regarding gliadin-induced apoptosis 
in intestinal cells (6, 31). These 
studies suggest the likely existence 
of a threshold for gliadin to cause 
toxicity. Wheat gliadin (0.5-1.5 mg/
mL for 48 h) induced apoptosis of 
not confluent intestinal cells (Caco-
2) by a receptor-mediated (Fas-Fas 
ligand) pathway (31) similarly to the 
results reported in the present study. 
In contrast, in confluent Caco-
2 cultures (5 days post-seeding) 
exposed to digested gliadin (0.25 
mg/mL for 15 h), apoptosis was not 
detected (6). All the aforementioned 
changes detected in the proteome of 
Caco-2 cells after gliadin exposure 
were associated to an inflammatory 
response, as reflected by increased 
TNF-a production (Figure 2); 
however, the exposure to digests of 
gliadin did not cause statistically 
significant (P>0.05) differences 
in IL-1b and IL-10 production, 
although the results showed a similar 
trend. 
In cell cultures exposed to digested 
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gliadin inoculated with B. longum 
CECT 7347, changes were detected 
in nine proteins (Table 1). The 
seven up-regulated proteins might 
participate in vesicular transport 
(GB8); in calcium homeostasis 
(GB2); in DNA binding (GB9); 
and in ubiquitination in the case of 
proteins associated with ubiquitin-
protein ligase activity (GB6). 
Ubiquitination is not only important 
in cellular homeostasis, but also in 
human disease, ensuring controlled 
degradation of proteins. Even if the 
up-regulation of proteins involved 
in this pathway was able to induce 
ubiquitination and degradation of 
the (IkBα) inhibitor and activate 
inflammation via the NFkB pathway, 
the exposure of Caco-2 cells to gliadin 
digested with the bifidobacteria was 
not associated with an inflammatory 
response (Figure 2). Previous data 
also demonstrate that NF-kB is not 
activated in intestinal cells exposed 
to digests of gliadin inoculated with 
B. longum CECT 7347 (6). These 
results could be explained, at least 
in part, by the fact that ubiquitin 
ligases become highly specific by 
post-translational modification of 
the substrate proteins, and targets 
of the ubiquitin ligase also include 
many other types of proteins, such 
as cell cycle regulatory proteins and 
proteins unable to fold properly at 
Figure 2. Effect of digested gliadin, inoculated or not with B. longum CECT 7347, on cell viability 
(Neutral red, NR uptake) and production (pg/mL) of tumor necrosis alpha (TNF-a), interleukin 
(IL)-1b, and IL-10. Different superscript letters indicate significant (P<0.05) differences for each 
treatment.
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the endoplasmic reticulum. 
EF-hand domain-containing pro-
teins (GB2), which participate in 
calcium homeostasis, were also 
up-regulated under the effects of 
gliadin digested in the presence of 
the bifidobacteria. This response 
could result from the activation 
of molecular systems controlling 
cytoplasmic Ca+2 levels into cells, 
which could contribute to stabilizing 
cytoskeletal alterations caused by 
gliadin in intestinal cells. It has been 
reported that gliadin-like peptides 
binding to CXCR3 receptor induced 
the over-expression of the glutamate 
receptor (7) coupled to ion channels 
controlling Ca+2 influx into cells (32) 
playing a critical role in the cellular 
resistance to apoptosis (33). This 
might suggest that B. longum CECT 
7347 could reduce gliadin-induced 
toxicity to intestinal epithelial cells 
by regulating Ca+2 homeostasis. 
This hypothesis could explain the 
increased viabilities of Caco-2 cells 
exposed to gliadin digested in the 
presence of B. longum CECT 7347 
compared to those not inoculated 
with the bacterium (Figure 2).
It has been suggested that 
Bifidobacterium strains play 
an important role in health by 
influencing the host’s intestinal 
barrier functions and the epithelial 
and immune cell response(s) (15, 34). 
To test this hypothesis, the influence 
of B. longum CECT 7347 alone 
on Caco-2 cell proteome was also 
evaluated. B. longum CECT 7347 
exposure induced significant changes 
in eight proteins, five of which were 
up-regulated and three were down-
regulated (Table 1). B. longum CECT 
7347 induced proteins involved in 
ribosomal translation (B3 and B7); 
in cell proliferation (B1); and in 
bacterial recognition (B4). The up-
regulation of proteins involved in 
ribosomal translation in the presence 
of B. longum CECT 7347 could 
contribute to the adequate synthesis 
of proteins in intestinal epithelial 
cells and thus their rapid turnover. 
Up-regulation of protein leucine-rich 
repeat-containing protein 45 (B4) 
could be involved in the bacterial 
recognition by Toll-like receptors as 
part of their leucine-rich domains 
(35). 
The exposure of Caco-2 cells to 
B. longum CECT 7347 also led 
the down-regulation of the SH3 
domain-binding glutamic acid-
rich-like protein 2 (B5), zinc finger 
protein 540 (B8) and spectrin alpha 
chain (SPTA) (B6). The SPTA is a 
membrane protein that plays a role 
in signal transduction, regulating 
voltage-dependent anion channels 
(36), which could contribute to gut 
physiology by modulating electrolyte 
transport processes through the 
apical side of enterocytes. 
The results from the present study 
reveal marked changes in the 
proteome of intestinal epithelial 
cells in response to their interaction 
with gliadin-derived peptides. 
Caco-2 cell cultures exposed to 
gliadin digested in the absence of 
B. longum CECT 7347 showed 
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alterations of key proteins involved 
in CK integrity, cell apoptosis and 
interactions with immune cells, 
and significant increases in TNF-α 
production. In contrast, when 
gliadin was digested in the presence 
of B. longum CECT 7347 their effect 
on the proteome was ameliorated, 
inducing alterations in a lower 
number of proteins. These proteins 
were involved in controlling ionic 
homeostasis, CK integrity and signal 
transduction. Altogether, the results 
suggest that B. longum CECT 7347 
reduces the toxic and inflammatory 
effects of gliadin-derived peptides, 
and could contribute to improving 
the survival and physiological 
function of intestinal epithelial cells. 
The significance of these proteomic 
changes in vivo deserves further 
investigation. 
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ABSTRACT
Coeliac disease (CD) is an autoimmune disorder triggered by gluten 
proteins (gliadin) that involves innate and adaptive immunity. In this 
study, we hypothesise that the administration of Bifidobacterium longum 
CECT 7347, previously selected for reducing giadin immunotoxic effects 
in vitro, could exert protective effects in an animal model of gliadin-
induced enteropathy. The effects of this bacterium were evaluated in 
newborn rats fed gliadin alone or sensitised with interferon (IFN)-g 
and fed gliadin. Jejunal tissue sections were collected for histological, 
NFkB mRNA expression and cytokine production analyses. Leukocyte 
populations and T-cell subsets were analysed in peripheral blood 
samples. The possible translocation of the bacterium to different organs 
was determined by plate counting and the composition of the colonic 
microbiota was quantified by real-time PCR. Feeding gliadin alone 
reduced enterocyte height and peripheral CD4+ cells, but increased 
CD4+/Foxp3+ T and CD8+ cells, while the simultaneous administration 
of B. longum CECT 7347 exerted opposite effects. Animals sensitised 
with IFN-g and fed gliadin showed high cellular infiltration, reduced villi 
width and enterocyte height. Sensitised animals also exhibited increased 
NFkB mRNA expression and TNF-α production in tissue sections. B. 
longum CECT 7347 administration increased NFkB expression and 
IL-10, but reduced TNF-α, production in the enteropathy model. In 
sensitised gliadin-fed animals, CD4+, CD4+/Foxp3+ and CD8+ T cells 
increased, whereas the administration of B. longum CECT 7347 reduced 
CD4+ and CD4+/Foxp3+ cell populations and increased CD8+ T cell 
populations. The bifidobacterial strain administered represented between 
75-95% of the total bifidobacteria isolated from all treated groups, and 
translocation to organs was not detected. These findings indicate that 
B. longum attenuates the production of inflammatory cytokines and the 
CD4+ T-cell mediated immune response in an animal model of gliadin-
induced enteropathy.
Keywords: Coeliac disease, Bifidobacterium, gliadin, weaning rats, 
enteropathy.
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INTRODUCTION
Coeliac disease (CD) is an 
autoimmune enteropathy triggered 
by cereal gluten proteins (gliadin) in 
genetically predisposed individuals 
(1). In CD patients, peptides 
resulting from incomplete protein 
hydrolysis by digestive enzymes cause 
a deregulated immune response 
and inflammation. The degree of 
intestinal inflammation can vary 
from intraepithelial lymphocytosis 
to severe infiltration of mononuclear 
cells in the lamina propria, causing 
villous atrophy and crypt cell 
hyperplasia in the small intestine (2). 
Several attempts have been made 
to develop animal models that 
reproduce CD pathogenesis, 
including the immune response, the 
mucosal lesions and the symptoms 
(3-5). The intragastric administration 
of gliadin to inbred rats after weaning 
(4) or to immunocompetent mice at 
10 days of age failed to reproduce 
the damage of the intestinal mucosa 
(6). Human leukocyte antigen 
(HLA)-DQ8/HCD4 or single HLA-
DQ8 transgenic mice sensitised 
with gluten developed an immune 
response to gliadin that involved 
both the adaptive and innate 
immune system (7, 8) and dependent 
changes in gut neuromuscular and 
epithelial secretory function (8), but 
did not develop a gluten-dependent 
enteropathy. Nevertheless, repeated 
oral administration of gliadin to rats, 
previously sensitised with interferon 
gamma (IFN-g) immediately after 
birth, caused mucosal lesions 
characterised by shortening of jejunal 
villi, crypt hyperplasia, and increased 
cellular infiltration, including 
CD8ab+ and CD4+ T lymphocytes 
(9). Activation of CD4+ T-helper 1 
(Th1) cells that produce IFN-g and 
intraepithelial CD8+ lymphocytes 
are responsible for the cytotoxic 
effects on intestinal epithelium, 
which in turn could increase passage 
of gliadin antigens to the lamina 
propria and further activate the 
CD4+ Th1 cell response (10,11). 
Thus, this model reproduces a CD4+ 
T cell mediated enteropathy, defined 
as hyperplasic-infiltrative (type II), 
similar to that described in CD 
patients (9). Undoubtedly, further 
refinement of the available animal 
model of CD is desirable, but it is 
considered appropriate to initially 
explore pathogenic mechanism 
and potential pharmaceutical or 
nutritional interventions (9). The 
production of T cells with regulatory 
activity (Tregs) constitutes one of 
immunosuppressive mechanisms 
that contribute to intestinal tolerance 
and prevention of autoimmunity. 
In particular, natural self-antigen-
reactive CD4+CD25+ cells acquired 
Foxp3 expression, a key marker 
of the development of regulatory 
activity, in the thymus and then 
enter peripheral tissues, where they 
can suppress the activation of other 
self-reactive T cells contributing 
to immune tolerance. These 
Tregs (CD4+CD25+Foxp3+) are 
particularly increased in the mucosa 
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and peripheral blood of active CD 
patients as a consequence of the 
activation of a regulatory response to 
counteract the inflammation caused 
by gluten (12, 13), but their role in 
animal models of CD has not been 
studied so far.   
In recent years, innate immunity and 
early interactions of gliadin-derived 
peptides with intestinal epithelial 
cells have also been considered 
critical in the development of the 
disease. Some gluten peptides 
can mediate an innate-immune 
response that involves induction of 
interleukine (IL)-15 production by 
epithelial and dendritic cells. IL-15 
induces up-regulation of the non-
MHC class I receptor NKG2D on 
intraepithelial lymphocytes (IELs), 
and its ligand MICA on epithelial 
cells, that interact and activate 
cytolytic function on enterocytes 
(14). The activation of the NFkB 
pathway in intestinal epithelial cells 
also mediates the production of other 
inflammatory cytokines, such as the 
tumour necrosis factor (TNF)-a, 
which facilitates the interaction of 
IELs and intestinal epithelial cells 
promoting tissue inflammation (15). 
In germ-free rat pups, colonisation 
by the whole microbiota has similar 
effects as administration of gliadin 
on IEL subpopulations, suggesting 
that both factors activate common 
immunological responses that may 
influence CD development (4). 
Human studies also report that CD 
is characterised by imbalances in the 
composition of the microbiota and, 
particularly, reduced numbers of total 
bifidobacteria and B. longum (16). In 
vitro studies have demonstrated that 
the presence of B. longum CECT 
7347 during the intestinal digestion 
of gliadin leads to the generation 
of different peptide sequences and 
reduces their toxic and inflammatory 
effects on intestinal epithelial cells 
(17). In addition, B. longum CECT 
7347 has been shown in vitro 
to counteract the inflammatory 
response induced by the altered 
faecal microbiota of CD patients in 
peripheral blood mononuclear cells 
(18). Yet, the possible in vivo effects 
of this bifidobacterial strain on CD 
have not been evaluated.
In the light of the evidence available, 
in this study we hypothesise that the 
administration of B. longum CECT 
7347, with immunoregulatory 
properties and ability to attenuate 
in vitro gliadin toxicity on epithelial 
cells, could exert protective effects 
in a model of gliadin-induced 
enteropathy in weaning rats.
MATERIAL AND METHODS
Bacterial strain and culture 
conditions 
Bifidobacterium longum CECT 7347 
was isolated from faeces of healthy 
infants as described elsewhere (18). 
The bacterial cultures were grown 
in Man-Rogosa-Sharpe agar and 
broth (Scharlau, Barcelona, Spain) 
supplemented with 0.05% (w/v) 
cysteine (MRS-C; Sigma-Aldrich, St. 
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Louis, USA), and kept at 37 ºC in 
anaerobic conditions (AnaeroGen, 
Oxoid, Basingstoke, UK) for 24 h. 
For animal studies, a pure culture of 
the strain was grown overnight and 
used to inoculate fresh MRS-C broth 
for 22 h. Cells were harvested by 
centrifugation (6,000 xg for 15 min) 
at stationary growth phase, washed 
twice in phosphate buffered saline 
(PBS, 130 mM sodium chloride 
and 10 mM sodium phosphate, pH 
7.4), and re-suspended in 10% (w/v) 
hypoallergenic milk-based formula 
(Nutramigen©, Mead Johnson B.V., 
Nijmegen, Netherlands). Aliquots 
of these cell suspensions were frozen 
in liquid nitrogen and stored at -80 
°C until used. The number of live 
cells after freezing and thawing was 
determined by plate counting on 
MRS-C agar after 48 h of incubation, 
and were expressed as colony-forming 
units (CFU) per mL. More than 90% 
of cells were alive upon thawing and 
no significant differences were found 
during storage time (4 months). One 
fresh aliquot was thawed for every 
new experiment to avoid variability 
in bacterial cell viability between 
experiments.
Animals and experimental design 
Animal experiments were carried 
out in strict accordance with the 
recommendations in the Guide for 
the Care and Use of Laboratory 
Animals of University of Valencia 
(SCSIE, University of Valencia, 
Spain) and the protocol was 
approved by its Ethic Committee. 
Experimental animals were female, 
weaning Wistar rats, provided by 
the SCSIE. The adult females were 
date-mated, and fed ad libitum with 
a standard diet (Harlan Bioproducts, 
Indianapolis, USA). Shortly after 
spontaneous birth, animals were 
randomly distributed into seven 
different groups (n=6 per group): 
1) artificially reared (AR) with the 
hypoallergenic milk-based formula; 
2) AR and fed B. longum CECT 
7347; 3) AR and fed gliadin-derived 
peptides (GP); 4) AR and fed GP 
and B. longum CECT 7347; 5) 
AR sensitised with 1,000 U IFN-g 
administered intraperitoneally 
immediately after birth; 6) AR 
sensitised with IFN-g and fed GP; 6) 
AR sensitised with IFN-g and fed GP 
and B. longum CECT 7347. 
Newborn animals were hand-fed 
(100 µL) using a micropipette every 
4 hours (4-5 times a day) until the 
age of 10 days. They were fed with the 
hypoallergenic milk-based formula 
for newborns, composed of: 19 g 
proteins; 34 g fats; 75 g carbohydrates; 
680 Kcal; 260 mOsm per L. The 
bacterium was administered at a 
concentration of 6.0 x 107-8.2 x 108 
CFU/day, as determined by plate 
counting on MRS-C agar, in a single 
dose during the 10 days. To obtain 
the GP, a commercially available 
extract of gliadin (Sigma-Aldrich, 
St. Louis, USA) was submitted to 
in vitro digestion and then dialysed 
using a 15 kDa cut-off membrane 
(17). Weaning rats were fed 50 mg 
gliadin/day in a single dose during 
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the 10 days and finally they received 
a provocative dose of gliadin 100 mg 
~2 hours before sacrifice. 
Changes in body weight were 
monitored every two days. After 
treatment, rats were anaesthetised 
(isofluran) and killed by 
exsanguination. Whole blood 
samples were preserved in EDTA-
treated tubes to prevent coagulation 
(at room temperature) for leukocyte 
analyses. Sections (1 cm) of the 
proximal jejunum were immersed 
in RNA later buffer (Qiagen, USA) 
or Krebs’s buffer and kept at -80 ºC 
for gene expression and cytokine 
analyses. Liver, spleen and colon 
content samples were also collected 
in PBS and immediately used for 
microbiological analyses by plate 
culturing.
Histologic and morphometric 
evaluation 
Jejunal tissue sections (1 cm) were 
fixed in formaldehyde 10% and 
then sections of 5 mm were stained 
with haematoxylin-eosin. The 
samples were analysed with a Nikon 
Eclipse 90i microscope equipped 
with a Nikon DS-5Mc digital 
camera. Photos were analysed with 
the Nis Elements software (Nikon 
Instruments Inc., Melville, USA). 
The parameters analysed included 
villi width and length and number of 
infiltrated cells in the lamina propria 
because their changes characterized 
the histologic lesions of this 
enteropathy, and the number and 
height of enterocytes that provide an 
indication of the disorganization of 
the cellular epithelial layer.
Leukocyte counts 
The morphological identification of 
immune cells was conducted by the 
May-Grünwald Giemsa’s staining 
procedure. Aliquots (25 mL) of blood 
samples were extended on glass slides 
and were allowed to air-dry. The 
samples were covered with May-
Grünwald’s solution (Sigma-Aldrich, 
St. Louis, USA) for 3 minutes, and 
afterwards an equal volume of PBS 
was added and incubated for 3 
additional minutes. The preparations 
were gently rinsed with PBS, and then 
covered with a dilution (1:20, v/v) of 
the Giemsa stain-modified solution 
in PBS for 12 minutes. Finally, the 
samples were washed, air-dried and 
analysed using an Olympus BX51 
microscope (Madrid, Spain).
Lymphocyte phenotyping
Aliquots (100 µL) of peripheral 
blood were mixed with the 
following fluorochrome-conjugated 
antibodies: Anti-rat CD45, CD4, 
CD8 and Foxp3 (eBiosciences, 
Hattfield, UK). Then samples 
were prepared for flow cytometry 
analysis with the Immunoprep kit 
(Beckman Coulter, USA) according 
to the manufacturer’s instructions, 
and further analysed on a Modular 
Flow Cytometer Cell Sorter (MoFlo 
Sorter, Dakocytomation, USA).
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Real-time reverse transcription-
polymerase chain reaction (RT-
qPCR)
Total RNA was extracted from 
tissue samples with the RNeasy 
mini kit (Qiagen) according to 
the manufacturer’s instructions. 
One microgram of total RNA was 
converted to double-stranded cDNA 
using AMV Reverse Transcriptase 
(Promega, Madison, USA). PCR was 
performed with primers designed for 
the following Rattus norvegicus genes: 
NFkB (forward 5’- CTT CTC GGA 
GTC CCT CAC TG-3’, reverse 5’- 
CCA ATA GCA GCT GGA AAA 
GC-3’) and β-actin (forward 5’- 
CTC TTC CAG CCT TCC TTC 
CT-3’; reverse 5’- TAG AGC CAC 
CAA TCC ACA CA-3’), the latter 
used as a housekeeping gene. The 
PCR mix (20 mL reaction volume) 
consisted of 7.5 mL SYBR Green I 
master mix, 1.3 mmol/L primers, 
and 2.5 mL cDNA. PCR reactions 
were performed in triplicate in a 
LightCycler® 480 (Roche) system 
with the following conditions: 1 
cycle at 95 ºC for 5 min, 35 cycles 
at 60 ºC for 20 s and 72 ºC for 45 
s. The relative mRNA expression of 
the tested gene relative to b-actin 
expression was calculated using 
the 2-DDCp method (19). Samples of 
each animal tissue were measured in 
duplicate and gene expression was 
expressed as fold-change. 
Cytokine protein assay
Jejunal tissue sections (1 cm) 
were kept in Krebs’s buffer (1 
ml) supplemented with protease 
inhibitors (Roche) until analysis. 
Tumour necrosis factor-a (TNF-a) 
(Diaclone, Besançon, France), 
and interleukine (IL)-10 (Abcam, 
Cambridge, UK) were determined 
by ELISAs according to the 
manufacturer’s instructions. Prior 
to cytokine determination, tissue 
samples were homogenised in cell 
lysis buffer using a TissueRuptor 
(Qiagen). Then, samples were 
centrifuged (1000 xg, 15 min) to 
get clear supernatants for cytokine 
determination. The results of the 
ELISA assay are expressed as pico-
grams per gram of tissue (pg/g).
Microbiological analyses
Aliquots (50 mg) of different biologic 
samples (colon content, mesenteric 
lymph nodes (MLN), spleen and 
liver) were diluted (1/9) in PBS 
and decimal dilutions were plated 
on MRS-C agar supplemented 
with mupirocin (80 mg/L) (Sigma-
Aldrich) and acetic acid (1ml/L) 
to increase the selectivity of the 
medium for bifidobacteria. Counts 
were performed on the highest 
dilution plates and were expressed 
as colony forming units (CFU) per 
gram of faeces. Isolated colonies (8-
10) from colon samples were also 
checked by RAPD PCR analysis to 
confirm whether the DNA profile of 
the isolates corresponded with the 
DNA profile of a pure culture of the 
administered strain B. longum CECT 
7347. The random primer 1254 (5’-
CCG CAG CCA A-3’) was used for 
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RAPID-PCR analysis as previously 
described (20). The RAPD-PCR 
products were visualised on a 1.5% 
w/v agarose gel after staining with 
ethidium bromide. 
The composition of the microbiota 
was also analysed by real-time PCR. 
Samples of colon content were 
collected, diluted 1/9 in PBS and 
homogenised thoroughly by agitation 
in a vortex. Aliquots were used for 
DNA extraction using the QIAamp 
DNA stool Mini kit (Qiagen, 
Hilden, Germany) following the 
manufacturer’s instructions.  Genus-, 
group- and species-specific primers 
were used as described previously 
to quantify the different bacterial 
groups of the intestinal microbiota 
(21, 22). Briefly, PCR reactions 
were performed in triplicate in a 
LightCycler® 480 (Roche). Each 
reaction mixture (15 μl) consisted of 
7.5 μl of SYBR® Green PCR Master 
Mix (Roche), 3.5 μl of sterile water, 
0.75 μl of each of the specific primers 
at a concentration of 10 μM, and 
2.5 μl of template DNA. 16 rRNA 
gene copy numbers of each bacterial 
group or species were calculated by 
comparing the Ct values obtained 
with those from a standard curve 
(23). Standard curves were generated 
from serial dilutions of a known copy 
number of the target gene cloned 
into a plasmid vector. For each 
reference strain the 16S rRNA gene 
was cloned into a pGEM-T Easy 
Vector System (Promega). An E. 
coli strain was transformed with the 
recombinant plasmids and plasmid 
DNA was extracted from E. coli 
by the miniprep method (24). Six 
non-zero standard concentrations 
were used to construct the standard 
curves for each reference strain 
representing a species or a group and 
the plasmid DNA concentrations 
ranged from 104 to 1010 copies of 
DNA per reaction. Standard curves 
were constructed by plotting the Ct 
values against the logarithm of their 
initial template copy number. DNA 
concentration was measured using a 
NanoDrop® and the corresponding 
copy number was calculated (25). 
The following reference strains were 
used as standards: Bifidobacterium 
longum subsp. longum CECT 4503, 
Bacteroides fragilis DSMZ 2451; 
Clostridium coccoides DSMZ 933; 
C. leptum DSMZ 935; Lactobacillus 
casei ATCC 393; and E. coli CECT 
4558.
Statistical analyses
Statistical analyses were performed 
using SPSS v.15 software (SPSS Inc., 
Chicago, IL, USA). For normally 
distributed data ANOVA and the 
Student t test were applied and, for 
non-normally distributed data, the 
Mann-Whitney U test was used. 
Statistical significance was established 
at P<0.05 for all comparisons.
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RESULTS
Body weight and morphometric 
analyses of jejunal sections
Significant (P>0.05) differences 
in body weight were not detected 
among the different experimental 
animal groups (data not shown). 
The animals sensitised with IFN-g 
and fed gliadin were the only ones 
that presented signs of diarrhoea. 
The animal group that was 
diagnosed with diarrhoea had faecal 
sports around the anal area and the 
colon contents recovered after the 
sacrifice had watery consistency. 
Morphometric analyses of jejunal 
tissue sections revealed that animals 
fed with gliadin alone did not exhibit 
significant alterations compared 
to controls, except for decreased 
(P=0.014) enterocyte height (Table 
1), but this alteration was restored 
by simultaneous administration of 
B. longum CECT 7347. In animals 
sensitised with IFN-g and fed gliadin, 
there was a significant decrease in 
villi width (P= 0.048) and enterocyte 
height (P=0.033) and an increase in 
enterocyte numbers (P=0.001) in the 
apical part of jejunal sections and 
also higher (P=0.001) infiltration of 
cells in the lamina propria compared 
to the controls (Figure 1). However, 
these changes were not observed in 
animals only sensitized with IFN-g 
but not fed gliadin. B. longum CECT 
7347 administration increased villi 
width (P=0.004) and enterocyte 
height (P=0.005), partially restoring 
the alterations detected in animals 
sensitised with IFN-g and fed gliadin 
but did not decrease the cellular 
infiltration observed in the IFN/
gliadin group. Feeding of B. longum 
CECT 7347 alone or together with 
gliadin increased (P=0.016 and 
P=0.020, respectively) villi length 
when compared to control animals.
NFkB mRNA expression analysis
Gliadin feeding significantly 
(P=0.013) reduced NFkB mRNA 
expression, while the simultaneous 
administration of B. longum CECT 
7347 restored its levels, reaching 
similar values as those of controls 
(Figure 2). In animals sensitised 
with IFN-g and fed gliadin, NFkB 
expression was markedly increased 
(P<0.001) and the simultaneous 
administration of B. longum CECT 
7347 produced even higher NFkB 
(P=0.045) gene expression. Feeding 
of B. longum CECT 7347 alone to 
weaning animals did not alter the 
basal expression of this inflammatory 
marker indicating that the intestinal 
inflammatory milieu and the 
simultaneous presence of other 
stimuli modify the immune effects 
of this bacterial strain. Sensitisation 
with IFN-g immediately after birth 
did not exert a significant effect in 
comparison with controls.
Cytokine production
The cytokine concentrations in 
jejunal tissue sections from different 
experimental animal groups 
quantified by ELISA are shown in 
Figure 3. In tissue samples from 
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animals fed either gliadin or B. longum 
CECT 7347 the concentration of 
the inflammatory cytokine TNF-a 
was not increased, but that of the 
anti-inflammatory cytokine IL-10 
(P=0.003, P=0.006, respectively) did 
increase in comparison with controls. 
The simultaneous administration of 
both gliadin and B. longum CECT 
7347 caused a significant increase 
in TNF-a and IL-10 production, 
in comparison with the control 
(P=0.012 and P=0.028, respectively) 
and with the administration of either 
gliadin (P<0.001 and P=0.017, 
respectively) or B. longum CECT 
7347 (P=0.029 and P=0.001, 
respectively) alone. In animals 
sensitised with IFN-g and fed 
gliadin, TNF-a concentrations were 
significantly (P=0.007) increased 
and, to a lesser extent, also those of 
IL-10 (P=0.008) in comparison with 
control animals. This effect could be 
only attributed to the administration 
of gliadin because animals sensitized 
with IFN-g but not fed with 
gliadins did not exhibit significant 
increases in cytokine production. 
The administration of B. longum 
CECT 7347 to the enteropathy 
model significantly reduced 
TNF-a (P=0.003) and increased 
IL-10 (P<0.001) production, 
indicating its ability to counteract 
the inflammatory response in the 
intestinal mucosa.
Leukocyte count and lymphocyte 
phenotyping
The alterations in peripheral 
leukocyte populations in different 
animal groups are shown in Table 
2. Gliadin administration did 
not cause significant alterations 
in the lymphocyte population 
compared to controls, except for an 
increase in eosinophils (P=0.048). 
This alteration was restored by 
simultaneous administration of B. 
Figure 1. Histology of jejunal tissue sections 
of different experimental rat groups, stained 
with hematoxylin-eosin showing the different 
degree of cellular infiltration in the lamina 
propria of animals sensitized or not with 
IFN-g and fed gliadins and B. longum CECT 
7347. 
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longum CECT 7347 (P=0.048). 
Sensitization of animals with IFN-g 
did not cause significant changes in 
leukocyte population, but feeding 
gliadins to animals sensitised 
with IFN-g decreased lymphocyte 
populations significantly (P=0.028) 
in comparison to non-sensitised 
animals that had been fed gliadin. 
In contrast, monocyte populations 
significantly increased in sensitized 
and gliadin-fed animals (P=0.039) 
and also in those simultaneously fed 
B. longum CECT 7347 (P=0.005) 
in comparison to controls. The 
administration of the bifidobacterial 
strain alone did not significantly 
modify the leukocyte populations in 
comparison to controls. 
In rats, leukocyte counts have been 
Figure 2. Expression (mRNA) of nuclear factor kappa B (NFkB) in jejunal sections of rats after 
different treatments. The results are expressed as mean ± standard deviation (n=6). *Indicates 
statistically significant (P<0.05) differences relative to the controls; bars indicate significant 
differences between the specific pair comparisons as determined by applying the Student t test.
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reported to be highly variable in 
the range 6000-18000 leukocytes/
µl (26), which is in agreement with 
the values found in our experimental 
animal groups. The lymphocyte 
population was identified with 
the lymphocyte marker CD45 
and further T-cell phenotyping 
analyses were done within this 
population (Figure 4). Feeding 
gliadin significantly reduced CD4+ 
lymphocyte numbers (P=0.003) 
compared to controls, whereas 
Foxp3+ T cell numbers increased 
(P<0.001). The administration of B. 
longum CECT 7347 together with 
gliadin exerted the opposite effects 
in all T-lymphocyte subpopulations, 
increasing CD4+ cells (P=0.010) 
and reducing CD8+ (P=0.008) and 
Figure 3. Tumour necrosis factor (TNF)-a and interleukine (IL)-10 production in jejunal tissue 
sections of rats after different treatments. The results are expressed as mean ± standard deviation 
(n=6). *Indicates statistically significant (P<0.05) differences compared to the controls; bars 
indicate significant differences between the specific pair comparisons as determined by applying 
the Student t test.
101
 
 
C
on
tr
ol
 
G
lia
di
n 
B.
 lo
ng
um
 
G
lia
di
n/
B.
 
lo
ng
um
 
IF
N
-
 
IF
N
-
/ 
G
lia
di
n 
IF
N
-
/G
lia
di
n 
/B
. l
on
gu
m
 
N
eu
tro
ph
il 
17
.1
 ±
 3
.8
 
18
.6
 ±
 4
.9
 
20
.2
 ±
 3
.9
 
19
.1
 ±
 1
.8
 
17
.2
 ±
 2
.3
 
22
.2
 ±
 4
.0
 
18
.5
 ±
 5
.5
 
Ly
m
ph
oc
yt
e 
73
.7
 ±
 7
.1
 
78
.0
 ±
 5
.6
 a  
72
.5
 ±
 6
.8
 
73
.4
 ±
 1
1.
1 
73
.3
 ±
 1
.9
 
66
.8
 ±
 5
.4
 a  
69
.2
 ±
 4
.8
 
M
on
oc
yt
e 
3.
3 
± 
0.
6 
b,
 c
 
3.
6 
± 
0.
9 
2.
9 
± 
1.
1 
3.
4 
± 
1.
2 
4.
1 
± 
1.
3 
6.
0 
± 
1.
9 
b  
6.
5 
± 
1.
5 
c  
Eo
si
no
ph
ilo
 
4.
3 
± 
0.
7 
d  
5.
3 
± 
0.
6 
d,
e  
5.
6 
± 
1.
3 
2.
7 
± 
1.
4 
e  
3.
3 
± 
1.
7 
4.
2 
± 
1.
2 
4.
9 
± 
1.
1 
B
as
op
hi
l 
1.
3 
± 
0.
4 
1.
6 
± 
0.
9 
1.
1 
± 
1.
0 
1.
1 
± 
0.
2 
2.
1 
± 
1.
1 
0.
8 
± 
0.
6 
0.
7 
± 
0.
5 
Ta
bl
e 
2.
 L
eu
ko
cy
te
 p
er
ce
nt
ag
es
 (%
) i
n 
pe
rip
he
ra
l b
lo
od
 o
f d
iff
er
en
t r
at
 e
xp
er
im
en
ta
l g
ro
up
s. 
Th
e 
re
su
lts
 a
re
 e
xp
re
ss
ed
 a
s m
ea
n 
± 
SD
 (n
=6
). 
a-
e 
Su
pe
rs
cr
ip
t l
et
te
rs
 in
 a
 sa
m
e 
ro
w
 in
di
ca
te
 st
at
ist
ic
al
ly
 (P
<0
.0
5)
 si
gn
ifi
ca
nt
 d
iff
er
en
ce
s b
et
w
ee
n 
th
e 
pa
ir 
of
 
sa
m
pl
es
 th
at
 h
as
 th
e 
sa
m
e 
le
tte
r a
s d
et
er
m
in
ed
 a
pp
ly
in
g 
th
e 
St
ud
en
t t
 te
st 
(*
).
* 
P 
va
lu
es
: a
, 0
.0
28
; b
, 0
.0
39
; c
, 0
.0
05
; d
, 0
.0
48
; e
, 0
.0
48
Chapter 2
102
Results and discussion
Foxp3+ T cells (P<0.001). Animals 
sensitized with IFN-g exhibited 
significantly (P=0.041) increased 
CD4+ cells, but not those of CD8+ 
and CD4+Foxp3 cells. In addition, 
in animals sensitised with IFN-g and 
fed gliadin, there was a much more 
marked increase in all T-lymphocyte 
subpopulations compared to 
controls. In this model, the 
administration of B. longum CECT 
7347 significantly reduced CD4+ 
(P=0.032) and Foxp3+ T (P=0.038) 
cell populations, but increased 
those of CD8+ cells (P=0.022). The 
administration of B. longum CECT 
Figure 4. Phenotyping of lymphocyte populations in peripheral blood of rats after different 
treatments. The results are expressed as mean ± standard deviation (n=6). *Indicates statistically 
significant (P<0.05) differences relative to the controls; bars indicate significant differences between 
the specific pair comparisons as determined by applying the Student t test. 
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7347 alone did not significantly 
affect any of the T cell lymphocyte 
populations analysed. 
Bacterial translocation and 
microbiota composition 
Translocation of Bifidobacterium spp. 
to liver, spleen and MLN was not 
detected by plate counting in any 
of the treated animal groups. RAPD 
analyses of colonies isolated from 
selective media for bifidobacteria 
present in colon samples indicated 
that the strain administered 
represented between 75-95% of the 
total bifidobacteria. The quantitative 
analyses of specific bacterial groups by 
real time-PCR also indicated that the 
administration of the bifidobacterial 
strain contributed to an increase in 
the total gene copies of this bacterial 
group by at least one logarithmic 
unit (Table 3). Neither feeding 
gliadin alone nor sensitization with 
IFN-g alone significantly modified 
the composition of the microbiota 
in comparison with controls. In 
animals sensitised with IFN-g and 
fed gliadin, significantly higher gene 
copy numbers of the Bacteroides 
fragilis group were detected in 
comparison with controls (P=0.030) 
and with rats fed gliadin (P=0.020) 
gliadin plus B. longum CECT 7347 
(P=0.049) and in those sensitized 
with IFN-g (P=0.025). The 
administration of B. longum CECT 
7347 did not restore microbiota 
alterations in the enteropathy model 
and only contributed to increasing 
total Bifidobacterium gene copy 
numbers.
DISCUSSION
This study reports for the first time 
the effects of feeding a bifidobacterial 
strain (B. longum CECT 7347) at 
an early postnatal period on the 
intestinal mucosal architecture and 
markers of innate and adaptive 
immunity in an experimental 
animal model of gliadin-induced 
enteropathy.
In previous studies, gliadin 
administration to inbred rats after 
weaning (4) or adult mice (6) failed to 
reproduce the enteropathy, probably 
due to immunocompetence of the 
experimental animals and lack of 
gliadin access beyond the epithelial 
cell layer. Moreover, feeding gliadin 
even during the early neonatal period 
was insufficient to cause mucosal 
damage and significant alterations in 
epithelium architecture in agreement 
with our study (4, 27). Sensitisation 
of animals with IFN-g appeared 
to be necessary to cause mucosal 
damage and immunologic changes 
resembling those observed in human 
CD (9). IFN-g administration 
to weaning animals increases 
macromolecular transport across 
Peyer’s patches (28), and macrophage 
priming (29) that favours the full 
establishment of a jejunal mucosal 
reaction and the instauration of 
the enteropathy (9). However 
sensitisation with IFN-g alone did not 
caused histological alterations in our 
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study, in accordance with previous 
reports (9). Thus, the animal model 
used in the present study approaches 
an intermediate state between 
proliferative and destructive phases of 
CD that ultimately lead to complete 
villous atrophy and disruption of 
intestinal epithelium integrity, which 
are major characteristics of fully 
developed CD (2, 30). B. longum 
CECT 7347 administration to 
gliadin-fed animals sensitised with 
IFN-g, partially reduced some of 
the alterations in jejunal architecture 
caused by the triggers of the disease, 
which could theoretically contribute 
to improving the gut barrier function 
and preventing gliadin translocation 
to the submucosa. Similarly, 
administration of Lactobacillus casei 
ATCC 9595 restored the intestinal 
damage caused by gliadins in HLA-
DQ8 transgenic mice treated with 
indomethacin (27).
In CD patients, gliadin acts as 
potent inducer of inflammatory gene 
expression and cytokine production, 
including TNF-a and NFkB (31-
33). In this study, NFkB expression 
(mRNA) was increased in animals 
sensitised with IFN-g and fed 
gliadin, in agreement with the NFkB 
activation found in the intestinal 
mucosa of CD patients (32). NFkB 
activation has been identified as the 
mechanism by which gliadin mediates 
TNFa production in enterocytes 
(17) and human monocytes (33). 
Accordingly, TNF-a production was 
also significantly increased in animals 
sensitised with IFN-g and fed gliadin. 
However, the administration of 
gliadin alone neither induced NFkB 
expression nor TNF-a production 
in comparison with controls. It is 
possible that gliadin administered 
alone stimulates a regulatory response 
reflected in the down-regulation of 
NFkB mRNA expression and the 
increased IL-10 production leading 
to tolerance in these animals, which 
are not genetically predisposed to 
the disease. In fact, previous authors 
also demonstrated that IFN-g 
administered intraperitoneally was 
necessary to induce the disease 
together with oral administration 
of gliadin (9). In contrast, the 
simultaneous administration 
of B. longum CECT 7347 and 
gliadin increased NFkB mRNA 
expression and cytokine production 
in comparison with the group 
only fed gliadin. This could be 
due to additional interactions of 
bacterial components with Toll-
like receptors (TLRs) that upon-
ligand binding can also activate 
the NFkB pathway and cytokine 
production. Therefore, the results 
indicate that this bacterial strain 
caused certain immune activation 
in the simultaneous presence of 
gliadin; however, these effects were 
not significant in comparison with 
the control group except for cytokine 
production and were not translated 
in other pathologic signs. Notably, 
the administration of B. longum 
CECT 7347 to animals sensitised 
with IFN-g and fed gliadin reduced 
TNF-a production and increased IL-
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10 production and NFkB expression, 
triggering an anti-inflammatory and 
regulatory response. Interestingly, 
the two treatments IFN-g 
sensitization plus gliadin feeding 
and IFN-g sensitization plus gliadin 
and B. longum feeding activated 
NFkB mRNA expression, but the 
final effect on cytokine production 
markedly differed. The effects 
on these inflammatory markers 
on our enteropathy model are in 
agreement with the inflammatory 
role of gliadins in CD patients and 
enterocytes previously reported 
(15, 32). However, an increased 
in NFkB mRNA expression does 
not always lead to an inflammatory 
response because this pathway is 
regulated at different stages and by 
diverse mechanisms controlling, for 
instance, the ubiquitination of the 
inhibitor IkB, which promotes the 
translocation of the heterodimer 
p50/p65 to the nucleus and the final 
induction of inflammatory cytokines 
such as TNF-a (34). In this context, 
it has been reported that some 
commensal bacterial can induce 
transient activation or inhibition 
of the NFkB signalling pathway 
at different steps that contribute 
to attenuating and regulating the 
pro-inflammatory responses. For 
example, B. thetaiotaomicron acts 
downstream NFkB activation by 
promoting nuclear export of NFkB 
subunit relA in complex PPAR-γ 
(35), while other commensal bacterial 
block NFkB at more proximal 
steps, inhibiting ubiquitination 
and proteolytic inactivation of the 
endogenous NFkB inhibitor IkB 
(36). Therefore, it is possible that the 
B. longum strain used in this study 
only causes a transient activation of 
NFkB mRNA expression without 
enhancing the final production of 
inflammatory mediators such as 
TNF-a in the enteropathy animal 
model. 
In addition, our results evidence 
significant differences between the 
immunomodulatory properties 
of B. longum CECT 7347 and L. 
casei ATCC 9595, since this latter 
strain was unable to rescue IL-10 
production in the enteropathy model 
of HLA-DQ8 transgenic mice (27). 
IL-10 production was also stimulated 
by the administration of B. longum 
CECT 7347 in control animals but 
not that of TNF-a, which is an 
additional indication of the anti-
inflammatory properties of this strain 
also in the absence of other stimuli 
such as gliadin or an inflammatory 
condition. IL-10 seems to be 
indispensable for the induction of 
oral tolerance to dietary antigens, the 
inhibition of chemokine production 
and the antigen-presenting capacity 
of monocytes and macrophages, 
and induction of the production 
of soluble antagonists of pro-
inflammatory cytokines such as IL-1 
and TNFa (37). 
Leukocyte counts and phenotyping 
analyses of T-cell subsets in 
peripheral blood support that 
IFN-g sensitisation of weaning 
animals is effective in stimulating a 
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T cell-mediated response to orally 
administered gliadin antigens, 
partially mimicking the effect in 
humans. Monocyte numbers were 
significantly increased in animals 
sensitised with IFN-g and fed 
gliadin, which suggests a response 
to inflammatory signals that could 
not be significantly reduced by B. 
longum CECT 7347. The data from 
lymphocyte phenotyping indicated 
that gliadin alone reduces CD4+ T 
cells and increases CD4+/Foxp3+ 
T cells, suggesting a regulatory 
response in agreement with previous 
data. Although these changes were 
reversed by B. longum CECT 7347 
administration, indicating that 
the bacterium can induce certain 
immune activation in an opposite 
direction, these effects were not 
significant in comparison with 
controls. Our study also demonstrates 
that IFN-g sensitisation, prior to 
gliadin administration, was necessary 
to induce an enteropathy mediated 
by CD4+ T cells, while IFN-γ 
sensitisation alone did not cause 
significant changes in lymphocyte 
subpopulations. In the enteropathy 
model, the changes in CD4+ were 
also accompanied by an increase in 
CD4+/Foxp3+ (Tregs) cells, which 
suggests the development of a counter-
regulatory response, as previously 
reported (7,11). The increased Treg 
cell numbers is concordant with the 
increased percentages of circulating 
regulatory CD4+CD25+Foxp3+ T 
cells found in untreated, compared 
to treated (gluten-free diet) CD 
patients (12,13). In this study, 
feeding of B. longum CECT 7347 
significantly decreased CD4+ and 
CD4+/Foxp3 Tregs cells in animals 
sensitised with IFN-g, indicating its 
ability to counteract the Th1-type 
inflammatory response triggered by 
gliadin. However, a recent study has 
demonstrated that L. casei ATCC 
9595 administration was unable to 
significantly modulate CD25+ T cell 
populations in HLA-DQ8 transgenic 
mice that had been fed gliadins 
(27). B. longum CECT 7347 also 
induced CD8+ T cells in this model 
of enteropathy in agreement with 
the microbiota-mediated increase 
in CD8+ lymphocytes previously 
reported (4); the role of which in this 
disease remains to be determined. 
Microbiota composition of animals 
sensitised with IFN-g and fed 
gliadins showed increased gene 
copy numbers of the Bacteroides 
fragilis group in comparison with 
control animals; these differences 
were not associated with gliadin 
intake and, therefore, could be 
due to the induced alterations in 
intestinal epithelium architecture 
and the underlying inflammation 
in the enteropathy model (30, 
31). This alteration resembles that 
found in paediatric CD patients 
that showed increased bacteroides 
numbers in faeces and duodenal 
biopsies, but not solely associated 
with the inflammatory phase of 
the disease (38, 39). Bifidobacteria 
and lactobacilli numbers were not 
related to gliadin intake or the 
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induced inflammation, in contrast 
to human data (38, 39). As expected, 
administration of B. longum CECT 
7347 led to increased gene copy 
numbers of total bifidobacteria in the 
colon, which could be responsible for 
the biological effects detected on the 
mucosa and inflammatory markers 
under gliadin or IFN-g and gliadin 
administration. Studies in vitro and 
in situ have reported positive effects 
of different Bifidobacterium strains 
in the context of CD, including the 
reduction of gliadin toxicity (17, 
40) and inflammatory potential of 
gliadin peptides on intestinal cells 
(17). This study has demonstrated 
the protective effects of B. longum 
CECT 7347 against the aberrant 
gliadin response in vivo, by reducing 
inflammatory cytokine production 
and increasing regulatory cytokine 
production (IL-10) in the jejunal 
mucosa, and reduced activation 
of CD4+ T cells. However, the 
limitations of the animal model used 
to flly reproduce the fundamental 
features of the disease makes necessary 
to consider the results reposted with 
caution and, undoubtedly, studies 
in humans will be necessary to 
really prove beneficial effects of this 
bacterium on the disease.
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ABSTRACT
 
To investigate whether breast-milk composition and microbiota differ 
in healthy mothers and mothers with celiac disease (CD) to ultimately 
contribute to identify additional factors determining CD risk. Breast-
milk samples from healthy mothers (n=12) and mothers with CD 
(n=12) were collected. Cytokines and secretory immunoglobulin A 
(sIgA) were analysed by bead-arrays and flow cytometry and human milk 
oligosaccharides (HMOs) were assessed by capillary electrophoresis with 
laser-induced fluorescence (CE-LIF) detection. Breast milk microbiota 
composition was analysed by conventional and quantitative real-time 
PCR. Breast-milk from CD mothers showed significantly lower levels of 
interleukin (IL) 12p70 (P< 0.042), transforming growth factor (TGF)-β1 
(P< 0.018) and sIgA (P< 0.003) and almost significantly lower levels of 
interferon (IFN)-γ (P< 0.058). Six mothers in each group belonged to 
the secretor Le(a-b+) type, one to the secretor Le(a-b-) type and five to 
the non-secretor Le(a+b-) type. CD mothers of non-secretor Le(a+b-) 
type showed increased Lacto-N-tetraose content (P< 0.042) compared 
with healthy mothers. CD mothers’ milk showed reduced gene copy 
numbers of Bifidobacterium spp. (P< 0.026) and B. fragillis group (P< 
0.044). CD mothers’ breast milk is characterized by a reduced abundance 
of immunoprotective compounds (TGF-β1 and sIgA) and bifidobacteria. 
The reduction of these components could theoretically diminish the 
protective effects of breast-feeding on the child’s future risk of developing 
CD.
Keywords: Celiac disease, human-milk, immunity, microbiota. 
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exposure, which could contribute to 
the protective effect of breast milk 
against CD development. It is also 
biologically plausible that breast-milk 
components (immune mediators, 
human milk oligosaccharides, etc.) 
promote oral tolerance to dietary 
antigens by modulating immune 
development and function, and 
infant’s gut microbiota composition 
(1, 6).
The colonization of the new-born 
intestine by an adequate consortium 
of bacteria may contribute to 
proper development of the host’s 
immune functions and, conversely, 
imbalances in micobiota can increase 
susceptibility to immune-mediated 
disorders in early and later life. Animal 
studies have provided direct evidence 
of the role gut microbial colonization 
plays in immune developmental 
processes and the orchestration of 
appropriate or aberrant immune 
responses (7). Human observational 
studies have also reported imbalances 
in gut microbiota composition that 
precede the development of specific 
immune-mediated diseases later in 
life, thus suggesting causation (8). 
Although colonization seems to be 
host-specific, breastfeeding is one 
of the main environmental factors 
influencing microbiota composition 
early in life (9, 10). These effects are 
thought to be primarily mediated 
by the presence of oligosaccharides, 
which are minimally hydrolysed 
by human enzymes and reach the 
large intestine, constituting the 
main substrate for the infants’ gut 
INTRODUCTION
Celiac disease (CD) is an 
autoimmune disorder for which the 
main genetic determinant (human 
leukocyte antigen (HLA)-DQ2/8) 
and environmental trigger (gluten) 
are known, although they do not 
fully explain CD onset. Perinatal 
and early postnatal environmental 
factors, influencing immune 
development and gut ecosystem 
of young children, have also been 
associated with CD susceptibility 
(1). Longer breast-feeding and, 
specially, breast-feeding at the time 
of gluten introduction seems to 
reduce the risk of developing CD or 
at least delay its onset in most case-
control observational retrospective 
studies included in the meta-analysis 
by Akobeng et al. (2). A more recent 
cross-sectional study performed in 
two birth cohorts, one born in the 
so-called “Swedish CD epidemic” 
(1993) and another born after the 
epidemic (1997) indicates that 
reduced CD prevalence (clinically 
and screening-detected cases) in the 
second cohort at 12 years of age were 
related to changes in early feeding 
practices. These practices included 
the gradual introduction of gluten-
containing foods from 4 months of 
age simultaneous to breastfeeding 
(3). However, no protective effect 
of breast-feeding on CD risk or CD 
autoimmunity was observed in other 
prospective studies (4, 5). Duration 
of breast-feeding could be associated 
with reduced or delayed gluten 
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microbiota and, particularly, for 
bifidobacteria (6). In recent years, 
breast milk has also been considered 
as a possible source of the bacteria 
colonizing the infant’s gut (10, 11). 
The demonstration that lactic acid 
bacteria isolated from breast skin 
and milk are different, demonstrate 
their different origin and suggest an 
endogenous route for breast milk 
colonization (12). Comparisons 
between bacterial strains present 
in mother-infant pair samples also 
suggest possible bacterial transference 
from the mother’s milk to the infant’s 
gut (10). The mechanism involved in 
colonization of human milk remains 
unclear but research reports that 
dendritic cells are able to capture 
bacteria from the intestinal lumen 
via the opening of the tight junctions 
between epithelial cells, subsequently 
reaching the mammary gland by the 
dendritic cells CD18+ (13). 
Human milk is also known to 
provide many bioactive substances 
involved not only in immune passive 
protection, but also in modulation 
of the neonate immunological 
development (14). A complex 
network of chemoattractants and 
cytokines in human milk are thought 
to play a role in compensating for 
the developmental delay of the 
neonate immune system, and in 
preventing the development of 
immune-mediated diseases (15). 
Human-milk cytokine and secretory 
immunoglobulin A (sIgA) content 
have been shown to differ depending 
on various factors, including the 
mother’s immune status and dietary 
content of fatty acids, with potential 
consequences on infant health (16). 
The intake of probiotic bacteria 
has also been related to changes in 
breast milk composition, including 
differences in cytokine content (17). 
Yet the origin of immunoactive 
components in breast milk and its 
possible relationship with the breast-
milk microbiota composition remain 
unknown.   
The primary objective of the 
present study was to establish 
possible relationships between 
microbiota composition, human 
milk oligosaccharides (HMO) and 
immune markers (cytokines and 
sIgA) in breast milk from healthy 
mothers and mothers with CD. A 
wider goal of this research is to gain 
a greater understanding of how early 
postnatal environmental factors, and 
their interaction with host-intrinsic 
factors, could influence the risk of 
developing CD.
MATERIAL AND METHODS
Collection and processing of 
samples
Breast-milk samples were collected 
one month after delivery from 12 
healthy mothers and 12 mothers 
with CD under a gluten-free diet 
(GFD) for more than 2 years and 
without disease symptoms. CD was 
diagnosed according to criteria set by 
the European Society for Pediatric 
Gastroenterology, Hepathology 
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and Nutrition (ESPGHAN) (18). 
Mothers enrolled in the study were 
instructed to collect the milk sample 
in aseptic conditions by manual 
expression into sterile tubes using 
sterile gloves at early feed. Samples 
were immediately stored at -20 
ºC. Five mL of breast milk were 
centrifuged (10,000 xg, 10 min) 
and the fatty layer was discarded. 
We collected the supernatant to 
determine immune markers and the 
pellet for bacterial DNA extraction, 
as described below.
Ethical standards
This study was conducted according 
to the guidelines laid down in 
the Declaration of Helsinki and 
all procedures involving human 
subjects/patients were approved by 
the Committee on Ethical Practice at 
the Hospital Universitari Sant Joan 
(Tarragona, Spain). All the mothers 
participating in the study gave 
written informed consent.
Cytokine and sIgA quantification
Supernatant concentration of 
interleukin (IL)-12p70, IL-10, IL-13, 
interferon (IFN)-γ, tumor necrosis 
factor (TNF)-α and transforming 
growth factor (TGF)-β1 in breast 
milk were quantified using the 
Multiple Analyte Detection 
FlowCytomixTM inflammation 
panel following the manufacturer’s 
instructions (eBioscience, San Diego, 
USA). Samples and standard curves 
were analyzed on a FACS-Canto II 
Deckton Dickinson cytometer (BD 
Bioscience). Data were processed 
using the FlowCytomixPro software 
(eBioscience). Threshold sensitivities 
for each cytokine were: 1.5 pg/mL 
for IL-12p70, 1.6 pg/mL for IFN-γ, 
1.9 pg/mL for IL-10, 4.5 pg/mL 
for IL-13, 3.2 pg/mL for TNF-α 
and 10.0 pg/mL for TGF-β1. 
The sIgA content was quantified 
in milk supernatants using a 
commercial ELISA kit following the 
manufacturer’s instructions (Bethyl, 
Montgomery, USA).
Bacterial DNA isolation and real-
time PCR for microbiota analysis 
DNA from breast milk was extracted 
using the QIAamp DNA Blood Mini 
Kit (Qiagen, Hilden, Germany) 
following the manufacturer’s 
instructions. Real time PCR analyses 
were carried out to quantified 
the content of different bacterial 
groups using specific primers as 
previously described (19, 20). PCR 
amplifications were performed 
in a LightCycler® 480 Real-Time 
PCR System (Roche, Mannhein, 
Germany) in a multiwell-plate with 
15 µL of reaction mixture that 
consisted of  7.5 µL SYBR Green 
PCR Master Mix (Roche), 3.5 µL 
DNase free water, 0.75 µL of each 
specific primer (10 mM) and 2.5 µL 
of the DNA sample. 16S rRNA gene 
copy numbers of each bacterial group 
were calculated by comparing the 
cycle threshold (Ct) values obtained 
with those from a standard curve. 
Standard curves were generated from 
serial dilutions of a known copy 
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number of the target gene cloned into 
a plasmid vector. For each reference 
strain the 16S rRNA gene was cloned 
into a pGEM-T Easy Vector System 
(Promega, Madison, USA). Standard 
curves were constructed by plotting 
the Ct values against the logarithm 
of their initial template copy number 
using LightCycler® 480 Software, 
Version 1.5.  
To study the prevalence of different 
Bifidobacterium species (B. bifidum, 
B. breve, B. catenolatum, B. longum 
and B. infantis) we used specific 
primers as described by Matsuki et al. 
(21).  PCR products were separated 
in a 2% (w/v) agarose gel stained 
with ethidium bromide and we 
recorded the presence or absence of 
the amplicon according to molecular 
mass.
Human milk oligosaccharide 
extraction from breast-milk 
samples
Carbohydrates were extracted from 
one aliquot (1 mL) of breast milk 
following Stahl et al. (22). The 
procedure included pasteurization 
(30 min, 70 °C), defatting at 4 °C 
and protein precipitation by adding 
double the amount (v/v) of cold 
ethanol. The carbohydrates extracted 
from milk were purified by solid 
phase extraction on graphitized 
carbon column cartridges (150 mg 
bed weight, 4 mL tube size; Alltech, 
Deerfield, Il) as described previously 
(23, 24). In short, the cartridges were 
washed with 80/20 (v/v) acetonitrile 
(ACN)/water containing 0.1% 
(v/v) trifluoroacetic acid (TFA) and 
later with millipore water. After 
loading the sample extract onto the 
cartridge, monomers and lactose 
were largely removed by elution with 
an aqueous 5% (v/v) ACN solution. 
The remaining carbohydrates on the 
cartridge were eluted with 40/60 
(v/v) ACN/water containing 0.05% 
(v/v) TFA. The solution was dried 
under a stream of air and the dried 
sample was then rehydrated with 
millipore water.
Human milk oligosaccharide 
determination by capillary 
electrophoresis-laser-induced 
fluorescence (CE-LIF)
For CE-LIF analysis, the 
carbohydrates present in the breast 
milk samples were derivatized with 
the fluorescent 9-aminopyrene-
1,4,6-trisulfonate (APTS) overnight 
at room temperature as reported 
elsewhere (25). Five nanomole 
xylose was added as internal standard 
and mobility marker. CE-LIF was 
performed on a ProteomeLab PA 800 
characterization system (Beckman 
Coulter, Fullerton, CA), equipped 
with a laser induced fluorescence 
detector (LIF) (excitation: 488 
nm, emission: 520 nm) (Beckman 
Coulter) and a polyvinyl alcohol-
coated capillary (50 µm x 50.2 cm 
(Beckman Coulter), detector after 
40 cm), kept at 25 °C. Samples 
were loaded hydrodynamically (4 
s at 0.5 psi, representing approx. 
14 nL sample solution) into the 
capillary. Separation was performed 
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in the reversed polarity mode (30 
kV, 20 min) in the 25 mM acetate 
buffer containing 0.4% polyethylene 
oxide provided in the ProteomeLab 
Carbohydrate Labeling and Analysis 
Kit (Beckman Coulter). Due to 
the low pKa of the sialic acid, 
residues (pKa 2.6) the separation 
buffer was adjusted to pH 2.4 by 
adding 1.2% (v/v) formic acid. 
Peaks were integrated manually 
using Chromeleon software 6.8 
(Dionex, Sunnyvale, CA). The 
HMOs quantified are schematically 
represented in Table 2. 
Statistical analysis
Data distribution was analysed using 
Shapiro-Wilk W test (SPSS Statistic 
19 v software). Normal distribution 
was found for cytokines, sIgA 
and HMO data and the t-test was 
applied to compare the means of the 
values of the two groups of mothers. 
Microbiota data did not show a 
normal distribution and, therefore, 
the non-parametric Mann-Whitney 
U test was applied to compare the 
medians of the values of the two 
groups of mothers. Categorical 
variables (presence or absence) for 
prevalence of Bifidobacterium spp. 
were analyzed using the Fisher test. 
Correlations between parameters 
were determined applying the 
Pearson coefficient. In all cases, 
statistically significant differences 
were established at P value< 0.05.
RESULTS
Demographic and clinical 
characteristics
The demographic and clinical 
characteristics of the mothers and 
their infants are summarized in Table 
1. No significant differences were 
detected in maternal age, duration 
of gestation and mode of delivery. 
All infants were born at term and 
their birth weight, length and sex 
distribution were not significantly 
different between groups. Therefore, 
the study groups and their milk 
samples were comparable. 
Immune parameters in breast milk 
from mothers with CD and healthy 
mothers
The cytokines and sIgA content in 
the supernatants of breast milk from 
12 healthy mothers and 12 mothers 
with CD were analyzed (Figure 1). 
The quantifications were positive 
(above the detection threshold) 
in 66.7% of cases for IL-13 and 
TNF-α, and in 37.5% for TGF-β1. 
The other cytokine quantifications 
were positive in at least 75% of 
the samples (data not shown). No 
differences in cytokine prevalence 
were observed between groups (data 
not shown). Overall, mothers with 
CD had lower cytokine content 
in breast milk compared with 
healthy mothers, being statistically 
significant for IL-12(p70), TGF-β1 
and sIgA levels (P= 0.042, 0.018, 
0.003, respectively) and of borderline 
significance for IFN-γ (P= 0.058). 
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 Characteristicsa Healthy mothers (n=12) 
Mothers with 
CD (n=12) 
 
P-value 
  Mean SE Mean SE  
Mothers      Age 33.2 1.3 34.5  3.6 0.570 
      Weeks of gestation  39.1 1.6 38.9  2.4 0.986 
      Mode of delivery  
        Vaginal  
        Caesarean 
 
10 (83.3) 
2 (16.7) 
 
10 (83.3) 
2 (16.7) 
 
0.704 
Infants      Birth weight (g) 3650 923 3590  1044 0.704 
      Birth length (cm) 48 4 49  4 0.751 
      Sex  
        Male 
        Female 
 
5 (41.7) 
7 (58.3) 
 
4 (33.3)  
8 (66.7) 
0.500 
 
 
Table 1: Clinical and demographic characteristics of healthy mothers and mothers with celiac 
disease (CD) and their infants.
aData of continuous variables are expressed as mean and standard error (SE) (in brackets) and data 
of categorical variables are expressed as absolute numbers and percentage (in brackets). Statistically 
significant differences were established at two-tailed P< 0.05 using the t-test for continuous 
variables and using the Fisher test for categorical variables. 
Figure 1. Cytokine and secretory IgA (sIgA) in breast-milk of healthy mothers and mothers 
with celiac disease (CD). Values are expressed as means and standard error of means. Statistically 
significant differences were establish at two-tailed P <0.050 using the t-test.
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No differences were detected for IL-
10 (P= 0.094), IL-13 (P= 0.228) and 
TNF-α (P= 0.173) between healthy 
mothers and mothers with CD.
Oligosaccharide concentrations in 
breast milk from healthy mothers 
and mothers with CD
Healthy mothers and mothers with 
CD were separated according to 
their Lewis and secretor profile as: 
Le(a-b+)-secretor, Le(a+b-)-non-
secretor, Le(a-b-)-secretor and Le(a-
b-)-non-secretor, which depends 
on fucosyltransferase expression 
influencing the composition of 
fucosylated HMOs (26). In both 
groups, six mothers belonged to 
the Le(a-b+)-secretor profile, five to 
the Le(a+b-)-non-secretor, one to 
Le(a-b-)-secretor type and none to 
the Le(a-b-)-non-secretor. Table 2 
α2,3 β1,4 
α1,2 β1,4 α1,3 β1,4 
β1,3 β1,3 β1,4 α1,2 
 
β1,4 α1,3 
 β1,3 β1,4 
α1,3 
β1,4 
 
β1,4 
β1,4 
β1,3 
β1,6 
β1,3 
α1,3 
α1,4 
β1,3 β1,3 β1,4 α1,2 
 
β1,4 
β1,3 α1,2 
β1,6 
β1,3 
β1,4 
β1,4 
β1,3 α1,2 
β1,6 
β1,3 
α1,3 
β1,4 
β1,4 
β1,3 
β1,6 
β1,3 
α1,3 
α1,4 
α1,4 
β1,3 β1,4 β1,3 
 
β1,4 
Structure name Structure name 
  3’SL  6’SL 
  2’FL 
 
 3’FL 
      DFL 
 
LNT 
 
LNFP II 
 
LNFP I 
     
LNFP III 
 
 
LNDFH I 
 
 F LNH I 
 
F LNH II 
 
DF LNH I 
 
DF LNH II 
 
      
                    Glucose                Galactose                     N-Acetylglucosamine 
                                     Fucose                          Sialic acid 
 
α2,6 β1,4 
β1,3 β1,3 β1,4 α1,2 
aSchematic representation of the molecular structure of the human milk oligosaccharides (HMOs) 
analysed in the present study by capillary electrophoresis-laser-induced fluorescence (CE-FIL). 
The analyses included two structures of sialyllactoses (SL) 3’SL and 6’SL; two fucosyllactoses (FL) 
2’FL and 3’FL; difucosyllactose (DFL); lacto-N-tetraose (LNT); three lacto-N-fucopentaoses 
(LNFP) LNFP I, LNFP II, LNFP III; one lacto-N-difucosylhexaose (LNDFH) LNDFH I; two 
fucosyllacto-N-hexaose (F LNH) F LNH I and F LNH II;  and two difucosyllacto-N-hexaose (DF 
LNH) DF LNH I and DF LNH II.
Table 2. Human milk oligosaccharides (HMO)a analyzed in the present study.
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summarizes HMO quantification. 
HMO contents were compared 
between healthy mothers and 
mothers with CD of the same 
secretor status (Table 3). In milk 
of the Le(a+b-)-non-secretor type, 
higher LNT and LNFPII contents 
were detected for mothers with CD 
compared with healthy ones, but 
only differences in LNT content 
differed significantly (P= 0.042 and 
0.075, respectively). No differences 
were detected in HMO content 
between the two groups of mothers 
with the Le(a-b+)-secretor type. 
Breast-milk microbiota
Breast-milk microbiota composition 
of healthy mothers and mothers with 
CD is shown in Table 4. Mothers with 
CD showed a statistically significant 
reduction in the gene copy numbers 
of Bifidobacterium spp. (P= 0.026) 
and B. fragillis group (P=0.044) 
compared with healthy mothers. Of 
the Bifidobacterium species analyzed 
only B. bifidum and B. breve were 
detected but their levels were too low 
for quantification by real-time PCR. 
No statistically significant differences 
were detected in the prevalence 
of these two species, although, as 
expected, they tended to be more 
prevalent in healthy mothers’ than in 
CD mothers’ breast milk (Table 5). 
DISCUSSION
Here we have demonstrated that 
breast milk from mothers with CD 
and from healthy mothers differs 
in immune parameters and, albeit 
to a lower extent, in microbiota 
and HMO composition. This sheds 
new light on how breast-feeding 
may affect the risk of offspring of 
developing CD, and help explain 
the controversy across diverse 
epidemiological studies. Several 
epidemiological studies have reported 
that breast feeding provides benefits 
to the infant’s health and may protect 
against CD, particularly if kept up 
when gluten is introduced into the 
diet (2, 3), whereas other studies 
have not found this association (4, 
5). There is also debate as to whether 
breast-feeding only delays CD onset 
or actually provides permanent 
protection, as seems to be the case in 
the longer study by Ivarsson et al. (3). 
Our case-control study showed 
TGF-β1 concentration was 
significantly lower in mothers with 
CD than in healthy mothers, which 
may influence the development of 
the newborn’s immune response. 
TGF-β is an important family of 
growth factors involved in developing 
oral tolerance and regulating most 
mechanisms triggered by antigen 
feeding, as well as in maintaining 
intestinal immune homeostasis 
(27). CD patients’ pathologic 
immune response to gluten 
proteins is characterized by the 
uncontrolled production of IFN-γ 
by intraepithelial T-cells, which is not 
sufficiently counteracted by TGF-β1 
production, possibly due partly to 
the inhibitory effect of IL-15 over 
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Bacterial groups aGene copy numbers/mL of breast-milk 
 Healthy mothers 
(n=12) 
Mothers with CD 
(n=12) 
P-value 
Bifidobacterium spp. 2.48 
 (2.37-2.78) 
2.36  
(2.29-2.57) 
0.026* 
B. fragillis group 2.04  
(1.89-2.16) 
1.96  
(1.90-2.03) 
0.044* 
Enterobacteriaceae 3.25  
(3.14-3.38) 
3.29  
(3.12-3.38) 
0.883 
Lactobacillus group 3.92  
(3.16-4.05) 
3,67 
 (3.29-3.77) 
0.140 
C. coccoides group 3.05  
(2.93-3.43) 
3.07 
(2.96-3.22) 
0.859 
Streptococcus group 2.76 
(2.70-2.95) 
2.99 
(2.77-3.04) 
0.160 
Enterococcus  group 2.77 
(2.71-2.91) 
2.92 
(2.71-2.93) 
0.093 
 
 
 
 
 aPrevalence of Bifidobacterium spp. 
 Healthy mothers (n=12) 
Mothers with CD 
(n=12) *P-value 
B. bifidum 10/12 7/12 0.185 
B. breve 10/12 7/12 0.185 
B. catenulatum 0/12 0/12 - 
B. longum 0/12 0/12 - 
B. infantis 0/12 0/12 - 
Table 4. Breast-milk microbiota composition in healthy mothers and mothers with celiac disease 
(CD).
aPrevalence is expressed as positive cases/total cases. Statistically significant differences were 
established using the Fisher test at two-tailed P< 0.050.
Table 5. Prevalence of Bifidobacterim spp. in breast-milk from healthy mothers and mothers with 
celiac disease (CD).
aData are expressed as median and 25th and 75th percentiles (in brackets) of log gene copy numbers 
of each bacterial group. *Statistically significant differences were established at two-tailed P< 0.05 
using the Mann-Whitney U test.  
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TGF-β1 signalling (28). Breast milk 
constitutes an important source of 
TGF-β1 for the neonate because its 
expression is absent in the neonatal 
intestine before day 10, after which it 
increases progressively (27). The low 
TGF-β1 levels detected in breast-
milk from mother with CD in our 
study could theoretically limit its 
protective role in CD prevention. 
Some authors have described that 
allergic mothers presented lower 
levels of TGF-β1 in mature milk 
(29) or TGF-β2 (17); although 
inconsistent results have also been 
reported (30, 31). In the present 
study, breast-milk of CD mothers 
was also characterized by a significant 
decrease in IL-12p70 and important 
but no significant reductions in 
IFN-γ and IL-10 compared with 
healthy mothers. IL-12 is one of the 
main cytokines involved in Th1-
type responses, together with IFN-γ, 
which is the main cytokine involved 
in CD. Therefore, an adverse role of 
reduced Th1-type pro-inflammatory 
cytokine concentrations in breast 
milk of mothers with CD could 
not be inferred, as anticipated for 
regulatory cytokine reductions. 
However, similar changes in 
cytokine levels in breast milk were 
associated with increased allergy 
incidence by Tomicic et al. (16). 
These authors described that reduced 
concentrations of proinflammatoy 
(IFN-γ) and regulatory (TGF-β2 
and IL-10) cytokines and sIgA in 
breast milk were associated with an 
increased allergy incidence in the 
Swedish population compared to 
the Estonian population (16). The 
same trend was reported for allergic 
mothers’ breast milk, where authors 
interpreted reductions in TGF-β2 
and IL-10 as a health risk for the 
infant (32). The latter is a suppressive 
cytokine, which plays a key role in 
intestinal tolerance and immune 
homeostasis. An animal study 
reports that transgenic mice with IL-
10 gene disruption spontaneously 
developed enterocolitis at the time 
of weaning, which was prevented by 
parenteral administration of IL-10. 
The study suggests administration of 
this cytokine with breast milk could 
play a crucial role in maintaining 
gut homeostasis (33). However, 
other authors concluded that IL-
10 in breast milk was not required 
for induction of tolerance and 
protection from allergic asthma 
(34). Research has also associated 
CD with a significant reduction in 
sIgA levels. This immunoglobulin 
is produced by breast secretory cells 
and is able to survive passage through 
the gastrointestinal tract (35), where 
it acts as a first-line of defence by 
interacting with intestinal antigens 
and microbes. Thus a reduction in 
sIgA concentrations supplied by 
breast milk could reduce the infant’s 
mucosal protection, which may 
precede gluten intolerance.  
Breast-milk of mothers with CD 
also showed statistically significant 
reductions in Bifidobacterium spp. 
and B. fragillis gene copy numbers 
in comparison with healthy mothers’ 
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milk, although differences in 
Bifidobacterium at species level were 
not detected. Previous studies report 
that reductions in bifidobacteria 
content in allergic mothers’ breast 
milk are parallel to reduced infant’s 
faecal bifidobacteria (11). 
Probiotic interventions support the 
hypothesis that gut microbiota plays a 
role in the immunological properties 
of breast-milk. For instance, 
administration of Lactobacillus 
rhamnosus GG was associated with 
increased TGF-β2 concentration 
in breast-milk (36) while 
administration of L. rhammnosus 
GG and Bifidobacterium lactis 
Bb12 together was associated with 
increased TNF-α, IL-10, IL-4, and 
IL-2 concentrations (17). However, 
neither of these studies investigated 
whether the administered bacteria 
were detectable in breast-milk 
samples. The administration of L. 
rhamnosus GG to mothers during 
pregnancy and breast-feeding was 
also associated with a reduction 
in atopic eczema, compared with 
mothers taking a placebo, but no 
direct correlation was detected 
between increased TGF-β2 
concentrations and atopic disease 
or atopy (36). Immunoactive agents 
present in breast milk can partly 
come from serum and, therefore, are 
able to reach the mammary gland via 
systemic circulation. Probiotics can 
modify humoral immune mediators 
via gut stimulation and, therefore, 
may also influence the composition 
of immune mediators in breast 
milk via a similar mechanism (37). 
Immune mediators may also be partly 
derived from the mammary gland 
epithelial cells (38) and produced 
locally by breast-milk immune cells 
(39) where a local stimulatory effect 
of the breast-milk microbiota on 
these immune cells is likely. In fact, 
our study supports this hypothesis, 
showing parallel reductions in both 
immune mediators and microbial 
components in breast-milk of 
mothers with CD. 
The presence and abundance of 
HMOs in breast milk is genetically 
determined by glycosyltransferase 
production in the mammary gland. 
Most of them are common to all 
women, with the exception of the 
fucosyltransferases. The expression 
of (α1,2)-fucosyltransferase (FUT2) 
and (α1,3/4)-fucosyltransferases 
(FUT3) responsible for the 
fucosylation of HMOs and 
others body glycoproteins (e.g. 
erythrocytes and mucins), depends 
on the maternal Secretor- (Se) 
and Lewis (Le) type, respectively 
(26). Recently, the expression of 
FUT2, which participates in ABH 
antigen synthesis in mucus and 
other secretions, has been associated 
with bifidobacteria diversity and 
abundance in the human intestinal 
tract (40). Likewise, the non-secretor 
phenotype (characterized by the 
lack of expression of FUT2 gene) 
has been associated with susceptibly 
to CD (41). However, the present 
study found no differences in the 
number of cases of the non-secretor 
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phenotype between healthy and CD 
mothers, although such differences 
may not be appreciable due to the 
limited population size. However, 
in Le(a+b-)-non-secretor mothers, 
LNT content increased in breast 
milk of mother with CD compared 
with healthy mothers’ milk. This is 
the first report of the influence of 
CD on the presence of HMOs in 
breast-milk in mothers of a particular 
secretor status. Mothers secretor 
status has not been associated with 
health outcomes in mothers, but with 
infants’ resistance to viral infections 
(42), which could also constitute risk 
factors for CD (43).
Bifidobacterium spp. can achieve high 
cell densities using HMOs as sole 
carbon source, and bifidobacteria are 
normally abundant in stools from 
breast-fed infants, therefore HMOs 
appear to act as a prebiotic substrate, 
helping to shape the microbiota of the 
infant’s intestinal tract (44). Likewise, 
HMOs may exert a similar effect on 
the mammary gland, favouring the 
presence of bifidobacteria in breast 
milk. Alternatively, bifidobacteria 
could be transient bacteria and their 
levels in the mammary gland may 
depend on their presence in the 
maternal intestinal microbiota. 
The ability of bifidobacteria 
to consume HMOs is species-
dependent. For example, research 
reports B. longum subsp. longum 
DJO10A and B. breve ATCC15700 
consumed only a portion of a 
single, nonfucosylated/nonsialylated 
HMO species (LNnT), while B. 
longum subsp. infantis ATCC15697 
consumed oligosaccharides with a 
low degree of polymerization (≤7) 
(44). Accordingly, differences in 
HMO composition would result in 
differences in Bifidobacterium species 
composition in human milk but we 
did not find such differences. Our 
finding is supported by a previous 
study that reported differences 
in infants’ microbiota only for B. 
adolescentis and B. catenulatum 
abundances, analysed by denaturing 
gradient gel electrophoresis (DGGE) 
in infants fed with milk group 4 
(Le(a-b-)-non-secretor) according 
to classification by Thurl et al. (45), 
which only represent 1% of general 
population (46). This could be 
explained by the fact that different 
bacterial species develop different 
strategies to use HMOs and by 
the existence of cross-feeding 
mechanisms among them which 
overall enable their growth. 
The study reported herein has 
some limitations partly related to 
its exploratory nature, including 
a small population size, lack of 
connexion with clinical outcomes 
in the offspring and lack of control 
of mother anthropometric measures 
and diet, which might also influence 
the breast milk composition. In 
particular, it has been recently 
described that women on a GFD 
reduce the dietary protein and fibre 
intakes and increase the fat intake 
(50), which could also have an 
impact on breast milk composition. 
Breastfeeding during the first months 
129
of life has been associated with a 
protective effect against asthma 
(47, 48), atopic dermatitis (49) 
and CD (2) although not all study 
results are consistent. Compositional 
differences between breast milk of 
mothers with allergic disease and 
controls have also been reported 
although their relationships with 
health outcomes are controversial 
yet. The results presented here show 
differences between breast milk 
composition from healthy mothers 
and mothers with CD in terms of 
immune mediators, microbiota and 
HMOs. It can be speculated that 
such differences could influence 
the protective effects of breast-
feeding on infant health, and partly 
explain controversy across studies. 
Nevertheless, further prospective 
studies are needed to reveal 
whether differences in breast-milk 
composition ultimately influence the 
risk of offspring of developing CD. 
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ABSTRACT 
Intestinal dysbiosis has been associated with celiac disease (CD), 
but whether the alterations are cause or consequence of the disease is 
unknown. This study investigated whether the HLA-DQ2 genotype is 
an independent factor influencing the early gut microbiota composition 
of healthy infants at family risk of CD. As part of a larger prospective 
study, a subset (n=22) of exclusively breast-fed and vaginally delivered 
infants with either high genetic risk (HLA-DQ2 carriers) or low genetic 
risk (non-HLA-DQ2/8 carriers) of developing CD were selected from a 
cohort of healthy infants with at least one first-degree relative with CD. 
Infant fecal microbiota was analyzed by 16S rRNA gene pyrosequencing 
and real time quantitative PCR. Infants with a high genetic risk had 
significantly higher proportions of Firmicutes and Proteobacteria and 
lower proportions of Actinobacteria compared to low risk infants. At 
genus level, high risk infants had a significant less Bifidobacterium and 
unclassified Bifidobacteriaceae proportions and more Corynebacterium, 
Gemella, Clostridium sensu stricto, unclassified Clostridiaceae, unclassified 
Enterobacteriaceae and Raoultella proportions. Quantitative real time 
PCR also revealed lower numbers of Bifidobacterium spp. in infants with 
high genetic risk than in those of low genetic risk. In high risk infants 
negative correlations were identified between Bifidobacterium spp. and 
several genera of Proteobacteria (Escherichia/Shigella) and Firmicutes 
(Clostridium). The genotype of infants at family risk of developing CD, 
carrying the HLA-DQ2 haplotypes, influences the early gut microbiota 
composition. This finding suggests that a specific disease-biased host 
genotype may also select for the first gut colonizers and could contribute 
to determining disease risk. 
Keywords: celiac disease, HLA-DQ genotype, microbiota, pyrose-
quencing,  real-time PCR
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is the main environmental trigger 
of CD but its intake does not 
fully explain the onset and clinical 
expression of the disease. In recent 
years, other environmental factors 
influencing the early gut microbiota 
composition such as type of 
delivery and milk-feeding, intestinal 
infections and antibiotic intake, have 
also been associated with the risk of 
developing CD (6-11). 
Colonization of the newborn 
intestine is thought to contribute 
to proper development of the host’s 
immune function and to determine 
susceptibility to immune-mediated 
disorders in early and later life (12, 
13). Most studies in CD patients 
report imbalances in the intestinal 
microbiota (14) with a few exceptions 
(15, 16). In our own studies, the 
microbiota of CD patients was 
characterized by decreased numbers 
of Bifidobacterium spp. and increased 
numbers of Bacteroides spp. in 
feces and intestinal biopsies (17, 
18). Intestinal dysbiosis was not 
completely restored after adherence 
to a gluten-free diet suggesting that 
some changes in microbiota are 
not secondary to the inflammatory 
milieu of the active phase of the 
disease, but could play a primary 
role in predisposition to CD 
development. To date, we have a 
limited understanding of the host 
genotype’s influence on the intestinal 
microbiota composition, but a few 
studies have been done in relation 
to chronic inflammatory bowel 
disorders (19-21). In the case of CD, 
INTRODUCTION
Celiac disease (CD) is a chronic 
intestinal inflammatory disorder 
caused by a deregulated immune 
response to cereal gluten proteins of 
wheat, barley and rye in genetically 
predisposed individuals. The 
expression of the Human Leukocyte 
Antigen (HLA) Class II molecules 
DQ2 and DQ8, coded by the 
DQA1 and DQB1 genes, is strongly 
associated with susceptibility to 
CD. The HLA-DQA1*05:01 and 
DQB1*02:01 alleles forming the 
particular DQ2.5 haplotype confer 
high susceptibility to CD (1). 
Susceptibility to CD is increased in 
those homozygous subjects with this 
haplotype in cis, or those carrying 
the DQ2.2 haplotype (HLA-
DQA1*02:01 and DQB1*02:02) 
in trans with the DQ7.5 haplotype 
(HLA-DQA1*05:05 and 
DQB1*03:01). (2). In CD patients, 
gluten peptides are deaminated by 
tissue transglutaminase in the lamina 
propria and recognized by dendritic 
cells expressing HLA-DQ2/
DQ8 molecules that mediate the 
typical Th1 response of the disease, 
producing mainly interferon (IFN)-γ 
(3). Most patients are carriers of the 
HLA-DQ2/DQ8 genes but these 
genes are also present in about 40% 
of the general population, and only 
a small percentage (2-5%) develops 
CD (4, 5). This indicates that the 
HLA-DQ genotype is necessary 
but not solely responsible for the 
development of the disease. Gluten 
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there is only one study in a cohort 
of infants at family risk of developing 
the disease that has reported reliable 
associations between the HLA-DQ 
genotype and the composition of 
the intestinal microbiota, assessed 
by fluorescent in situ hybridization 
(FISH) and real-time polymerase 
chain reaction (PCR) (22-23). 
Nevertheless, these preliminary 
associations could be confounded 
by diverse environmental variables 
(e.g. type of milk-feeding, type 
of delivery, etc). Furthermore, 
the abovementioned studies were 
limited by their use of molecular 
techniques, which can only detect a 
small number of intestinal bacterial 
groups for which primers and probes 
are available. However, this problem 
can be now overcome by analyzing 
16S rRNA gene fragments from the 
whole fecal DNA (metagenome) by 
next generation sequencing (NGS) 
techniques, which help to study the 
intestinal ecosystem in greater depth 
(24).
The objective of this study was 
to characterize the microbiota of 
exclusively breast-fed and vaginally 
delivered infants at family risk of 
developing CD to reveal possible 
associations between the HLA-
DQ2 genotype, the early microbiota 
composition and the ecological 
interactions between relevant taxa. 
The broader aim is to gain a greater 
understanding of the genetic and 
environmental factors influencing 
the early colonization process of the 
newborn intestine, and their impact 
on the risk of developing CD.  
MATERIALS AND METHODS
Subjects and sampling
A subset (n=22) of one-month-old, 
exclusively breast-fed and vaginally 
delivered infants with either high 
genetic risk (HLA-DQ2 genotype, 
including homozygous HLA-DQ2.5 
or heterozygous DQ2.5/DQ2.2 
and DQ2.2/DQ7.5 carriers) or 
low genetic risk (non-HLA-DQ2/8 
genotype) of developing CD were 
selected from a cohort of healthy 
infants with at least one first-degree 
relative with CD participating in a 
larger prospective study (23). The risk 
of developing CD was determined by 
PCR-SSP DQB1 and DQA1 typing 
as previously described (23). The 
group of 11 infants classified as high 
risk (HR) represented the highest 
probability (>20%) of developing 
CD and included those carrying the 
DQ2.5 haplotype (DQA1*05:01-
DQB1*02:01) in homozygosis and 
the DQ2.5/DQ2.2 or the DQ2.2/
DQ7.5 haplotypes in heterozygosis 
(Supplementary table 1). The low 
risk (LR) group included those 
individuals with other common 
genotypes unassociated with CD, 
thus having the lowest probability 
(<1%) of developing CD. None of 
the infants included in the study 
received antibiotics during the 
sampling period.
The study was approved by the 
local Ethic Committees and written 
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informed consent was obtained from 
the parents of infants included in the 
study.
DNA extraction 
For DNA extraction, 0.2 g of fecal 
sample was homogenized in 15 mL 
of phosphate buffer saline (PBS) 
(130 mM sodium chloride, 10 mM 
sodium phosphate buffered saline, 
pH 7.4). Afterwards, the suspension 
was filtered through a 100 μm nylon 
filter, washed twice with PBS and re-
suspended in tris-EDTA (TE) buffer 
(10 mM Tris, 1 mM EDTA, pH 8.0 
[HCl]). One mL of the suspension 
was added to 2 mL of lysozyme (2.5 
mg/mL) and incubated at 37 ºC 
for 1 hour. After adding 0.67 mg of 
proteinase K, the mix was incubated 
at 55 ºC for 10 min. A volume of 
400 μL 10% (w/v) sodium dodecyl 
sulfate (SDS) was added to the mix 
and samples were incubated at 55 ºC 
for 1 hour under gentle shaking. One 
aliquot of the mix was used for DNA 
extraction following the DNeasy 
Blood and Tissue kit protocol 
(Qiagen, Hilden. Germany)
Sequencing the 16S rDNA 
amplicons
The extracted metagenomic DNAs 
were used to amplify the V5 and 
V6 hypervariable regions of the 
16S rRNA using the primers 784F 
5´-AGGATTAGATACCCTGGTA-
3´ and 1061R 5´-CRRCACGAGCT
GACGAC-3´ by PCR, as previously 
described (25).  The forward primer 
contained the sequence of the 
Titanium A adaptor 5′-CCATCTCA
TCCCTGCGTGTCTCCGACTC
AG-3′ and the barcode sequence. 
For each sample, a PCR mix of 
100 μL was prepared containing 
1× PCR buffer, 2U of KAPA HiFi 
Hotstart polymerase blend and 
deoxynucleotide triphosphates 
(dNTPs) (Kapa biosystems, 
Wilmington, USA), 300 nM primers 
(Eurogentec, Liege, Belgium), and 
60 ng gDNA. Thermal cycling 
consisted of initial denaturation 
at 95 °C for 5 min, followed by 
25 cycles of denaturation at 98 °C 
for 20 s, annealing at 56 °C for 40 
s, and extension at 72 °C for  20 s, 
with a final extension of 5 min at 72 
°C. Then 3 µl of PCR product were 
added to a new PCR mix (identical 
to the first round of PCR) for the 
nested PCR of 15 cycles. Amplicons 
were visualized on 1% agarose gels 
using GelGreen Nucleic Acid gel 
stain in 1x tris-acetate-EDTA (TAE) 
buffer (Biotium, Hayward, USA) 
and were cleaned using the Wizard 
SV Gel and PCR Clean-up System 
(Promega, Madison, USA) according 
to the manufacturer’s instructions. 
Amplicon DNA concentrations 
were determined using the Quant-iT 
PicoGreen dsDNA reagent and kit 
(Life Tech, Carlsbad, USA) following 
the manufacturer’s instructions. 
Assays were carried out using 2 μL 
cleaned PCR product in a total 
reaction volume of 200 μL in black, 
96-well microtiter plates. Following 
quantitation, cleaned amplicons 
were combined in equimolar ratios 
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into a single tube. The final pool 
of DNA was eluted in a volume 
of 100 µL nuclease-free water, 
purified using Agencourt Ampure 
XP Purification systems (Agencourt 
Biosciences Corporation-Beckman 
coulter, Beverly, USA) and then 
resuspended in 100 µl of TE 1x. 
The concentration of the purified 
pooled DNA was determined using 
the Quant-iT PicoGreen dsDN 
reagent and kit (Life Tech, Carlsbad, 
USA) following the manufacturer’s 
instructions. Pyrosequencing 
was carried out using primer A 
on a 454 Life Sciences Genome 
Sequencer FLX instrument (Roche, 
Basel, Switzerland) with titanium 
chemistry. 16S rDNA amplicons 
were sequenced by DNA Vision 
Agrifood S.A. (Liège, Belgium).
Sequence and clustering analysis
Original reads were filtered by 
length (> 240 bp) and quality 
(average Phred value > 25) and 
then for chimeras using UCHIME 
(26) resulting in 12,188 ± 3,191 
sequence reads per sample on 
average. Reads were identified at 
phylum, family and genus level at 
an 80% confidence level using the 
Ribosomal Database Project (RDP) 
multiclassifier tool. Rarefaction 
curves and cluster analysis were 
calculated with the mothur package 
using 1000 randomizations (27). For 
analysis of Clostridia sequences the 
Living Tree Project dataset available 
from www.arb-silva.de was used and 
the respective reads were subjected to 
a BlastN search against a database of 
microbial 16S rRNA gene sequences 
(SILVA 111, www.arb-silva.de). 
Similarity of the subject’s microbiota 
was evaluated by cluster analysis 
of Bray-Curtis distances between 
individuals, considering the relative 
abundances of different genera. 
Decimal logarithms of raw abundance 
data were classified according to an 
arithmetic progression in a scale 
from 0 to 7 (28). Logarithms were 
obtained adding 1 to each raw 
value, 0 corresponded to absence 
of the genera and 7 was fixed as the 
maximum raw datum considering all 
genera and individuals. Bray-Curtis 
distances between subjects were 
computed and agglomerative nesting 
cluster (AgNes function of the cluster 
package of R) analysis was applied to 
obtain the distances (28). Weighted 
UniFrac analysis was performed with 
a set of 258 dereplicated sequences 
with abundances of at least 100 
reads (26) using QIIME and the 
FastUniFrac tool at the URL http://
unifrac.colorado.edu.  
Richness and diversity index
Microbial biodiversity and richness 
were analyzed for each sample. Both 
parameters are based on operational 
taxonomic units (OTUs), which are 
clusters of reads defined by their 
inter-distance using the Chao index. 
Richness is directly related to the 
number of observed OTUs whereas 
the Shannon diversity index depends 
on the distribution of sequence 
abundances in the observed OTUs. 
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The Simpson index is a measure 
of the probability of randomly 
resampling an OTU. Microbial 
richness, Shannon, and Simpson 
indices were calculated with the 
mothur package (27).
Correlation analyses 
To study possible ecological 
interactions between different 
bacterial taxa, we established 
correlations within the bacterial 
groups identified in the low and 
high genetic risk groups of infants. 
We considered only those genera 
present in at least nine of the 11 
infants in each group. The weighted 
number of reads for each infant was 
expressed as a logarithm and cases 
with double zero (absence of both 
bacteria compared) were dismissed. 
The significance (P value) of the 
correlation coefficients between 
abundance of any two genera was 
estimated by a permutation test, 
performing 1,000 simulations for 
each coefficient (29). Only positive 
correlations with |1-P|< 0.100 and 
negative correlations with P< 0.100 
were considered. Additionally, we 
considered possible correlations 
among the genera Bifidobacterium, 
Corynebacterium, Gemella, 
Clostridium sensu stricto and 
Raoultella because they enabled us to 
discriminate between both groups of 
infants in previous analyses.
Real time quantitative PCR 
(qPCR)
DNA was amplified using group- 
and genus-specific primers as 
described previously (30, 31) to 
quantify different bacterial groups 
in the intestinal microbiota. Each 
reaction mixture consisted of 7.5 μL 
of SYBR Green PCR Master Mix 
(Roche), 3.5 μL of DNase RNase 
free water, 0.75 μL of each of the 
specific primers (10 μM) (Isogen, 
Barcelona, Spain), and 2.5 μL of 
template DNA. PCR amplification 
and detection were performed using 
a Light Cycler LC480 (Roche). Gene 
copy numbers of each bacterial group 
were calculated by comparing the 
cycle threshold (Ct) values obtained 
with those from a standard curve. 
Standard curves were generated 
from serial dilutions of a known 
copy number of the 16S rRNA gene 
cloned into a pGEM-T Easy Vector 
System (Promega). E. coli DH5α was 
transformed with the recombinant 
plasmids and plasmid DNA was 
extracted by the miniprep method 
(32).
Data processing and statistical 
analyses
Of the demographic data, the 
categorical variables (number of 
first-degree relatives with CD) were 
analysed using the Chi-Square test 
and the continuous variables (size, 
weight and weeks of gestation at birth) 
using a t-test since data distribution 
was normal as assessed with Shapiro-
Wilk W test (SPSS software V19). 
Data of microbiota composition was 
not normally distributed as assessed 
by the same test. Comparisons of data 
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from qPCR were done by applying 
the non-parametric Mann-Whitney 
U test (SPSS software V19). Read 
numbers for each taxon obtained for 
each infant by pyrosequencing were 
weighted using the mean values of 
the total reads for all 22 individuals. 
The recalculated numbers of reads 
assigned to each taxon for the high 
(n= 11) and low genetic risk (n= 11) 
groups of infants were compared 
using permutation analyses (DAAG 
package of R software). To compare 
diversity indices we implemented 
the R-software Wilcoxon test. 
Correlations between the data 
obtained by pyrosequencing and 
qPCR were analyzed using 
Pearson correlation coefficient 
(SPSS software V19). In all cases, 
statistically significant differences 
were established at P <0.050.
RESULTS 
Characteristics of the infants 
included in the study
The demographic characteristics 
and the HLA genotype of the study 
infants are included in Table 1. No 
statistical differences (P> 0.050) 
were observed in size, weight and 
weeks of gestation at birth or in the 
number of first-degree relatives with 
CD (mother, father, brother or/and 
sister) between the two infant groups.
Microbiota composition by 16S 
rRNA gene sequencing 
The pyrosequencing analysis 
detected sequences belonging to four 
phyla in all samples: Actinobacteria, 
Bacteroidetes, Firmicutes and 
Proteobacteria (Figure 1a). The 
intestinal microbiota of infants with 
low genetic risk of developing CD 
was characterized by a very high 
proportion of Actinobacteria (mean 
[SD] 79.6 [19.1]%), a moderate 
proportion of Firmicutes (14.9 
[16.6]%) and a low proportion of 
Proteobacteria and Bacteroidetes 
(3.3 [7.3] and 2.2 [6.2]%, 
respectively). Infants at high genetic 
risk of developing CD showed a 
more heterogeneous and evenly 
distributed microbiota among the 
phyla Actinobacteria, Firmicutes 
and Proteobacteria (36.1 [39.5], 
38.2 [28.2] and 22.6 [28.8]%, 
respectively), with a small proportion 
of Bacteroidetes (3.0 [9.9]%). 
High SD values revealed notable 
inter-individual variability of the 
microbiota composition (Figure 1b). 
Infants with a high risk of developing 
CD showed significantly higher 
proportions of Firmicutes (P= 0.026) 
and Proteobacteria (P= 0.039) and a 
lower proportion of Actinobacteria 
(P= 0.005) than those with low 
genetic risk. The high risk group 
of infants also presented higher 
proportions of Bacteroidetes than the 
low risk group (3.0 [9.9] versus 2.2 
[6.2]%) but the differences were not 
statistically significant (P= 0.954). 
In Figure 2 is shown a schematic 
representation of the principal 
families characterizing the microbiota 
in the low and high genetic risk 
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ID 
First-degree 
relatives 
with CD 
Genotype * Size 
(cm) 
Weight  
(g) 
Gestation 
(weeks) 
** Hospital 
LR1 brother DQ7.5/DQ5.1 47.0 3060 40 1 
LR2 brother DQ5.1/(DQ8) 52.1 3850 40 2 
LR3 sister (DQ8)/(DQ5) 54.0 4720 39 3 
LR4 sister DQ5/DQ7.5 51.3 4120 40 1 
LR5 sister DQ5.1/DQ7.5 52.0 3980 40 3 
LR6 sister DQ7/(DQ5) 49.0 4350 41 1 
LR7 brother DQ5/DQ5.3 50.4 4255 35 2 
LR8 brother DQ6.1/DQ4.2 53.1 3750 38 1 
LR9 mother DQ5.1/DQ5.1 53.5 4600 40 2 
LR10 sister DQ6/DQ8 52.0 4290 38 4 
LR11 mother DQ2/DQ4 51.0 4130 39 4 
Mean 
(SE)   
51.4 
(0.6) 
4100.5 
(136.2) 
39.1  
(0.5)  
HR12 sister DQ2.5/DQ2.5 51.7 3800 41 2 
HR13 sister DQ2.5/DQ2.5 50.0 4210 40 1 
HR14 sister DQ2.5/DQ2.5 50.0 4260 40 2 
HR15 father DQ2.5/DQ2.5 51.5 3890 39 2 
HR16 brother DQ2.5/DQ2.5 53.7 4050 40 2 
HR17 sister DQ2.5/DQ2.5 54.0 3680 39 1 
HR18 mother + sister DQ2.5/DQ2.2 53.5 4860 40 2 
HR19 mother DQ2.2/DQ7.5 48.8 3800 38 2 
HR20 sister DQ2.5/DQ2.2 49.0 3680 40 3 
HR21 mother DQ2.5/DQ2.2 52.6 3900 39 4 
HR22 brother DQ2.5/DQ2.2 54.1 4730 37 4 
Mean 
(SE)   
51.7 
(0.6) 
4078.2 
(121.6) 
39.4  
(0.3)  
P value # 0.590  0.717 0.904 0.654  
Table 1: Demographic characteristics and genotype of the infants included in the study.
* Displayed in parentheses are genotypes inferred from the DQB1 allele. ** 1-Hospital La Paz 
(Madrid); 2-Sant Joan de Reus (Tarragona); 3- Hospital Niño Jesús (Madrid); 4-Nuestra Señora de 
la Candelaría (Canarias) # Differences for the categorical variables between the low (LR) and high 
risk (HR) infant groups were analyzed using the Chi-Square test and for the continuous variables 
with the t-test. In all cases differences were established at a P value < 0.050.
Results and discussion
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groups of infants. In infants with 
low genetic risk of developing CD 
the majority (96.4% of sequence 
reads) of the total bacterial 
population belonged to five families: 
Bifidobacteriaceae, Streptococcaceae, 
Lachnospiraceae, Coriobacteriaceae 
and Enterobacteriaceae. In infants 
with high genetic risk of developing 
CD, the majority (95.9% of 
sequence reads) of the total bacterial 
population belonged to ten families 
comprising: Bifidobacteriaceae, 
E n t e r o b a c t e r i a c e a e , 
Streptococcaceae, Lachnospiraceae, 
Clostridiaceae 1, Bacteroidaceae, 
E r y s i p e l o t r i c h a c e a e , 
Lactobacillaceae, Actinomycetaceae 
and Enterococcaceae. In infants 
with low genetic risk of developing 
CD, sequences belonging to 
the phyla Actinobacteria and 
Firmicutes were mainly represented 
by the families Bifidobacteriaceae, 
and Lachnospiraceae plus 
Streptococcaceae, respectively. 
However, in infants with high 
genetic risk of developing CD, 
sequences belonging to the phyla 
Actinobacteria, Proteobacteria and 
Firmicutes were mainly represented 
by the families Bifidobacteriaceae, 
Enterobacteriaceae and 
Lachnospiraceae, Streptococcaceae 
plus Clostridiaceae, respectively. 
Infants with a high risk of developing 
CD had significantly higher 
abundance of Clostridiaceae 1 (P< 
Figure 1: Microbiota analysis by pyrosequencing the V5 and V6 hypervariable regions of the 
16S rRNA. Mean distribution of the four phyla Actinobacteria, Firmicutes, Proteobacteria and 
Bacteroidetes detected in the high genetic risk (HR) and low genetic risk (LR) groups of infants (a) 
and their corresponding individual percentages in each infant (b).
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0.001), Bacillales Incertae Sedis 
XI (P= 0.009), Enterobacteriaceae 
(P= 0.039), Corynebacteriaceae 
(P= 0.050) and unclassified 
Clostridiaceae (P= 0.012); and lower 
abundance of Bifidobacteriaceae (P= 
0.010) than those with low genetic 
risk.
At genus level, high risk infants had 
significantly increased proportions of 
Corynebacterium (P= 0.050), Gemella 
(P= 0.009), Clostridium sensu stricto 
(P< 0.001), Raoultella (P= 0.035), 
unclassified Clostridiaceae (P= 0.013) 
and unclassified Enterobacteriaceae 
(P= 0.009) and decreased proportions 
of Bifidobacterium (P= 0.010) and 
unclassified Bifidobacteriaceae (P= 
0.011) compared to low risk infants 
(Table 2). 
AgNes cluster dendrogram based on 
Bray-Curtis distances showed that at 
Figure 2: Percentages of the average values of the different families detected in the high and low 
genetic risk groups of infants. The families are represented with different shades and patterns 
indicating that they belong to the phyla Actinobacteria (blue), Firmicutes (green), Proteobacteria 
(yellow) and Bacteroidetes (red). Families shaded black in the figure had abundances below 0.1% 
and thus their shares are not visible.
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genus level the microbiota of infants 
can be partially differentiated based 
on their HLA-DQ genotype and 
cluster together with a few exceptions 
(Figure 3). A weighted UniFrac 
analysis clustered the microbiota 
according to predominant bacterial 
genera in each case. Consistent 
with the AgNes clustering the basic 
differentiation was between samples 
containing or not bifidobacteria. Six 
high risk infants dominated either by 
more than 40% Enterobacteriaceae 
reads (Escherichia or Klebsiella, 
subcluster C) or by more than 50% 
Streptococcus (subcluster D) and 
both not containing bifidobacteria 
(≤ 0.2%) grouped with each other. 
A large group of samples (subcluster 
A) comprising seven from low risk 
 
GENUS level 
LOW RISK HIGH RISK   
P 
Mean      SD Median  Q25   Q75 Range Mean SD Median Q25 Q75 Range 
Bacteroides 226.61 674.77 0 0 0 0-2253 351.49 1163.33 0 0 0 0-3859 0.945 
Parabacteroides 25.39 59.98 0 0 0 0-192 0.11 0.36 0 0  0-1 0.214 
Bifidobacterium 8811.79 2834.90 10287 6853 10287 3399-11479 3903.72 4777.42 19 6 19 1-11395 0.010 
Parascardovia 5.57 18.48 0 0 0 0-61 0.07 0.24 0 0 0 0-1 1.000 
Unclassified Bifidobacteriaceae 81.71 45.10 89 46 90 0-157 27.26 43.46 0 0 0 0-143 0.011 
Propionibacterium 2.82 8.97 0 0 0 0-30 4.64 14.62 0 0 0 0-49 0.738 
Rothia 27.43 45.06 1 0 1 0-131 126.92 276.16 35 2 35 0-942 0.225 
Corynebacterium 0.44 0.62 0 0 0 0-1 3.23 6.13 1 0 1 0-21 0.050 
Actinobaculum 0.11 0.37 0 0 0 0-1 19.39 64.32 0. 0 0 0-213 1.000 
Actinomyces 9.56 27.79 0 0 0 0-93 146.83 438.71 4 0 4 1468-0 0.351 
Eggerthella 3.44 6.08 0 0 0 0-18 3.17 10.52 0 0 0 0-35 0.935 
Atopobium 2.62 7.37 0 0 0 0-25 1.29 2.13 0 0 0 0-6 0.913 
Collinsella 412.68 1130.39 0 0 0 0-3789 0.65 1.05 0 0 0 0-3 0.214 
Streptococcus 833.16 1520.25 174 82 173 4-4029 2024.71 3446.25 371 80 371 29-10243 0.351 
Unclassified Streptococcaceae 7.72 15.94 0 0 0 0-41 8.19 13.67 3 0 3 0-43 0.939 
Lactococcus 2.04 5.15 0 0 0 0-17 5.80 16.83 1 0 1 0-56 0.704 
Lactobacillus 41.65 80.71 11 0 11 0-276 212.42 463.85 1 0 1 0-1531 0.279 
Unclassified Lactobacillaceae 0.32 1.07 0 0 0 0-4 2.01 4.20 0 0 0 0-14 0.270 
Enterococcus 30.18 49.47 2 0 2 0-119 139.15 274.49 16 7 16 0-931 0.175 
Unclassified Enterococcaceae 2.06 3.55 0 0 0 0-9 6.37 12.51 1 0 1 0-42 0.358 
Leuconostoc 3.25 10.36 0 0 0 0-34 0.00 0.00 0 0 0 0-0 0.476 
Fructobacillus 1.88 6.24 0 0 0 0-21 0.00 0.00 0 0 0 0-0 1.000 
Granulicatella 0.52 1.73 0 0 0 0-6 3.59 11.90 0 0 0 0-39 1.000 
Staphylococcus 32.05 64.21 5 0 5 0-205 74.62 82.23 41 5 41 0-194 0.194 
Gemella 0.32 0.76 0 0 0 0-2 23.85 54.89 8 0 8 0-186 0.009 
Anaerococcus 0.00 0.00 0 0 0 0-0 26.55 87.77 0 0 0 0-291 0.476 
Lachnospiracea incertae sedis 34.92 86.34 0 0 0 0-278 114.64 364.60 0 0 0 0-1213 0.807 
Blautia 47.11 155.88 0 0 0 0-517 0.00 0.00 0 0 0 0-0 0.476 
Unclassified Lachnospiraceae 561.95 1274.64 1 0 1 0-3714 591.07 1266.05 1 0 1 0-4239 0.995 
Clostridium XlVb 0.27 0.91 0 0 0 0-3 1.18 3.62 0 0 0 0-12 0.738 
Dorea 121.16 401.85 0 0 0 0-1333 0.21 0.71 0 0 0 0-2 1.000 
Clostridium sensu stricto 0.00 0.00 0 0 0 0-0 642.65 1079.04 103 27 103 0-3308 <0.001 
Clostridium IV 0.00 0.00 0 0 0 0-0 12.48 41.38 0 0 0 0-137 1.000 
Clostridium XVIII 6.85 15.01 0 0 0 0-38 306.12 1009.16 0 0 0 0-3349 0.843 
Unclassified Clostridiaceae 0.00 0.00 0 0 0 0-0 18.64 38.45 1 0 1 0-110 0.013 
Unclassified Eubacteriaceae 0.00 0.00 0 0 0 0-0 10.28 34.11 0 0 0 0-113 1.000 
Veillonella 2.23 6.79 0 0 0 0-23 137.45 439.45 1 0 1 0-1462 0.225 
Escherichia/Shigella 345.32 828.59 46 8 46 0-2790 1950.50 3355.77 79 2 79 0-8941 0.151 
Klebsiella 2.55 7.18 0 0 0 0-24 426.16 1395.66 0 0 0 0-4634 0.269 
Serratia 0.82 2.73 0 0 0 0-9 5.72 18.15 0 0 0 0-60 0.738 
Raoultella 0.00 0.00 0 0 0 0-0 20.52 42.06 0 0 0 0-134 0.035 
Unclassified Enterobacteriaceae 40.73 55.09 3 1 3 0-135 247.94 261.58 179 59 179 1-657 0.009 
Table 2: Mean, standard desviation, median, Q25, Q75 values and ranges of the number of reads 
in each infants weighted using the total number of reads of all the infants
Statistical differences between the two risk groups were established at P< 0.050 using permuta-
tion analyses.
Chapter 3
146
infants and three from high risk 
infants (HR12, HR13 and HR14) all 
containing 72 – 98% Bifidobacterium 
spp. grouped closely whereas three 
samples sharing the presence of 25 
– 40% unclassified Lachnospiraceae 
(subcluster B) clustered together. 
Rarefaction curves for each group 
indicate that the total bacterial 
diversity was well represented since 
clustering curves for all individuals, 
except HR16, approached saturation 
at 90% (Data not shown).
Richness and diversity analysis 
Differences in richness and Simpson 
index between the high and low 
genetic risk groups of infants showed 
a borderline statistical significance 
(P = 0.065) (Table 3). Richness was 
18.1 [6.2] (mean [SD]) for the low 
genetic risk group and 27.0 [10.3] 
for the high genetic risk group. The 
respective Simpson indices were 0.68 
[0.26] and 0.56 [0.23]. 
Correlation analysis
The possible interactions between 
Figure 3: (a) AgNes dendrogram shows the clustering of the infants based on Bray-Curtis distances 
calculated on the basis of the abundance data (number of 16S rRNA gene sequence reads) at genus 
level. (b) Weighted UniFrac clustering of 166,799 reads (representing 64.4% of all reads) based 
on a set of 258 sequences with total abundances between 16577 and 100. Capital letters indicate 
subclusters of infants according to common dominant bacterial genera in their microbiota. (A): 
Bifidobacterium spp. > 80%, (B): unclassified Lachnospiraceae 25 – 40%, (C): Enterobacteriaceae 
> 40%, and (D): Streptococcus >50%. Low risk (LR) individuals are shown in blue and high risk 
(HR) in red. 
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   Sample 
No. of 
sequences  
%assig. 
Phylum 
%assig. 
Family 
%assig. 
Genus 
No. 
OTUs 
Shannon 
index 
Simpson 
index 
LR1 8594 96.2 96.0 95.9 9 0.095 0.971 
LR2 9513 98.5 98.5 98.3 13 0.104 0.962 
LR3 10147 98.2 98.1 98.0 23 0.332 0.888 
LR4 12248 99.6 99.6 99.6 10 0.252 0.909 
LR5 9963 95.4 95.4 95.2 16 0.334 0.869 
LR6 9770 93.6 93.5 93.4 21 0.886 0.475 
LR7 9881 97.1 97.0 96.9 22 0.931 0.482 
LR8 10628 96.2 95.9 95.6 22 1.215 0.343 
LR9 7909 98.5 98.4 98.4 28 1.512 0.255 
LR10 9896 99.7 99.7 99.7 13 0.540 0.775 
LR11 12210 96.7 96.6 96.5 22 0.741 0.582 
HR12 11568 92.7 86.9 85.3 8 0.152 0.947 
HR13 13126 95.5 94.6 94.3 22 0.483 0.825 
HR14 10267 95.9 95.7 95.4 21 0.710 0.657 
HR15 10067 99.1 99.0 98.9 21 1.272 0.372 
HR16 15726 88.7 88.2 87.1 42 1.300 0.360 
HR17 17080 96.7 96.5 96.3 29 0.984 0.518 
HR18 20010 97.3 97.1 97.1 16 0.399 0.795 
HR19 17660 94.4 94.0 93.6 33 1.646 0.262 
HR20 13284 99.4 99.3 99.3 31 1.225 0.320 
HR21 13869 96.8 96.6 96.5 37 1.121 0.474 
HR22 14732 98.4 98.3 98.1 37 0.810 0.624 
Table 3: Number of sequences obtained in samples from the low genetic risk (LR) and high gene-
tic risk (HR) groups and percentage of reads assigned at the phylum, family and genus level. 
OTU numbers and Shannon and Simpson indices were calculated at a clustering level of 90%.
the bacterial genera detected in 
infants at low genetic risk are 
summarized in Figure 4a. Nine 
interactions involving nine bacteria 
were selected that comprise only one 
positive correlation between Rothia-
Streptococcus (r= 0.630, 1-P= 0.029). 
The highest negative correlations 
were between Bacteroides-
Enterococcus (r= -0.756, P= 0.014), 
and Bifidobacterium-Eggerthella (r= 
-0.613, P= 0.024). The increased 
diversity in the microbiota of high 
risk infants resulted in a higher 
number of significant correlations 
(a total of 35) involving 14 different 
bacterial genera (Figure 4b). 
Bifidobacterium showed a significant 
negative correlation with Veillonela 
(r= -0.590, P= 0.010), Rothia (r= 
-0.800, P= 0.004), Streptococcus (r= 
-0.761, P= 0.007) and borderline 
significant with Escherichia/
Shigella (r= -0.497, P= 0.059) and 
Clostridium (r= -0.397, P= 0.121). 
Of bacterial genera that enabled 
to discriminate between the two 
groups of infants, Bifidobacterium 
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Figure 4: Representation of the correlations among bacterial genera that met the criteria |1-
P|< 0.100 (positive correlation) or P< 0.100 (negative correlations) in low (a) and high genetic 
risks groups (b) of infants. The color of the different genera indicate they belong to the phyla 
Actinobacteria (blue), Firmicutes (green), Proteobacteria (yellow) and Bacteroidetes (red). Circle 
sizes are relative to the logarithm of the mean weighted number of reads (see scale). Blue or red node 
colors indicate positive and negative correlations, respectively. Node style represents the correlation 
coefficient as continuous line (R≥ 0.75 or ≤ -0.75), discontinuous line (|R|=0.75 - 0.1) and weak 
line (0.1 >R> -0.1)
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showed a no significant positive 
correlation with Corynebacterium (r= 
0.103, 1-P= 0.627) and Raoutella 
(r= 0.070, 1-P= 0.582) and negative 
with Gemella (r= -0.206, P= 0.270). 
Clostridium spp. showed a statistically 
significant negative correlation with 
Lactobacillus (r= -0.573, P= 0.041), 
but not with Corynebacterium (r= 
-0.130, P= 0.379), Gemella (r= 
-0.212, P= 0.268) and Raoultella (r= 
-0.057, P= 0.438). 
Prevalence of Clostridium sensu 
stricto discriminates between the 
infant groups
The genus Clostridium sensu 
stricto was considered indicative 
of differences in the microbiota 
between low and high genetic risk 
groups, because its proportions were 
quantitatively different between 
both groups and it was present in 
nine individuals of the high genetic 
risk group but in none of the low 
genetic risk group. Therefore, the 
composition of this genus was 
analyzed in more detail. 
Clostridium sensu stricto was present 
in three high risk group individuals 
representing 28.1 (HR20), 14.0 
(HR21) and 13.3% (HR17) of all 
reads and in five more representing 
between 0.4 and 1.4%. The 10,173 
reads classified in this genus were 
therefore further analyzed. In total, 
these represented 1,879 different 
sequence types. BlastN comparisons 
showed nine Clostridium species 
as best hits (Table 4). Three of 
them were dominant, to which 
9,577 reads (94.1%) belonged to 
Clostridium paraputrificum (41.2%), 
C. chartatabidum (33.2%) and C. 
perfringens (19.8%) with average 
sequence similarities to the reference 
sequences X75907, X71850, and 
CP000246 of 97.8, 98.3 and 99.2%, 
respectively. C. perfringens was 
present in five individuals, proving 
the most widely distributed species. 
The highest diversity of Clostridium 
was found in individuals HR20 and 
HR21, with seven and five of the 
nine species identified, respectively. 
Interestingly, two closely related 
species (C. paraputrificium and C. 
chartatabidum) were coexisting 
in HR20, both in relatively high 
numbers. On the contrary, the 
presence of C. perfringens was 
practically exclusive.
Real time quantitative PCR 
(qPCR)
The characterization of the microbiota 
composition by qPCR (Table 5) 
revealed that infants in the high 
genetic risk group had reduced gene 
copy numbers of Bifidobacterium 
spp. (median log values [interquartil] 
6.86 [6.36-11.28] versus 11.00 
[10.73-11.42] P= 0.018) compared 
to the low genetic risk group 
according to pyrosequencing data. 
The high genetic risk group also 
had reduced gene copy numbers of 
Bacteroides fragilis group and Blautia 
(C. coccoides) group compared to the 
low genetic risk group (> 1 log unit 
difference), but the latter differences 
did not reach statistical significance 
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Best hit   Individual samples* 
Species Acc. no. 
    All 
indiv. 
HR 
13 
HR 
14 
HR 
15 
HR 
16 
HR 
17 
HR 
19 
HR 
20 
HR 
21 
HR 
22 
C. paraputificium X75907 4190 2   5  60 4118 5  
C. chartatabidum X71850 3376       1268 2108  
C. perfringens CP000246 2011 203 84  81 1461    182 
C. vincentii X97432 306       79 227  
C. isatidis X98395 140       42 98  
C. sartagoforme Y18175 106       106   
C. roseum Y18171 34       27 7  
C. butyricum AJ458420 9   9       
C. tertium Y18174 1       1   
 All types 10173 205 84 9 86 1461 60 5641 2445 182 
Table 4: Distribution of pyrosequencing reads classified as Clostridium sensu stricto. 
Results of BlastN matches against reference sequences from the LTP-Silva database.
*Samples HR12 and HR18 did not contain reads classified into this genus.
 
 Low genetic risk group  High genetic risk group  
Bacterial groups 
log gene copy numbers/g stools 
Median (IQR) 
*P value 
Bacteroides fragilis group 7.62 (5.86-8.11) 6.04 (5.53-8.03) 0.336 
Bifidobacterium spp. 11.00 (10.73-11.42) 6.86 (6.36-11.28) 0.018 
Lactobacillus group 6.80 (5.15-9.45) 6.43 (5.28-9.69) 0.470 
Staphylococcus spp. 6.81 (5.78-7.20) 8.41 (5.96-9.41) 0.142 
Enterococcus spp. 8.15 (6.67-9.08) 8.26 (6.92-8.83) 0.922 
Streptococcus spp. 8.90 (7.90-8.99) 8.98 (7.64-9.81) 0.563 
C. leptum  group 5.28 (4.12-6.53) 4.68 (4.13-8.92) 0.555 
Blautia ** group  8.20 (5.42-10.13) 6.88 (6.02-10.34) 0.630 
 
Table 5: Fecal microbiota of infants with high or low genetic risk of developing CD determined 
by qPCR.
*Statistically differences were established at P<0.050 applying the Mann-Whitney U test. 
** Formely Clostridium coccoides group.
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(P= 0.336 and 0.630, respectively). 
The high genetic risk group of 
infants also showed increased gene 
copy numbers of Staphylococcus 
spp. compared to the low genetic 
risk group; however, the difference 
was not statistically significant  (P= 
0.142).
Statistically significant correlations 
between the data obtained by qPCR 
and pyrosequencing were detected for 
Bacteroides fragilis group (r= 0.998, 
P< 0.001), Bifidobacterium spp. (r= 
0.469, P= 0.037) and Lactobacillus 
group (r= 0.869, P< 0.001). No 
significant correlation between the 
data obtained by the two techniques 
was detected for the other bacterial 
groups analyzed by qPCR. 
DISCUSSION
Emerging evidence supports the 
hypothesis that host genotype 
influences gut microbiota 
composition, but there is a limited 
number of studies revealing these 
interactions (33). The present 
study is the first to demonstrate 
by high-throughput sequencing 
of 16S rRNA genes that the HLA-
DQ2 genotype per se influences 
the intestinal bacterial community 
structure of infants at family risk of 
developing CD. Indeed, compared 
to low risk infants, the intestinal 
microbiota of high risk infants was 
characterized by increased Firmicutes 
and Proteobacteria proportions 
but reduced Actinobacteria 
proportions. The increased 
Firmicutes proportions were 
reflected by increased proportions of 
the genera Clostridium (Clostridium 
sensu stricto and unclassified 
Clostridiaceae) and Gemella. The 
higher abundances of Proteobacteria 
were due to increases in Raoultella 
and unclassified Enterobacteriaceae. 
The reduced proportions of 
Actinobacteria were due to decreases 
of the genera Bifidobacterium and 
Corynebacterium. 
Reductions in Bifidobacterium spp. 
have also been detected previously 
in duodenal biopsies and feces of 
subjects with the disease, even after 
long-term adherence to a gluten-free 
diet, indicating that this bacterial 
group could contribute to the 
etiopathogenesis of CD (17, 18). 
Previous studies have investigated 
the influence of the HLA-DQ2/8 
genotype on the intestinal microbiota 
composition of this cohort of infants 
with a family history of CD, but 
they used molecular techniques 
with a more limited resolution such 
as FISH, qPCR and denaturing 
gradient gel electrophoresis (22, 
23, 34). Notwithstanding, initial 
results revealed that although both 
the HLA-DQ2/8 genotype and 
milk-feeding type (breast-milk 
or formula) influence the infant’s 
gut colonization, infants with 
higher genetic risk (HLA-DQ2/8 
positives) had lower Bifidobacterium 
spp. and B. longum numbers, and 
higher Staphylococcus spp. numbers 
irrespective of milk-feeding type 
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(23). However, our present study 
conducted in exclusively breast-fed 
infants did not reveal differences 
in Bacteriodes spp., confirming 
the hypothesis that breast-feeding 
attenuated the HLA-DQ–driven 
microbiota differences in this 
bacterial group, which were detected 
only in the formula-fed infants in 
our previous study by qPCR. 
Our present pyrosequencing data 
also revealed that the HLA-DQ2 
genotype influences colonization 
by Clostridium spp. (Clostridium 
sensu stricto and unclassified 
Clostridiaceae). Clostridium sensu 
stricto was detected in nine out of 
11 samples from high risk infants, 
while it was absent in samples from 
low risk infants. C. perfringens was 
the species showing the highest 
prevalence (in five out of nine cases). 
A recent study that analyzed the 
intestinal microbiota by 16S rRNA 
gene pyrosequencing in children 
with the HLA-DQB1 (DQB1*02, 
DQB1*03:02) genotype, β-cell 
autoimmunity was positively 
associated with C. perfringens (35). 
However, this association could not 
be related to the HLA genotype 
because this was similar in children 
with β-cell autoimmunity (defined 
as positive diabetes-associated 
autoantibodies at least twice) and in 
those negative for the autoantibody. 
Also Clostridium difficile (cluster XI) 
infection, defined as positive toxin 
detection, has been associated with 
the NOD2 genotype and phenotype 
of patients with Crohn’s disease (21). 
In the present study, correlation 
analyses for high risk infants also 
revealed negative correlations 
between Bifidobacterium spp. and 
Clostridium spp., which might explain 
the absence of Clostridium spp. in low 
risk infants where Bifidobacterium 
spp. are clearly dominant. Data from 
a previous prospective study reported 
that a lower ratio of Bifidobacterium 
to Clostridium counts in the fecal 
microbiota of infants was associated 
with atopic disease (15). 
Our pyrosequencing study has also 
been the first to detect differences 
in proportions of the genera 
Corynebacterium, Gemella and 
Raoultella as a function of the HLA-
DQ2 genotype in the infant’s gut. 
Although the biological role of these 
genera is not well-documented, 
mice with alcoholic liver disease also 
showed increases in Corynebacterium 
and Alcaligenes (36). The authors 
proposed that these changes in 
microbiota might contribute to 
the disease by increasing intestinal 
permeability via alterations in tight-
junction related protein expression 
(zonula occludens-1 and claudin-1), 
which could be prevented by probiotic 
administration (36). In the light of 
our results, we cannot disregard the 
possibility that specific microbiota 
alterations (e.g. Corynebacterium 
spp.) may also contribute to this 
phenomenon in CD as increased 
intestinal permeability is also 
characteristic of the active phase of 
CD and is considered a potential 
pre-developmental event (37).
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Another study analyzed the 
microbiota of a small subset of subjects 
(eight per group) by pyrosequencing 
to investigate how early (from 6 
months on) or late (after 12 months) 
gluten introduction into the infant 
diet affected CD development in 
genetically predisposed infants 
(HLA-DQ2/8) (38). The authors 
reported that the microbiota 
of HLA-DQ2/8 carriers was 
characterized by higher abundance of 
Firmicutes and lower abundance of 
Bacteroidetes (1% to undetectable) 
as compared to data from another 
study on non-genotyped healthy 
infants (39). However, samples 
from each of the aforementioned 
studies were analyzed using different 
techniques (SSU rDNA microarray 
versus 454 pyrosequencing) which 
could explain the differences that 
the authors attributed to the HLA-
DQ genotype (38). Differences in 
sample handling (storage time and 
temperature) and processing (e.g. 
DNA extraction method) could also 
lead to different results from massive 
sequencing analysis; therefore, 
studies using different methodologies 
are considered non cross-comparable 
(40). Furthermore, the genotype 
of infants included in the Palmer 
study was unknown (39), thus there 
may have been HLA-DQ carriers, 
because they represent up to 40% of 
the general population (5). 
Another prospective study that 
analyzed possible associations 
between the intestinal microbiota 
composition and the risk of 
developing neonatal sepsis or 
systemic inflammation revealed a 
dominance of Proteobacteria in 
infants who developed the disease 
(12) as in the case of our high genetic 
risk infants. Furthermore, correlation 
analyses in high risk infants also 
revealed negative correlations 
between Bifidobacterium spp. and 
Proteobacteria (Escherichia/Shigella), 
which might explain reduced levels 
of the latter in low risk infants 
whose microbiota was dominated by 
bifidobacteria. Also, the phenotype 
of patients with inflammatory 
bowel diseases (Crohn’s disease and 
ulcerative colitis), and the NOD2 
and ATG16L1T300A genotypes have 
been associated with compositional 
shifts in the phylum Proteobacteria 
in intestinal biopsies (41).
In the present study, statistically 
significant correlation between 
pyrosequencing and qPCR data was 
only obtained for bifidobacteria, 
bacteroides and lactobacilli.  This can 
be partially explained by differences 
between the range of bacteria targeted 
by the qPCR primers used, and the 
classification of the corresponding 
taxa by pyrosequencing, as previously 
reported (40). 
Several studies have attempted to 
establish relationships between gut 
microbiota diversity and health 
status, but conclusions have been 
rather inconsistent to date. It is 
well known that breast-fed babies 
have a low diverse microbiota, 
mainly dominated by the genus 
Bifidobacterium, and breast-feeding 
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exerts a positive effect over infants’ 
health (42, 43). In our present 
study, infants with low genetic risk 
of developing CD also had lower 
bacterial diversity compared to high 
risk infants. Especially, in those high 
risk infants in which bifidobacteria 
were absent or present in only 
small numbers, the microbiota 
was much more diverse. Other 
studies report that decreased gut 
microbiota diversity is associated 
with diseases such as necrotizing 
enterocolitis (44) and type 1 diabetes 
(45) in infants, and with obesity 
in adults (46). A prospective study 
of neonatal infants also showed 
that those who developed sepsis or 
systemic inflammation presented 
low microbial diversity, from the 
meconium through to disease onset 
(12). One of the reasons that can 
explain the controversial conclusions 
regarding the relationship between 
microbial diversity and disease 
reported in infants is that some 
of the previous studies have used 
primers that are not appropriate for 
detection of bifidobacteria (12, 44, 
45), which is the bacterial group that 
mainly determine gut microbiota 
diversity early in life. Under-
representation of bifidobacteria in 
16S rRNA pyrosequencing analyses 
has been described and led to the 
design of alternative wobbled PCR 
amplification primers that improve 
the detection of bifidobacteria (47) 
and that were used in our study.
In conclusion, the results of our 
study based on high-throughput 
sequencing reveal that the HLA-
DQ2 genotype strongly influences 
the intestinal colonization of infants 
at family risk of developing CD. 
Infants with high genetic risk of 
developing the disease (HLA-DQ2 
carriers) show reduced abundance 
of Actinobacteria (Bifidobacterium 
spp.) and increased abundance of 
Firmicutes (Clostridium sensu stricto 
and unclassified Clostridiaceae 
and Gemella) and Proteobacteria 
(Raoultella and unclassified 
Enterobacteriaceae). Some of these 
bacterial groups were negatively 
correlated, suggesting that one 
excludes the others. Follow-up of 
this study cohort is underway to 
determine whether the microbiota 
changes dictated by the HLA-DQ 
genotype precede the development 
of CD in later life.
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SUPPLEMENTARY TABLE
Sup. table 1: List of haplotypes and their respective DQA1 and DQB1 genotype.
 
 
 Haplotype HLA genotype 
DQ2 DQB1*02 
DQ2.2 
DQA1*02:01 
DQB1*02:02 
DQ2.5 
DQA1*05:01 
DQB1*02:01 
DQ4 DQB1*04 
DQ4.2 
DQA1*04:01 
DQB1*04:02 
DQ5 
DQA1*01 
DQB1*05 
DQ5.1 
DQA1*01:01 
DQB1*05:01 
DQ5.3 
DQA1*01:04 
DQB1*05:03 
DQ6 
DQA1*01 
DQB1*06 
DQ6.1 
DQA1*01:03 
DQB1*06:01 
DQ7 
DQA1*05 
DQB1*0301 
DQ7.5 
DQA1*05:05 
DQB1*03:01 
DQ8 
DQA1*03:01 
DQB1*03:02 
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ABSTRACT 
Interactions between immune system and intestinal microbiota may play a 
role in celiac disease (CD). The potential effects of Bifidobacterium longum 
CECT 7347 on children with newly diagnosed CD were evaluated. A 
double-blind, randomized, placebo-controlled trial was conducted in 33 
children that received a capsule containing either B. longum CECT7347 
(109 colony-forming units) or placebo (excipients) daily for 3 months 
in parallel to the gluten-free diet. Outcome measures (baseline and 
after intervention) included immune phenotype of peripheral-blood 
cells, serum cytokines, faecal secretory immunoglobulin A (sIgA), 
anthropometric parameters and intestinal microbiota. Comparisons 
between groups revealed greater height percentile increases (P= 0.048) 
in the B. longum CECT 7347 group than in the placebo group, as well 
as decreased peripheral CD3+ T-lymphocytes (P= 0.004) and slightly 
reduced tumour necrosis factor (TNF)-α concentration (P= 0.067). 
Within group comparisons of baseline and final values did not reveal 
differences in T-lymphocytes and cytokines in the placebo group, while 
decreased CD3+ (P= 0.013) and HLA-DR+ T lymphocytes (P= 0.029) 
and slightly reduced TNF-α concentration (P= 0.085) were detected in 
the B. longum CECT 7347 group. Comparison between groups showed 
that B. longum CECT 7347 administration reduced Bacteroides fragilis 
group numbers (P= 0.020) and stool sIgA (P= 0.011) in comparison 
with the placebo. Although this is a first exploratory intervention with 
limitations, the findings suggest that B. longum CECT 7347 could help 
to improve the health status of CD patients, who tend to show alterations 
in gut microbiota composition and a biased-immune response even on a 
GFD. 
Keywords: celiac disease, Bifidobacterium longum CECT 7347, probiotics, 
gluten-free diet.
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composition in comparison with 
controls and patients with dermatitis 
herpetiformis, suggesting that the 
microbiota may play a role in the 
manifestation of the disease (9). 
In vitro and animal studies have 
demonstrated that the dysbiotic 
gut microbiota of CD patients and 
specific isolates may potentially 
enhance the inflammatory response 
elicited by gluten and contribute 
to increasing intestinal epithelial 
permeability and gliadin peptide 
translocation (10-13). In contrast, 
Bifidobacterium longum CECT 7347 
has been shown to attenuate the 
inflammatory effects of the dysbiotic 
gut microbiota of CD patients on 
peripheral blood mononuclear cells 
(PBMCs) partially via induction 
of interleukin (IL)-10 production 
(10, 14). This strain has also been 
proven to reduce the cytotoxic and 
inflammatory effects of gliadin 
peptides on epithelial cells in vitro 
via degradation of gliadin peptides 
(15, 16). B. longum CECT 7347 
administration has also been shown 
to reduce the numbers of peripheral 
T CD4+ cells, and increase IL-10 
and reduce tumour necrosis factor 
(TNF)-α production in jejunal 
sections in an animal model of 
gliadin-induced enteropathy (17). 
The only current treatment for CD 
is adherence to a strict GFD, which 
usually results in symptomatic, 
serologic and histological remission 
(18, 19). However, compliance 
with a strict GFD is very difficult 
due to the presence of gluten in 
INTRODUCTION
Celiac disease (CD) is an 
autoimmune enteropathy caused by 
a permanent intolerance to dietary 
proteins of wheat, barley and rye 
in genetically predisposed (human 
leukocyte antigen (HLA)-DQ2/8) 
individuals. In CD patients, gluten 
proteins induce a deregulated 
immune response that typically 
leads to severe small intestine 
mucosal injury, malabsorption 
and gastrointestinal symptoms 
(1). Gluten proteins are the main 
environmental factor involved in 
CD pathogenesis; however, recent 
studies have shown that other 
factors influencing the interplay 
between the gut microbiota and the 
mucosal immune system, including 
breastfeeding and gastrointestinal 
infections, could contribute to 
determining the disease onset (2). 
Observational studies conducted 
so far have reported associations 
between intestinal dysbiosis and 
celiac disease (3), with a few 
exceptions (4, 5). Our own studies 
reported that the duodenal and 
faecal microbiota of CD patients is 
unbalanced with decreased numbers 
of Bifidobacterium spp. and increased 
numbers of Bacteroides spp. and E. 
coli clones with higher virulence 
features, which are only partially 
normalized after a long-term gluten-
free diet (GFD) (6-8). One of the 
most recent studies has also reported 
that CD patients with gastrointestinal 
symptoms had different microbiota 
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most processed foods and the social 
restriction implied; thus overall the 
GFD is far from optimal. In practice, 
CD patients may continue suffering 
from clinical symptoms, nutritional 
deficiencies and higher health risks 
(20-22). For example, it has been 
reported that even under GFD, 
CD children (23) and women (24) 
have a much higher prevalence of 
gastrointestinal symptoms than do 
controls, and they also use healthcare 
services more often (22). Whether 
or not this is due to residual chronic 
inflammation, exposure to minimum 
amounts of gluten and/or intestinal 
dysbiosis remains unknown. 
Whether complete normalization 
of lymphocyte subsets in peripheral 
blood can be achieved remains 
unclear (19, 25). Other studies also 
indicate that small intestine bacteria 
overgrowth is often associated 
with non-responsive CD (26). The 
duodenal and faecal microbiota of 
CD patients has also been shown not 
to be completely normalized after 
adherence to a GFD, which can also 
contribute to the lack of complete 
restoration of the intestinal immune 
homeostasis in the patients (6, 7). 
Therefore, adjunctive strategies that 
can improve the effects of a GFD are 
being investigated (27).
The aim of this study was to 
conduct a three-month double-blind 
randomized placebo-controlled trial 
on children with newly diagnosed 
CD following a GFD in order to 
evaluate the effects of B. longum 
CECT 7347 administration on 
immune and anthropometric 
parameters, and on the intestinal 
microbiota composition.
MATERIAL AND METHODS
Subjects and study design
A total of 36 children were recruited 
at the Hospital Universitari Sant 
Joan (Reus, Tarragona) and Hospital 
Universitario Sant Joan de Deu 
(Barcelona) from November 2011 
to June 2012. The inclusion criteria 
were children aged 2-17 years with 
newly diagnosed CD according to 
the European Society of Pedriatric 
Gastroenterology Hepatology and 
Nutrition (ESPGHAN) criteria, 
based on symptoms, positive anti-
tissue transglutaminase antibodies 
quantified using tTG-IgA ELISA 
kit (Pharmacia Diagnostics GmbH, 
Freiburg, Germany) and duodenal 
biopsy demonstrating villous 
atrophy. The exclusion criteria 
did not allow subjects enrolled in 
another clinic study, treated with 
antibiotics 30 days before starting 
the study, and/or with food allergy 
or others pathologies. Demographic 
and clinical characteristics of the 
subjects included in the study are 
shown in Table 1. 
A double-blind, randomized, 
placebo-controlled intervention 
trial was conducted. A graphic 
representation of the study protocol 
is shown in Figure 1.  All children 
recruited (n=36) met the inclusion 
criteria and were randomly assigned 
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to the B. longum CECT 7347 (n=18) 
or the placebo (n=18) group. The 
randomization design was generated 
using the SAS module PROC 
PLAN (9.1.3 version, service pack 
2) multiple of two sized blocks and 
1:1 pattern through a centralized 
randomization list. The test group 
received B. longum CECT 7347 
(109 CFU per capsule daily) and 
the placebo group received an 
indistinguishable capsule containing 
only the excipient (skimmed milk 
with 30% sucrose and 0.5% vitamin 
C daily) taken at lunch time or with 
other food intake, for 3 months after 
CD diagnosis and in parallel to the 
GFD. Capsule groups were labelled 
 
 
 
 Study group  
*P  value 
Characteristics Placebo  B. longum CECT 7347 
Number of cases 16 17  
Male/Female 8/8 7/10 0.437 
Age, [mean (SE)] 8.5 (1.2) 6.8 (0.9) 0.265 
Baseline height (cm) [mean (SE)] 26.5 (3.8) 21.8 (3.4) 0.301 
Baseline weight (kg) [mean (SE)] 119.8 (5.7) 109.3 (6.4) 0.449 
Height percentile baseline/post-treatment  0.530/0.530 
Children up percentile 50 2/2 3/3  
Children at percentile 50 0/0 0/0  
Children under percentile 50 14/14 14/14  
Increased height percentile   
Mean (SE) 7.0 (1.5) 7.8 (2.2) 0.591 
Post-treatment-baseline/baseline [median (IQR)] 0.30 (0.1-0.53) 1.29 (0.22-2.85) 0.048* 
Weight percentile baseline/post-treatment  0.530/0.365 
Children up percentile 50 3/3 4/6  
Children at percentile 50 0/1 0/0  
Children under percentile 50 13/12 13/11  
Increased weight percentile   
Mean (SE) 3.2 (1.7) 5.7 (1.8) 0.186 
Post-treatment-baseline/baseline [median (IQR)] 0.22 (0.09-0.47) 0.26 (0.14-1.64) 0.234 
Histology (Marsh categorization)**  0.701 
Marsh 1 0 1  
Marsh 2 0 1  
Marsh 3a 5 3  
Marsh 3b 8 10  
Marsh 3c 3 2  
Anti-transglutaminase antibodies 
(post-treatment-baseline/baseline) 
[median (IQR)] 
-0.60 
(-0.88 to -0.61) 
-0.84 
(-0.88 to -0.75) 0.418 
Table 1. Clinical characteristics of the subjects of the two study groups
*Categorical variables were analysed using the Fisher test and continuous variables were analysed 
using the t-test except for few exceptions for which the Mann-Whitney U test was applied (increased 
height and weight percentile expressed as quotient of post-treatment-baseline/baseline and changes 
in the anti-transglutaminase antibodies content) for comparison between groups (placebo versus B. 
longum CECT 7347). In all the cases differences were established at a P value < 0.050. 
** Histological data were obtained only at the diagnosis stage. 
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Figure 1: Graphical representation of the study protocol and the timing of sample collection and 
asseessments during the 3 months of intervention. 
with codes consisting of a letter 
and 3 numbers assigned randomly 
by an external scientist involved 
in bacterial strain production but 
not in its evaluation in the present 
study. Study personnel, including 
clinicians and research assistants 
involved in experimental work and 
data analysis, were naïve as to which 
treatment these labels represented. 
All these measures ensured true 
allocation concealment and proper 
blinding. Visits to paediatricians and 
parameters monitored are shown in 
Figure 1. The trial was not registered 
because it was a first exploratory 
study. 
Gluten free diet (GFD) and dietary 
records
Children adhered to a strict GFD, 
after confirmation of CD diagnosis, 
by replacing gluten-containing 
foods by equivalent ones certified as 
gluten free (less than 20 ppm [mg/
kg] according to the EC Regulation 
Nº41/2009). Dieticians provide 
dietary counselling to select naturally 
and certified gluten-free products. 
They were also advised not to 
consume prebiotic and probiotic 
containing foods. To control diet 
as variable, food diary records were 
collected for 72 h (2 weekdays and 1 
weekend day) before the start of the 
intervention and at the end of the 3 
months of intervention. At the front 
of the dairy, detailed information on 
how to record food and beverages 
consumed using common household 
measure was provided. Food 
diary records were returned to the 
dietician for their analysis for energy, 
macronutrient and micronutrients 
contents based on the CESNID food 
composition database of Spanish 
foods (28).
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Clinical assessments 
At baseline and after the three-
month intervention, serologic 
markers of CD, anthropometric 
parameters (height and weight) and 
evolution of clinical symptoms were 
assessed by paediatricians specialized 
in gastroenterology. Parents were also 
instructed to weekly register data on 
compliance with probiotic intake, 
gastrointestinal symptoms (presence 
or absence of vomiting, diarrhoea, 
constipation or abdominal pain), 
and concomitant treatments (e.g. 
antibiotics, drugs interfering with 
intestinal function, etc.) and serious 
adverse events (hospitalization, any 
life-threatening event, etc.) and to 
report them to the paediatrician 
at each visit.  Compliance was 
considered to be accomplished 
when the intake of the test capsules 
was not interrupted for more than 
two consecutive days and no more 
than three times during the whole 
intervention period (three months). 
Parents were also provided a round-
the-clock call service and e-mail 
address for immediate reporting if 
necessary.  
Lymphocyte phenotyping
At baseline and the end of the 
three-month trial period, peripheral 
blood samples were collected in 
heparin tubes and separated in 
two aliquots; one was mixed with 
stabilizing blood Transfix reagent 
(Cytomark, Buckingham, UK) and 
sent immediately to IATA-CSIC 
at room temperature for cytometry 
analysis. The second blood sample 
was centrifuged (1,200 xg, 10 min, 
4 ºC) and the serum was stored 
at -80ºC. Furthermore, a routine 
hemogram was carried out with all 
the blood samples.
Flow cytometry was used to 
determine the expression of surface 
markers of different lymphocyte 
subsets. Aliquots (100 μL) of 
stabilized peripheral blood 
were incubated with different 
fluorochrome-conjugated antibodies 
(eBiosciences, Hattfield, UK) at 
room temperature for 10 minutes 
and then prepared for flow cytometry 
analysis using the Immunoprep kit 
(Beckman Coulter, USA) according 
to the manufacturer’s instructions. 
Samples were analysed in a FACS-
Canto II Deckton Dickinson 
cytometer (BD Bioscience). To 
analyse the T lymphocytes subsets 
cells were stained with the following 
monoclonal antibodies: CD45-
phycoerythrin (PE) (clone HI30), 
CD3-allophycocyanin (APC) (clone 
OKT3), HLA-DR-fluorescein 
isothiocyanate (FITC) (clone LN3), 
CD4-FITC (clone OKT4), Foxp3-
APC (clone PCH101) and CD8-
APC (clone RPA-T8). Lymphocyte 
subsets were classified based on 
the pattern of their surface marker 
expression as CD45+CD3+ (mature 
T lymphocytes); CD45+HLA-DR+ 
(late activation marker positive 
T lymphocytes); CD45+CD4+ 
(helper T cells); CD45+CD4+ 
and Foxp3+ (regulatory T cells) 
and CD45+CD8+ (cytotoxic T 
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cells). Data from 100,000 events 
were acquired and percentages of 
each subpopulation related to the 
gated lymphocytes labelled with 
the leukocyte marker CD45+ were 
estimated using the BD FACSDiva™ 
software v5.0. 
Cytokine and immunoglobulin 
quantification 
In serum samples, the initial and 
final content of the pro- and anti-
inflammatory cytokines (TNF-α, 
interferon (IFN)-γ, IL-13 and 
IL-10) were quantified using a 
commercial ELISA kit following 
the manufacturer’s instructions 
(Catalogue nº 31673019, 31333539 
and 31330139, Immunotools, 
Friesoythe, Germany; Catalogue 
nº 430605, Biolegend, Cambridge, 
UK). Transforming growth factor 
(TGF)-β1 analysis included 
the activation of the molecule 
(incubation with 1 N HCl for 1 
hour and neutralization with 1 N 
NaOH) prior to its quantification 
with an ELISA (Catalogue nº 
437708, Biolegend, Cambridge, 
UK). Immunoglobulin (Ig) G1 
(Catalogue nº ELH-IGG1-001, 
RayBiotech, Gwinnett, USA) and 
IgG4 (Catalogue nº CSB-E13728h, 
Cusabio, Wuhan, China) content 
were also quantified using specific 
ELISA kits.
Secretory IgA (sIgA) quantification
Faecal samples were collected at 
baseline and at the end of the trial 
and stored at -80 ºC. One gram 
of faecal sample was weighed, 
diluted 1/10 (w/v) with PBS buffer 
(130 mM sodium chloride and 10 
mM sodium phosphate buffered 
saline, pH 7.4) and homogenized 
in a stomacher for 5 minutes. The 
mixture was also homogenized in a 
tube with glass beads of 5 mm using 
a vortex and subjected to low-speed 
centrifugation (600 xg, 2 min). The 
supernatants were collected for sIgA 
quantification by ELISA according 
to the manufacturer’s instructions 
(Catalogue nº E80-102, Bethyl, 
Montgomery, USA) as well as for 
DNA extraction as described below.
Microbiota analysis by real-time 
PCR 
DNA was extracted using the 
QIAamp DNA Stool Mini Kit 
(Qiagen, Hilden, Germany) 
following the manufacturer’s 
instructions. Real-time PCR analyses 
were run to quantify the content 
of different bacterial groups and 
Bifidobacterium spp. using specific 
primers as previously described 
(Supplementary table 1). PCR 
amplification was performed in a 
LightCycler® 480 Real-Time PCR 
System (Roche) in a multi well-plate 
with 15 µL of reaction mixture that 
consisted of 7.5 µL SYBR Green 
PCR Master Mix (Roche), 3.5 µL 
DNase free water, 0.75 µL of each 
specific primer (10 mM) and 2.5 µL 
of the DNA sample. 16S rRNA gene 
copy numbers were calculated by 
comparing the cycle threshold (Ct) 
values obtained with those from a 
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standard curve (29). Standard curves 
were generated from serial dilutions 
of a known copy number of the 
target gene cloned into a plasmid 
vector. For each reference strain the 
16S rRNA gene was cloned into 
a pGEM-T Easy Vector System 
(Promega, Madison, USA) and an 
E. coli DH5α strain was transformed 
with the recombinant plasmids. 
Plasmid DNA was extracted from E. 
coli by the miniprep method (30).
Statistical analysis
Data distribution of continuous 
variables was tested using Shapiro-
Wilk W test. When data showed a 
normal distribution (P> 0.050) a 
t-test for paired sample comparisons 
was used and results are expressed as 
mean values and the standard error 
of the mean [SE]). When no-normal 
distribution was found, the Mann-
Whitney U test was applied for paired 
sample comparisons and data are 
expressed as median and interquartile 
range (IQR). Microbiological data 
were transformed from exponential 
numbers into logarithms to adjust 
to normal. All parameters measured 
during the intervention were 
expressed as the difference between 
the baseline value and the post-
intervention value, divided by the 
baseline value for pair comparisons 
between the two study groups 
applying either the t-test or the Mann-
Whitney U test. A generalized linear 
model was also applied to absolute 
values of all parameters measured to 
establish differences between the two 
study groups and possible time by 
treatment interactions. Correlations 
between the microbiota composition 
data and immunological data were 
stabilised by applying the Pearson 
coefficient. 
Categorical demographic data of 
the study subjects (Table 1) and 
the incidence of gastrointestinal 
symptoms (Table 2) are expressed as 
absolute values or proportions and 
analysed using the Fisher test. 
The analyses were conducted using 
the SPSS software (version 19.0, 
Inc, Chicago, IL, USA) and in all 
the cases, statistically significant 
differences were considered at a P 
value below 0.050.
Ethical considerations
The study was approved by the ethics 
committees of Consejo Superior 
de Investigaciones Científicas 
(CSIC) and the hospitals involved 
in the study, Hospital Universitario 
Sant Joan (Reus, Tarragona) and 
Hospital Universitario Sant Joan 
de Deu (Barcelona) and conducted 
in accordance with the Helsinki 
Declaration of 1975 as revised in 
1983. Written informed consent was 
obtained from the parents of children 
included in the study. 
RESULTS
Trial subject characteristics  
From November 2011 to June 
2012 a group of 36 children newly 
diagnosed with CD were enrolled 
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in a randomized, double-blind, 
placebo-controlled intervention trial 
to evaluate the effects of intervention 
in the gut ecosystem with B. longum 
CECT 7347 in parallel to those 
of the GFD. Three withdrawals 
were registered one due to parents’ 
complaints of the child’s reduced 
appetite and two due to the intake of 
antibiotics. Two of the withdrawals 
belonged to the placebo treatment 
and one to the B. longum group. 
Finally, data from 17 subjects of 
the probiotic group and 16 of the 
placebo group were included in the 
statistical analysis. Taking account 
the number of the children enrolled, 
the mean missed doses in the placebo 
group was 1.3 and in the probiotic 
1.9, which did not differ significantly 
(P=0.193). 
Dietary records did not revealed 
significant differences between 
groups in the intake of energy and 
specific nutrients (P> 0.050). The 
adherence to the GFD only led to a 
slight reduction in the dietary fibre 
intake in both group of children 
(Supplementary table 2). Intake of 
other probiotics or prebiotics was not 
reported during the study period.
The demographic and clinical 
characteristics of the child groups 
are shown in Table 1. Proper 
randomization was achieved as there 
were no significant differences in the 
baseline characteristics between the 
two groups. The serum antibodies 
to tissue transglutaminase (tTG)-
IgA were normalized, decreasing 
to similar levels (P= 0.418) in both 
groups after 3 months of adherence 
to a GFD and intervention (Table 
1). No adverse events were reported 
during the intervention. Height 
and weight data were analysed 
according to the WHO growth chart 
percentiles. As is shown in Table 1, at 
the time of diagnosis 84.8% (28/33) 
and 78.8% (26/33) of the children 
enrolled in the study were under 
percentile 50 (P50) for height and 
weight, respectively, corresponding 
to their age. After 3 months of 
intervention, two children in the B. 
longum CECT 7347 group and one 
child in the placebo group gained 
weight so as they were included in 
the group of children up P50 and 
in the group of children at P50, 
respectively.  The mean increases 
in height and weight percentiles 
(difference in the percentile from 
baseline and post-treatment) were 
higher in the B. longum CECT 7347 
group (∆7.8 [2.2] and ∆5.7 [1.8], 
respectively) than in the placebo 
group (∆7.0 [1.5] and ∆3.2 [1.7], 
respectively). Comparison of these 
changes between groups revealed 
that increases in height percentile 
were significantly greater in the B. 
longum CECT 7347 group than in 
the placebo group (P= 0.048), while 
statistically significant differences in 
weight percentile increases were not 
detected (P= 0.234).
The incidence of gastrointestinal 
symptoms (diarrhoea, constipation, 
abdominal pain and vomiting) in the 
two study groups during the three 
months of intervention are showed 
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in Table 2. No statically differences 
in the number of cases self-reporting 
incidence of these symptoms were 
detected either between groups or 
within the placebo or B. longum 
group. 
Lymphocyte phenotype and 
hemogram 
The results of immune phenotyping 
of peripheral blood cells by flow 
cytometry are shown in Table 3 and 
Figure 2. Within group comparisons 
did not reveal statistically significant 
changes in the placebo group during 
the three-month intervention on 
comparing baseline with post-
treatment values (Table 3). In 
contrast, B. longum CECT 7347 
administration led to significant 
decreases in CD3+ (P= 0.013) 
and HLA-DR+ (P= 0.029) T cell 
populations on comparing baseline 
with post-treatment values within 
this group (Table 3). Baseline values 
of the measured parameters were 
not significantly different between 
groups. Comparisons between groups 
revealed that the administration of 
B. longum CECT 7347 significantly 
reduced (P= 0.004) CD3+ T cell 
population as compared to the 
placebo (Figure 2). No statistically 
significant differences detected in the 
T lymphocytes subsets HLA-DR+, 
CD4+, CD4+Foxp3+ and CD8+ 
between groups (P= 0.328, 0.970, 
0.504 and 0.376, respectively) 
(Figure 2).
Similar differences were detected 
between groups by applying a 
generalized linear model. This model 
also revealed a significant effect of the 
B. longum CECT 7347 intervention, 
consisting in a reduction of the 
CD3+ population that was opposite 
to the effect of the GFD (P= 0.020) 
and a statistically significant time by 
treatment interaction (P= 0.021). 
Baseline values for CD3+ were no 
different between the two groups (P= 
0.950).  
 
 
 
 Nº of cases reporting gastrointestinal symptoms 
 Placebo (n=16) *P-value 
B. longum CECT 7347 (n=17) *P-
value Initial Final Initial Final 
Diarrhoea 6/16 4/16 0.352 6/17 5/17 0.500 
Constipation 3/16 2/16 0.500 3/17 2/17 0.500 
Abdominal pain 6/16 4/16 0.352 10/17 9/17 0.500 
Vomiting 5/16 1/16 0.087 4/17 1/17 0.206 
Table 2. Number of cases self-reporting gastrointestinal symptoms at least once during the three-
month intervention period in parallel to the GFD. 
*Data were compared applying the Fisher test and differences were established at P value <0.05.
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 Baseline  Post-treatment 
*P value 
 Mean SE Mean SE 
Placebo      
CD3+ 66.96 2.85 70.03 2.17 0.144 
HLA-DR+ 0.99 0.19 0.72 0.24 0.422 
CD4+ 41.78 4.37 42.60  4.89 0.898 
CD4+Foxp3+ 2.99 0.82 3.77 1.36 0.322 
CD8+ 22.08 1.95 20.68 1.13 0.344 
      
B. longum CECT 7347      
CD3+ 70.05 2.23 63.42 2.04 0.013 
HLA-DR+  0.62 0.10 0.38 0.82 0.029 
CD4+ 44.68 2.40 45.96 3.59 0.748 
CD4+Foxp3+ 3.13 0.66 3.45 0.73 0.728 
CD8+ 23.92 1.55 21.59 0.98 0.152 
Table 3. Changes in CD45+ T lymphocytes subsets within the placebo group or B. longum CECT 
7347 group in the three-month intervention parallel to the GFD. 
*Differences between baseline and post-treatment within the study groups (placebo or B. longum 
CECT 7347) were established at two-sided P< 0.05 using the t-test.
Figure 2.  Changes in CD45+ T lymphocytes subsets estimated as the difference between the 
baseline value and the post-intervention value, divided by the baseline value in placebo (light grey 
colour) and B. longum CECT 7347 (dark grey colour) groups in the three-month intervention 
parallel to the GFD. Data are expressed as mean and SE. Statistically significant differences between 
groups were established at two-sided P< 0.05 using the Mann-Whitney U test.
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No changes in the total leukocyte 
and leukocyte subtype (lymphocytes, 
monocytes, granulocytes, 
eosinophils and basophils) counts or 
haemoglobin content were observed 
on analysing the hemogram (data 
not shown), either within groups or 
between groups. 
Cytokines and immunoglobulin 
content
The results of serum cytokines and 
immunoglobulin concentrations 
are shown in Table 4 and Figure 
3. Within group comparisons, 
revealed that B. longum CECT 7347 
administration slightly reduced 
serum TNF-α concentrations, but 
differences did not reached statistical 
significance (P=0.085). Changes 
in other serum cytokines and 
immunoglobulin concentrations, 
comparing baseline and post-
treatment values within groups, 
were not significantly different in 
the B. longum CECT 7347 group 
or in the placebo group (Table 4). 
Comparisons between groups (B. 
longum CECT 7347 and placebo) 
of changes in serum cytokines 
and immunoglobulin levels are 
shown in Figure 3. Baseline values 
of the measured parameters were 
not significantly different between 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Baseline  Post-treatment *P value  Mean SE Mean SE 
Placebo      
TNF-α  1669.56 338.47 1515.24 254.34 0.443 
IFN-γ  306.42 32.59 297.59 36.32 0.815 
IL-10  42.99 9.25 59.30 9.33 0.249 
IL-13  137.71 12.85 163.86 21.16 0.239 
TGF-β1  116.43 38.62 146.63 25.71 0.537 
IgG1  441.85 84.04 477.39 94.43 0.644 
IgG4  4.63 0.42 6.29 1.18 0.212 
     
B. longum CECT 7347     
TNF-α 1803.29 187.95 1442.94 153.20 0.085 
IFN-γ 267.02 33.52 235.49 23.97 0.423 
IL-10 69.14 12.15 52.02 5.28 0.240 
IL-13 116.21 20.85 119.96 7.11 0.854 
TGF-β1 130.67 34.41 138.42 33.52 0.851 
IgG1 368.91 57.51 400.82 74.43 0.590 
IgG4 4.38 0.19 4.42 0.34 0.919 
Table 4: Changes in the cytokine (pg/mL) and immunoglobulin (ng/mL) content within the group 
placebo (a) or B. longum CECT 7347 (b) in the three-month intervention parallel to the GFD. 
*Differences between baseline and post-treatment values within the group placebo or B. longum 
CECT 7347 were stabilised at two-sided P<0.05 using the t-test. 
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groups. The administration of 
B. longum CECT 7347 slightly 
reduced serum TNF-α concentration 
compared to the placebo but statistical 
significance was not reached (P= 
0.067). No statistically significant 
differences were detected in serum 
IL-10, IFN-γ, IL-13, TGF-β1, IgG1 
and IgG4 concentrations between 
groups.
Applying a generalized linear 
model significant differences in 
IgG4 (P= 0.038) were detected, 
showing increased values in the 
placebo group. Significant effects or 
interactions were not detected for 
other parameters. 
Microbiota composition and faecal 
sIgA content
Within group changes in microbiota 
composition as a result of the 
interventions showed that the GFD 
plus placebo administration caused 
a statistically significant increase in 
gene copy numbers of the Bacteroides 
fragilis group (P= 0.013) and in 
the family Enterobacteriaceae (P= 
0.038) (Table 5). Bifidobacterim 
spp. gene copy numbers were also 
slightly reduced as a consequence of 
the GFD although differences did 
not reach statistical significance (P= 
0.151). Within group comparisons 
also showed that the ratio of 
Lactobacillus group + Bifidobacterium 
spp./Bacteroides fragilis group + 
Enterobacteriaceae was significantly 
Figure 3. Changes in the cytokine (pg/mL) and immunoglobulin (ng/mL) content estimated as 
the difference between the baseline value and the post-intervention value, divided by the baseline 
value in placebo (light grey colour ) and B. longum CECT 7347 (dark grey colour ) groups in the 
three-month intervention parallel to the GFD. Data are expressed as mean and SE. Statistically 
significant differences between groups were established at two-sided P< 0.05 using the t-test.
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reduced in the placebo group (1.26 
[0.08] versus 1.00 [0.04]; P= 0.006), 
while B. longum CECT 7347 group 
did not show statistically significant 
differences  (1.19 [0.07] versus 1.16 
[0.07]; P= 0.811). Comparison 
between groups revealed that gene 
copy numbers of the Bacteroides 
fragilis group increased significantly 
in the placebo group compared 
to the B. longum CECT 7347 
group (P =0.020) (Figure 4). The 
quantification of sIgA content in faces 
showed that the treatments caused 
opposite changes within groups, 
which were statistically significant 
for the placebo group, showing an 
increase in faecal sIgA concentration 
(P=0.009) (Table 5). Comparisons 
between groups revealed that B. 
longum CECT 7347 administration 
led to significant reductions in faecal 
sIgA compared to the placebo (P= 
0.011) (Figure 5). 
In the B. longum CECT 7347 group, 
decreases in stool sIgA levels correlated 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Baseline  Post-treatment P value  Mean SE Mean SE 
Placebo      
Total bacteria 11.10 0.14 11.15 0.18 0.689 
B. fragilis group 9.07 0.17 9.59 0.22 0.013 
Enterobacteriaceae 6.03 0.38 6.93 0.34 0.038 
Lactobacillus group 8.55 0.14 8.45 0.18 0.589 
Bifidobacterium spp. 9.37 0.19 9.01 0.24 0.151 
C. coccoides group 8.85 0.33 9.31 0.28 0.115 
C. leptum group 9.86 0.23 10.07 0.30 0.434 
sIgA (mg/mL) 67.07 5.75 84.15 6.01 0.009 
      
B. longum CECT 7347     
Total bacteria 11.27 0.15 11.08 0.16 0.393 
B. fragilis group 9.43 0.20 9.29 0.16 0.583 
Enterobacteriaceae 5.90 0.46 6.34 0.43 0.424 
Lactobacillus group 8.46 0.21 8.54 0.33 0.858 
Bifidobacterium spp. 9.08 0.27 9.16 0.42 0.875 
C. coccoides group 9.22 0.23 9.60 0.42 0.469 
C. leptum group 10,23 0,23 10.01 0.16 0.447 
sIgA (mg/mL) 77.53 4.89 60.83 7.16 0.109 
* Differences between baseline and post-treatment values within the group placebo or B. longum 
CECT 7347 were stabilised at two-sided P< 0.05 using the t-test.  
Table 5. Changes in intestinal microbiota composition (log of gene copy numbers/g stools) within 
the group placebo or B. longum CECT 7347 in the three-month intervention parallel to the GFD. 
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Figure 4. Changes in intestinal microbiota composition (log of gene copy numbers/g stools) 
estimated as the difference between the baseline value and the post-intervention value, divided 
by the baseline value in placebo (light grey colour) and B. longum CECT 7347 (dark grey colour) 
groups in the three-month intervention parallel to the GFD. Data are expressed as mean and SE. 
Statistically significant differences between groups were established at two-sided P< 0.05 using the 
Mann-Whitney U test.
Figure 5.  Changes in the sIgA content in stools (mg/g) estimated as the difference between the 
baseline value and the post-intervention value, divided by the baseline value in placebo (light grey 
colour) and B. longum CECT 7347 (dark grey colour) groups in the three-month intervention 
parallel to the GFD. Bars represent the mean of individual data and SE. Statistically significant 
differences between groups were established at two-sided P< 0.05 using the t-test. 
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with decreases in total bacteria and 
the Bacteroides fragilis group gene 
copy numbers (P= 0.005, r= 0.729 
and P= 0.047, r= 0.522, respectively, 
Figure 6). No correlations were 
found between bacteria and other 
immune parameters either in the 
placebo group or in the B. longum 
group. 
Applying a generalized linear model 
of analysis, the placebo group showed 
increases in Bacteroides fragilis group 
numbers of borderline significance 
compared to the probiotic group 
(P= 0.055). Significant and opposite 
changes in the sIgA content 
depending on the treatment were also 
detected (P= 0.031) as well as a time 
by treatment interaction (P= 0.016); 
faecal sIgA decreased in the B. longum 
CECT 7347 group, while increased 
in the placebo group. Baseline values 
for Bacteroides fragilis group numbers 
and faecal sIgA were no different 
between the two groups (P= 0.972 
and P=0.416, respectively).  
lymphocytes (CD3+) and HLA-
DR+ T lymphocytes, according to 
within group comparisons, while 
the placebo did not. Moreover, 
there were reduced mature T 
lymphocytes (CD3+) in between 
group comparisons with respect to 
the placebo. Altogether, these results 
indicate that the bifidobacterial 
strain exerted a greater effect on 
these lymphocyte subsets than the 
GFD alone, which could presumably 
contribute to better recovery from 
the inflammatory status associated 
with the active phase of the disease, 
which is characterized by increased 
T cell activation that drives an 
inflammatory response with 
increased pro-inflammatory cytokine 
production (33). Statistically 
significant correlations between the 
densities of mucosa CD3+ with the 
serum tTG 2 antibody levels have 
been established in untreated and 
treated CD patients, and the number 
of intraepithelial CD3+ cells was also 
Figure 6. Correlation analyses of the changes between baseline and post-treatment values of sIgA 
concentrations (ng/g stools) and log gene copy numbers of total bacteria and Bacteroides fragilis 
group in the group of children treated with B. longum CECT 7347 plus GFD. 
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DISCUSSION
The influence of administering 
B. longum CECT 7347 orally to 
children with newly diagnosed CD 
following a GFD was evaluated 
in a three-month double-blind 
randomized placebo-controlled 
intervention trial. The aim was to 
assess whether intervention in the 
gut ecosystem via B. longum CECT 
7347 administration improved the 
efficacy of the GFD. 
Adherence to the GFD, with and 
without B. longum CECT 7347 
supplementation, led to positive 
effects on growth-related parameters 
in the children under study, as 
expected. Furthermore, B. longum 
CECT 7347 administration led 
to additional improvements, 
corresponding to greater increases 
in the height percentile compared 
to the placebo. Adherence to a GFD 
is associated with restoring growth, 
measured as the increase in height 
percentile and the decrease in weight 
deficit, as reported in a cohort of 
90 children (aged 0.5-7.5) with the 
disease (31) The effect of GFD on 
the growth of a cohort of 60 CD 
children (aged 2.3-10) in a four-year 
study also showed that the weight-
for-height parameter normalized by 
the end of first year, while height 
recovery caught up steadily until the 
3rd year of adherence to the GFD, 
revealing faster catch-up of weight 
than height (32). The administration 
of B. longum CECT 7347 caused 
significant decreases in mature T 
associated with the villous height-
crypt depth ratio(33). Another study 
in newly diagnosed CD children 
(aged 2-5) also reported increased 
peripheral prevalence of HLA-DR+ 
cells, which was partially reduced 
after adherence to a GFD(19). This 
is in agreement with our findings, 
pointing to an improved effect 
of the GFD combined with B. 
longum CECT 7347 intake on this 
lymphocyte subpopulation. In our 
study, only regulatory (CD4+Foxp3+) 
T cells tended to increase in the 
placebo group, and increased even 
more in the B. longum CECT 
7347 group together with helper 
(CD4+) T cells. Although changes 
were not statistically significant, 
this could indicate induction of the 
regulatory mechanisms controlling 
the unbalanced inflammatory T cell 
response associated with CD. 
Compared to the placebo, B. longum 
CECT 7347 administration also 
tends to decrease serum TNF-α 
concentration, suggesting this 
bifidobacterial strain could contribute 
to reducing the inflammatory status 
of patients to a greater extent than 
the GFD alone. This finding is also 
supported by a recent study in an 
animal model of gliadin-induced 
enteropathy, reporting that B. 
longum CECT 7347 administration 
reduced TNF-α production in the 
small intestinal tissue but increased 
IL-10 production (34). Statistically 
significant positive correlations have 
been reported between IgA-anti-
tTG and serum TNF-α in subjects 
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with both type 1 diabetes mellitus 
and CD (35). Also patients with 
newly diagnosed CD have been 
reported to have increased TNF-α 
serum concentration (36). In the 
context of CD, TNF-a production, 
together with IFN-g, are thought to 
contribute to increasing intestinal 
epithelial permeability favouring 
the access of higher antigen loads 
to the submucosa and, therefore, 
aggravating CD pathogenesis 
(37). Recent studies in intestinal 
cultures in vitro and ex-vivo have 
also demonstrated that TNF-α 
may contribute to exacerbating 
the pathogenic mechanism of CD 
by inducing tTG 2 expression, 
synergically with IFN-γ (38).
The present study also demonstrated 
that in newly diagnosed CD children, 
imbalances in the microbiota resulting 
from the GFD were counteracted by 
parallel administration of B. longum 
CECT 7347. In this respect, in 
the placebo group the GFD led to 
significant increases in potentially 
pathogenic bacteria (B. fragilis 
group and Enterobacteriaceae) and 
reductions in the ratio of harmless 
to potentially harmful bacteria. In 
agreement with our present findings, 
increases in the ratio of Bacteroides-
Prevotella plus E. coli/Bifidobacterium 
plus Lactobacillus group proportions 
were detected in stools of untreated 
and treated CD children with a GFD 
previously (6). In addition, increases 
in Bacteroides fragilis numbers in 
both stools and duodenal biopsies 
of patients with active and non-
active disease have been reported 
previously (7). Furthermore, it was 
demonstrated that the abundance of 
the species Bacteroides fragilis coding 
for metalloproteases was increased 
in both untreated and treated CD 
patients, which could presumably 
play a pathogenic role in CD (13). In 
fact, Bacteroides fragilis and the strains 
producing metalloproteases are 
frequently involved in opportunistic 
infections and aggravate colitis in 
animal models (39). Studies in 
healthy adults have also shown that 
the GFD per se shifts gut microbiota 
composition reducing numbers of 
Bifidobacterium spp., B. longum and 
Lactobacillus group, and increasing 
those of Enterobacteriaceae and E. coli 
(40). In vitro and animal studies have 
also shown that these microbiota 
alterations could contribute to 
pathogenesis in the active phase of 
the disease as well as to the lack of 
complete restoration of immune 
homeostasis in GFD-treated patients 
(10, 12, 14). However in the 
present study statistically significant 
changes specifically in numbers 
of Bifidobacterim spp. were not 
detected neither associated with the 
adherence to the GFD nor with the 
probiotic administration. It has been 
reported that changes in microbiota 
resulting from a dietary intervention 
depend among other factors on 
the initial microbiota composition 
and, accordingly, previous studies 
have indicated that changes in 
bifidobacterial numbers can be 
minor after probiotic or prebiotic 
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administration in subjects with high 
initial bifidobacterial counts (41) as 
it was the case for our study. Also, 
according to our previous studies, 
the GFD does not favour the growth 
of bifidobateria (40).
The changes induced by B. longum 
CECT 7347 administration in 
the intestinal microbiota were 
parallel to decreases in faecal sIgA 
concentration. The sIgA is considered 
to be the most likely host secretion 
to affect the localization, growth and 
composition of gut microbiota, and 
can restrict colonization of harmful 
bacteria (42, 43). Nevertheless, it is 
also speculated that gut microbiota 
composition may influence sIgA 
concentration and specificities as a 
result of a bi-directional cross-talk 
between the host and its microbiota 
(42, 43). The fact that B. longum 
CECT 7347 administration caused a 
sIgA reduction that was statistically 
correlated with the lower gene copy 
numbers of total bacteria and the 
Bacteroides fragilis group would 
suggest a reduction in the host sIgA-
mediated protective response against 
luminal bacterial antigens due to 
restoration of the gut ecosystem with 
decreases in harmful bacteria (44). 
A recent randomized, double-blind 
placebo-controlled study evaluated 
the effect of B. infantis NLS in 
untreated CD patients consuming 
gluten to establish the effect of the 
probiotic independently of the GFD 
(45). The beneficial properties of B. 
infantis NLS included the reduction 
of gastrointestinal symptoms, 
specifically indigestion, constipation 
and reflux with borderline 
significance. However, it did not 
improve diarrhoea or abdominal pain, 
nor modify intestinal permeability 
or the pro-inflammatory status as 
reflected by the analysis of serum 
cytokines and chemokines (45). 
Despite the experimental differences, 
it is presumable that the mechanism 
behind the effects exerted by B. 
infantis NLS differ from those 
exerted by B. longum CECT 7347, 
as the latter influences inflammatory 
markers and the gut microbiota and 
host-related defence mechanisms.  
The study reported herein has 
some limitations partly inherent to 
exploratory interventions. These 
include: small population size, lack of 
previous data for power calculation, 
inclusion of children with a wide 
age range, which could increase the 
variability of immune parameters 
determined, and a relatively short 
duration to detect clinical effects. 
Nonetheless, the findings are 
interesting enough to encourage 
further well-powered intervention 
studies, which would provide 
sound data on the efficacy of this 
bifidobacterial strain and shed light 
on its mode of action in ameliorating 
inflammatory conditions such as 
CD. 
In conclusion, the oral administration 
of B. longum CECT 7347 together 
with the GFD led to shifts in the 
intestinal microbiota, characterized 
by reductions in potentially pro-
inflammatory bacteria (B. fragilis 
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group) related to CD in previous 
human observational studies as 
well as faecal sIgA. Likewise, B. 
longum CECT 7347 administration 
led to reductions in activated T 
lymphocytes and also tended to 
reduce inflammatory markers 
(TNF-α) that may contribute to 
recovery of the immune homeostasis 
in patients.  
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SUPPLEMANTARY TABLES
Sup. table 1: Sequence of the 16S rRNA gene target primers used for real time quantitative PCR 
analyses. 
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Targeted  bacteria Sequence (5'-3') Tª anne. 
Amplicon 
size (pb) Reference 
Total bacteria ACT CCT ACG GGA GGC AGC AG CTA TTA CCG CGG CTG CTG GCAC 59 200 
Matsuki et al., 
2002 
Bacteroides fragilis group ATA CGG AGG ATC CGA GCG TTA CTG TTT GAT ACC CAC ACT 48 287 
Matsuki et al., 
2002 
Enterobacteriaceae CAT TGA CGT TAC CCG CAG AAG AAG C CTC TAC GAG ACT CAA GCT TGC 63 195 
Bartosch et al., 
2004 
Lactobacillus group AGC AGT AGG GAA TCT TCC A ATT YCA CCG CTA CAC ATG 61 340 
Walter et al., 
2000 
Bifidobacterium spp. CTC CTG GAA ACG GGT GG GGT GTT CTT CCC GAT ATC TAC A 55 550 
Matsuki et al., 
2002 
C. coccoides group AAA TGA CGG TAC CTG ACT AA CTT TGA GTT TCA TTC TTG CGA A 50 438 
Matsuki et al., 
2002 
C. leptum group GCA CAA GCA GTG GAG T CTT CCT CCG TTT TGT CAA 50 239 
Matsuki et al., 
2004 
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 Baseline Treatment period *P value  Mean SE Mean SE 
Placebo      
Energy (Kcal) 1904.98 113.40 2144.60 326.41 0.476 
Protein (g) 67.50 8.00 85.92 17.01 0.589 
Lipids (g) 92.34 5.82 104.84 17.28 0.673 
Carbohydrates (g) 200.98 17.15 214.34 27.58 0.576 
Phosphorous (mg) 1053.74 141.81 1457.70 400.54 0.458 
Magnesium (mg) 181.04 11.69 190.58 14.81 0.583 
Calcium (mg) 939.42 174.55 1057.02 258.03 0.767 
Iron (mg) 8.46 0.71 10.32 0.96 0.103 
Zinc (mg) 6.66 0.75 7.68 1.04 0.553 
Vitamin C (mg) 81.86 16.94 77.68 13.30 0.848 
Vitamin A (retinol) (μg) 718.04 142.76 2129.40 712.16 0.119 
Vitamin D (μg) 2.10 0.83 3.98 1.73 0.443 
Vitamin E (mg) 7.30 1.17 9.98 1.89 0.171 
Fibre (g) 10.80 1.35 8.56 2.45 0.355 
      
B. longum CECT 7347     
Energy (Kcal) 2079.57 523.42 2087.82 414.30 0.989 
Protein (g) 78.67 17.10 78.75 15.02 0.272 
Lipids (g) 107.17 30.65 95.82 22.39 0.447 
Carbohydrates (g) 200.10 45.74 227.62 46.41 0.966 
Phosphorous (mg) 1130.05 204.61 1139.77 208.90 0.917 
Magnesium (mg) 171.42 22.67 197.78 48.43 0.495 
Calcium (mg) 795.60 110.08 825.55 138.82 0.493 
Iron (mg) 11.37 1.91 13.23 3.40 0.526 
Zinc (mg) 9.08 1.98 9.62 2.25 0.672 
Vitamin C (mg) 78.55 11.78 96.03 34.09 0.519 
Vitamin A (retinol) (μg) 1298.32 315.24 1237.83 395.49 0.915 
Vitamin D (μg) 3.80 1.24 5.42 1.37 0.319 
Vitamin E (mg) 9.12 1.33 9.33 1.80 0.903 
Fibre (g) 12.32 3.12 9.4 1.89 0.161 
Sup. table 2. Nutrient intake in the placebo and B. longum CECT 7347 groups at baseline and 
during the three-month intervention.
*Differences between baseline and post-treatment within the groups (placebo or B. longum CECT 
7347) were established at P<  0.05 using the t-test. 
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The findings of this Doctoral Thesis, which are presented in the previous four 
chapters, respond to the common objective of progressing in the understand-
ing of the role of the intestinal microbiota and specific bacterial components 
in the pathological process of CD, and contributing to the disease prevention 
and treatment by identifying factors that beneficially modulate gut microbiota 
composition and function. Figure 7 shows a schematic representation of the dif-
ferent studies carried out during this Thesis and their main findings and scientific 
contribution.
IV – GENERAL DISCUSSION
Figure 7: Schematic representation of the studies included in the present Thesis
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Genetic and environmental factors together modulate the early intestinal 
colonization and may influence the CD onset
The expression of the HLA-DQ2 or HLA-DQ8 heterodimers and the gluten 
intake do not explain why some subjects develop CD meanwhile others not (27, 
28). Among the environmental factors possibly involved in CD in addition to 
gluten, breast feeding is the most intensively investigated but without conclusive 
results. A protective role of breast-feeding has been reported, mostly based on 
a few observational, retrospective studies (92-95) which were summarized in a 
meta-analysis (55) and a systematic review (96). However, not all the studies 
support a protective effect (97) and any of them clarifies whether breast-feeding 
provides permanent protection against CD or simply delays the onset of CD 
development.
In the first study included in Chapter 3, the differences between breast-milk 
composition of healthy mothers and mothers with CD on a GFD have been ana-
lyzed for the first time. Mothers with CD presented a decrease in several immune 
markers (IL-12p70, TGF-β1 and sIgA) and in Bifidobacterium spp. in their breast 
milk. These differences might influence the protective effects of breast-feeding on 
the infant since it constitutes a source of immunoglobulins and cytokines that 
compensates the immature immune system of the neonate. These differences in 
the breast milk composition could also explain, at least in part, the controver-
sy across studies regarding the effects of human milk in the protection against 
CD. Mothers with the disease also presented a reduction in the Bifidobacterium 
spp. 16S rRNA gene copy numbers, which could mean a reduction in the trans-
fer of protective bacteria to the newborn. Although more studies are needed, it 
could be speculated that a reduction in immune protective components (sIgA 
and TGF-β1), involved in oral tolerance development, as well as of potential 
beneficial bacteria could influence the development of the immune system of the 
neonate and the intestinal colonization patter, that may influence the develop-
ment of CD later in life.
In the second study of Chapter 3, we have also analyzed the influence of the 
HLA-DQ genotype on the intestinal microbiota composition of healthy infants 
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at family risk of developing CD. This study is part of a larger prospective cohort 
study aiming to unravel whether alterations in the intestinal microbiota could 
precede the onset of CD. Our first studies with this cohort of infants using real 
time qPCR showed that the milk-feeding practices and the HLA-DQ2/DQ8 
genotype influence the intestinal colonization (69). To progress beyond this first 
observation, in the study included in the present Thesis we have analyzed the in-
fluence of the genotype on the microbiota in a sub-group of 22 infants including 
only exclusively breast-fed and vaginally delivered infants to reduce the number 
of confounding variables, and using 16S rRNA gene pyrosequencing. We have 
observed that the infants with a high genetic risk (HLA-DQ2) of developing 
CD showed increased proportions of Firmicutes (Clostridium sensu stricto and 
unclassified Clostridiaceace and Gemella) and Protebacteria (Raoultella and un-
classified Enterobacteriacea) and reduced proportions of Actinobacteria (Bifido-
bacterium) compared to infants with a low genetic risk (non-HLA-DQ2/DQ8). 
This observation let us to confirm that the HLA-DQ2 genotype per se influences 
the intestinal microbiota composition, even though the mechanism underlying 
the association of these imbalances with the later development of the CD remains 
unknown.
HLA genotype encodes for proteins expressed on the surface of cells that bind to 
antigen fragments for their presentation to the T cells. Thus, when CD patients 
ingest gluten, HLA molecules recognize gluten peptides and activate T CD4+ 
cells, triggering an aberrant immune response. In order to propose a mechanism 
by which HLA selects for intestinal microbiota, we can speculate that HLA mol-
ecules could present phagocytized antigens of intestinal bacteria, which may then 
be presented to T cells. Depending on the antigen presented, effector T-cell ac-
tivation could contribute to regulating the gut microbes colonizing the gut by 
activating B cells to secrete protective antibodies directly into the gut mucosa and 
lumen (98). Bacterial antigens presented via MHC II molecules, could also lead 
to T cell maturation into effector cells (Th1, Th2 or Th17) or Foxp3+Treg cells 
with immunosuppressive activity, which could contribute to developing toler-
ance towards components of the intestinal microbiota. In this context, studies in 
rodents indicate that the repertoire of thymus-derived Treg cells, which constitute 
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most Treg cells in all lymphoid and intestinal organs including the colon, is heav-
ily influenced by microbiota composition, thus supporting this hypothesis  (99).
In summary, from the results presented in Chapter 3, we can conclude that 
breast-milk from CD mothers and healthy mothers differs in composition and 
that this could reduce the protective effects of breast-feeding and the transfer of 
bifidobacteria to the offspring increasing CD risk. In addition, the HLA-DQ2 
genotype influences the intestinal microbiota composition of infants at fami-
ly risk of developing CD, especially reducing the proportion of Actinobacteria 
(Bifidobacterium) in the gut, which could also be a factor that confers less re-
silience to disease in this population group. These observations, together with 
the evidence that bifidobacteria numbers were reduced in CD patients reported 
previously (reviewed in 31), seem to indicate that this bacterial genus might play 
a protective role in CD.
B. longum CECT 7347 as potential probiotic for CD
The associations between CD and intestinal dysbiosis and the role attributed to 
some probiotics in the regulation of the gut barrier function and immune re-
sponse have motivated investigations of the potential beneficial effect of dietary 
intervention based on these functional ingredients (reviewed in 100). Some of 
the studies included in this Doctoral Thesis have been focused on the evaluation 
of the protective role of B. longum CECT 7347 and its mechanisms of action in 
CD, which are reported in Chapters 1, 2 and 4.
B. longum CECT 7347 (also called IATA-ES1) was isolated in 2007 from a three-
month old healthy breast-fed infant. This strain of the specie Bifidobacterium 
longum was selected for its ability to withstand the passage through the diges-
tive tract, a very hostile environment where the acidity and secretion of bile and 
other compounds kills many bacteria, and also for its in vitro ability to inhibit 
pathogens isolated from CD patients, immunoregulatory properties and ability 
to hydrolyse gluten peptides (e.g. the 33-mer). Later studies with this bacterium 
also demonstrated that B. longum CECT 7347 could counteract the pro-inflam-
matory effects induced by the CD patients’ microbiota in PBMC cultures. In 
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particular the co-incubation of B. longum CECT 7347 with PBMCs reduced the 
production of pro-inflammatory cytokines (IFN-γ and TNF-α) induced by the 
altered microbiota of CD patients and increase the release of the anti-inflamma-
tory cytokine IL-10 counteracting the Th1-type response (87). In a later study, 
B. longum CECT 7347 was also demonstrated to be able to hydrolyze gliadin 
peptides reducing their toxicity and inflammatory properties in Caco-2 cells (91).
The present Thesis has progress in the understanding of the mechanisms by which 
B. longum CECT 7347 could protect against CD using different and comple-
mentary experimental approaches. The Chapter 1 reported the in vitro studies, 
the Chapter 2 described the in vivo pre-clinical studies in an animal model of 
the enteropathy and the Chapter 4 included a double-blind randomized inter-
vention study in children newly diagnosed with CD to demonstrate the clinical 
efficacy of B. longum CECT 7347.
The articles of Chapter 1 were conceived to study whether some specific compo-
nents of the intestinal microbiota (especially some Bifidobacterium strains) could 
contribute to ameliorating the response to gluten peptides using in vitro models. 
To do so, monocytes derived dendritic cells (MDDCs) and Caco-2 cultures were 
chosen as both cells types are located at the interface between the host and the mi-
crobiota, and regulate intestinal barrier function and innate immune responses.
In the first study of Chapter 1, we concluded that specific components of the gut 
microbiota could define the role of dendritic cells (MDDCs) in T cell activation 
and the progression of CD, via their influence in the maturation of MDDCs and 
their interactions with epithelial cells (Caco-2). Specifically, some enterobacteria 
exerted pathogenic effects similar to the ones exerted by gliadin, contributing to 
the MDDCs maturation and the induction of pro-inflammatory cytokine release. 
In contrast, the two Bifidobacterium strains tested (B. bifidum CECT 7365 and 
B. longum CECT 7347) did not cause gliadin-induced morphological changes of 
MDDCs and showed reduced inflammatory cytokine release. Furthermore, B. 
longum CECT 7347 reduced the IFN-γ release induced by gliadins and increased 
IL-10 secretion when both stimuli were combined. Also this bacterium reversed 
the gliadin-reduced ZO-1 expression in Caco-2 cells, which alters permeability. 
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Altogether, these data showed that B. longum CECT 7347 could play a role in 
CD through the polarization of the immunological response and strengthening 
the gut barrier function, making this strain the most interesting one for further 
studies. 
In the second in vitro study included in Chapter 1, we evaluated the potential 
protective properties of B. longum CECT 7347 by contributing to the digestion 
of gliadin peptides and reducing their toxicity on Caco-2 cells using a proteomic 
approach. To do so, the proteome of Caco-2 cells exposed to gliadin peptides 
digested in vitro in the presence or absence of B. longum was evaluated. We ob-
served a higher number of proteins with altered expression when Caco-2 cells 
were exposed to gliadin digested without B. longum, indicating a higher damage, 
than when gliadin was digested in the presence of the Bifidobacterium. Some of 
these proteins were involved in the maintenance of the cell cytoskeleton, cell 
apoptosis and interactions with the immune cells. Besides, this differential pro-
teomic response was associated with a reduction in cell viability and an increase 
in TNF-α release. By contrast, when Caco-2 cells were exposed to gliadin digest-
ed in the presence of B. longum CECT 7347, a lower number of proteins were 
altered and no differences in the inflammatory markers were detected compared 
to the control. Thus, it was concluded that B. longum CECT 7347 reduced the 
toxic and the inflammatory effects of gliadin-derived peptides generated during a 
simulated gastrointestinal digestion. In addition to the proteolytic effect on glia-
din peptides, a role of other molecules released by B. longum during the digestion 
process cannot be discarded.
In Chapter 2, we have evaluated the potential effects of B. longum CECT 7347 
in an in vivo model of gluten induced enteropathy in newborn rats fed gliadin 
and sensitized with IFN-γ. We selected this animal model because it was de-
scribed that reproduces the CD4+ T cell mediated enteropathy  defined as hy-
perplasic-infiltrative similar to the one described in CD patients and the CD 
symptoms (101). The results confirmed that the sensitization with IFN-γ was 
necessary to partially reproduce the disease. In previous studies was also shown 
that sensitization of animals with IFN-γ was  necessary to cause mucosa damage 
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and immunological changes that resemble the enteropathy observed in human, as 
IFN-γ increases the paracellular transport and the activation and priming of mac-
rophages (102, 103). In sensitized newborn rats fed gliadin, the administration of 
B. longum CECT 7347 increased the NF-kB expression and IL-10 concentration 
and reduced TNF-α production in the small intestine. The administration of B. 
longum CECT 7347 also reduced CD4+ and CD4+/Foxp3+ cell populations and 
increased CD8+ T cell populations in peripheral blood from sensitized gliadin-fed 
animals. These results suggest that the Bifidobacterium partially counteract the 
inflammatory response locally in the gut. However, results from animal models 
have limitations and the potential beneficial effects should be interpreted with 
caution.  
Finally, Chapter 4 includes the most conclusive study as it evaluated whether 
B. longum CECT 7347 could help improve the recovery of children with newly 
diagnosed CD when administered in addition to the GFD.
When compared between groups after the 3 months of intervention, the ad-
ministration of B. longum CECT 7347 caused a decrease in peripheral activat-
ed CD3+ T lymphocytes and a slightly reduction in the TNF-α concentration. 
In the gut, the administration of B. longum was associated with a reduction of 
sIgA and Bacteroides fragilis numbers, which could contribute to restoring the gut 
ecosystem since bacteroides are known to be increased in the microbiota of CD 
patients (64). The production of sIgA plays a protector role as it binds harmful 
antigens (allergens or pathogens) and prevents the colonization and invasion of 
pathogens, as it can be the case for pathobionts of the genus Bacteroides (104). 
However, in active CD patients the sIgA may not play a protective role as the ab-
normal retro-transport of the complex IgA-gluten peptide by the CD71 receptor 
has let to consider sIgA as a “Trojan horse” able to promote the entrance of gluten 
peptides (104, 105). Thus, it could be speculated that the reduction observed in 
the children who received B. longum CECT 7347 may reduce the translocation 
of gluten to the lamina propria, when eventually ingested. It can also be a con-
sequence of reductions in the total load of pathobionts in the intestine, such as 
Bacteroides fragilis group. 
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Despite no differences in the incidence of gastrointestinal symptoms were re-
ported, our findings suggest that B. longum CECT 7347 could help to restore 
the intestinal ecosystem of CD patients. To date, two more randomized, dou-
ble-blind placebo-controlled human intervention trials have been conducted in 
CD patients (106, 107). One of this trials has evaluated the effects of the ad-
ministration of B. infantis NLS to untreated CD patients independently of the 
GFD. This study reported an improvement in some gastrointestinal symptoms 
(indigestion and constipation) after the administration of B. infantis NLS, but 
no differences in the permeability or the pro-inflammatory cytokines were found 
(106). The more recent intervention study published evaluated the effect of a 
strain combination (B. breve BR03 and B. breve B632), as compared to a placebo 
in children with CD on a GFD. In this case, the two B. breve strains decreased 
the production of the pro-inflammatory cytokine TNF-α in children with CD on 
a GFD (107) as detected in our study. 
Although these three studies report promising results since the interventions with 
specific probiotics strains ameliorate the symptoms or the inflammatory status 
of CD patients, the reproducibility of the effects in larger population groups 
should be confirm to be able to draw firm conclusions and make recommenda-
tions about their use in practice.
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V – CONCLUSIONS
1. CD mothers’ breast milk is characterized by a reduced abundance of immu-
noprotective compounds (TGF-β1 and sIgA) and DNA sequences form Bifido-
bacterium spp. The reduction in these components could theoretically diminish 
the protective effects of breast-feeding on the child’s future risk of developing CD 
and explain the controversy across previous epidemiological studies.
2. Infants with high genetic risk of developing CD (HLA-DQ2) have 
higher proportions of Firmicutes (Clostridium species) and Proteobacteria 
(Enterobacteriaceae) and lower proportions of Actinobacteria (Bifidobacterium 
species) than those with low genetic risk (non-HLA-DQ2/DQ8-carriers) in 
exclusively breast-fed infants. Therefore, the HLA-DQ2 genotype per se influences 
the early gut microbiota composition in infants at family risk of developing CD 
and could be an additional factor that contributes to CD onset. 
3. Specific components of the gut microbiota may influence phenotypic and 
functional maturation of DCs differently, and their interactions with epithelial 
cells aggravating (enterobacteria) or protecting (bifidobacteria) from the adverse 
effects of gluten peptides in vitro.
4. B. bifidum CECT 7365 and B. longum CECT 7347 did not cause gliadin-
induced morphological changes, and induced adhesion and spreading ability 
of MDDCs and inflammatory cytokine production to a lesser extent than the 
enterobacteria. B. longum CECT 7347 reduced IFN-γ production induced by 
gliadins and increased IL-10 secretion and also reversed the gliadin-reduced 
ZO-1 expression in Caco-2 cells, suggesting that protects from the adverse effects 
of gluten
5. The presence of B. longum CECT 7347 during the in vitro digestion of 
gliadin reduces its toxicity, measured as increased cell viability and reduced pro-
inflammatory cytokine secretion. It also modifies the proteomic response of 
intestinal epithelial cells (Caco-2 cells) to gliadin, reducing the altered protein 
expression. 
6. In an animal model of gliadin-induced enteropathy, the administration of B. 
longum CECT 7347 attenuated the production of inflammatory cytokines in the 
small intestine and the increased CD4+ T-cell mediated immune response in the 
periphery.
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7. In children newly diagnosed with CD, the oral administration of B. longum 
CECT 7347 together with the GFD reduced  the numbers of potentially pro-
inflammatory bacteria (B. fragilis group) related to CD in previous human 
observational studies and faecal sIgA concentration. It also led to reductions in 
activated T lymphocytes and slightly in inflammatory markers (TNF-α) that may 
contribute to recovery of the immune homeostasis in CD patients.  
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